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The incidence of both obesity and type 2 diabetes continues to rise, creating 
a major worldwide public health challenge. Understanding the mechanisms 
determining the normalisation of blood glucose levels and the limitations to 
complete reversal of diabetes by bariatric surgery or a very low calorie diet 
(VLCD) has important implications for the treatment of type 2 diabetes, but 
also for improving our understanding of the pathophysiology. A unifying 
hypothesis to explain the major pathophysiological changes in type 2 
diabetes, hepatic insulin resistance and pancreatic beta cell insufficiency, 
involves excess triglyceride accumulation in liver and pancreas. This is 
supported by in vitro demonstration of impaired insulin signalling (and 
thereby insulin resistance) and defective insulin secretion, induced by the 
toxic metabolites of fat. Triglyceride content in liver and pancreas can now 
be measured non-invasively and precisely using the three point Dixon 
magnetic resonance technique. This thesis presents data on a direct 
comparison of bariatric surgery and VLCD, suggesting that the mechanisms 
involved in the reversibility of type 2 diabetes using these two interventions 
are similar. Pancreatic triglyceride content appears to decrease with 
substantial weight loss in obese individuals with type 2 diabetes but not 
those with normal glucose tolerance. The clinical characteristics which limit 
reversal of diabetes are investigated, particularly the effect of longer 
diabetes duration. Both a retrospective study of bariatric surgery and a 
prospective study using VLCD suggest that long duration diabetes is 
reversible, however, normal blood glucose levels are less likely to be 
achieved than in short duration disease. Diabetes duration may be a 
surrogate marker for beta cell reserve. Finally, the longer term durability of 
the beneficial effects of an 8 week very low calorie diet is demonstrated. 
Over a subsequent 6 month weight maintenance period the decrease in 
hepatic and pancreatic triglyceride content, and the improvements in 
hepatic insulin sensitivity and first phase insulin secretion are maintained. 
The latter appears to be a key mechanism for determining a glucose 
response to VLCD.  
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Chapter 1. Introduction 
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1.1 Global importance of type 2 diabetes and obesity 
The increasing prevalence of type 2 diabetes is precipitating a public health 
crisis in the UK and worldwide. The disease causes considerable personal 
morbidity but also causes a significant societal burden, with just over 8% of 
the annual NHS budget being spent on the treatment of type 2 diabetes and 
its complications (NICE, 2012). In 2012 in England, 7.4% of people aged 
over 16 years had diabetes, 90% of which is type 2 diabetes, and the burden 
of unrecognised disease is also thought to be high (PHE, 2014). In the last 2 
decades type 2 diabetes has also been recognised as a disease of childhood 
and adolescence; this has important implications for future health service 
requirements (Haines et al., 2007). The increasing prevalence seems to be 
due to the increasing rates of obesity. In England in 2013, 26.0% of men and 
23.8% of women were regarded as obese (defined as a body mass index 
(BMI) of more than 30kg/m2) (HSCIC, 2015). The last 60 years in the history 
of man has been unique in terms of being the only period in human history 
where food availability for the majority has been surplus to requirements. 
This positive calorie balance has not been matched by increased energy 
expenditure, in fact technologies have inadvertently decreased physical 
activity levels. This has resulted in a shift in the BMI curve of the 
population to the right over time (Figure 1-1).  
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Figure 1-1 Change in the adult BMI distribution for England 1991-1993 
and 2008-2010. Adapted from Public Health England Health Survey Data.  
 
Obesity is a major predictor of risk of type 2 diabetes: compared to those of 
healthy weight, there is a seven times greater risk of diabetes in obese 
individuals and a threefold increased risk in those who are overweight 
(Abdullah et al., 2010). Despite this, type 2 diabetes also exists in those with a 
BMI apparently indicating healthy weight. This may in part result from the 
fact that BMI is an epidemiologically defined measurement of obesity, which 
is a relatively insensitive marker in metabolic terms, particularly in some 
racial groups. Also, it does not reflect body composition, which is an 
important determinant of the metabolic sequelae of obesity, particularly fat 
mass and distribution. It is probable that on an individual level, 
susceptibility factors determine the development of  the metabolic 
consequences of obesity; only about 50% of people with a BMI of more than 
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40kg/m2 will develop diabetes (Steven and Taylor, 2012). It has been 
hypothesised that each individual has a personal fat threshold, which if 
exceeded, makes the development of type 2 diabetes probable (Taylor and 
Holman, 2015).  
The natural history of type 2 diabetes is characterised by a progressive 
deterioration in blood glucose control despite an initial response to oral 
therapy; the failure rate of maintaining an HbA1c target of < 7% (53 
mmol/mol) is 5-10% per year (UKPDS, 1995a; UKPDS, 1995b; UKPDS, 
1998). There is also progressive weight gain, which may be partly due to the 
natural history of the disease, but is also compounded by medications, 
particularly sulphonylureas, thiazolidinediones and insulin (UKPDS, 1998; 
Kahn et al., 2006). There is now a plethora of drug therapies available to 
treat type 2 diabetes, targeting different identified pathophysiological 
defects in the condition (Nathan et al., 2009). However, all have only modest 
effects on glucose levels, and it is this parameter (specifically HbA1c) which 
has a very clear association with both the microvascular and macrovascular 
complications of type 2 diabetes (Stratton et al., 2000). In the UK, bariatric 
surgery used to be considered a treatment option for people with type 2 
diabetes and a BMI of more than 35kg/m2, but the most recent guidelines 
include individuals with a BMI of 30-34.9kg/m2 and recent onset diabetes 
(NICE, 2014 ). However, financial and resource limitations mean that this 
treatment can only be applied to a very small percentage of the eligible 
population. The importance of weight management in the treatment of type 
2 diabetes is now recognised and despite the scarcity of anti-obesity 
medications there are now multiple glucose lowering medications which can 
aid weight loss, including glucagon-like peptide-1 (GLP-1) receptor agonists, 
and sodium glucose co-transporter 2 (SGLT2) inhibitors (Wilding, 2014).  
1.2 Pathophysiology of type 2 diabetes 
Type 2 diabetes is characterised by two pathophysiologic defects: insulin 
resistance and reduced insulin secretory capacity (Ferrannini et al., 2011). 
Insulin resistance is a concept describing the phenomenon whereby normal 
concentrations of insulin produce less than the normal biological response 
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(Kahn, 1978). Insulin resistance usually precedes a diagnosis of type 2 
diabetes by many years, and although insulin resistance is the first 
detectable defect in type 2 diabetes (Petersen et al., 2012), this defect is 
insufficient on its own to cause blood glucose levels to rise (Taylor, 2012). It 
is the decline in insulin secretion that determines the onset of 
hyperglycaemia (Ferrannini et al., 2004; Festa et al., 2006). The ability to 
maintain normal glucose tolerance in these pre-diabetic states is determined 
by the ability of pancreatic beta cells to acutely increase insulin secretion in 
response to an increase in plasma glucose levels. Although fasting glucose 
levels have been shown to steadily rise for many years prior to a diagnosis of 
type 2 diabetes, there is a rapid rise in glucose levels relating to 
deteriorating beta cell function just prior to diagnosis (Sattar et al., 2007; 
Tabák et al., 2009).  
1.2.1 Fasting and postprandial metabolism in health  
Plasma glucose concentration is determined by the rate of release of 
glucose into the bloodstream and the rate of uptake of glucose by cells, both 
of which are under the control of insulin. There are 3 main target cells for 
insulin action: hepatocytes, skeletal myocytes and adipocytes. The major 
effect of insulin in the fasting state is to regulate first hepatic 
glycogenolysis and then hepatic gluconeogenesis in order to maintain a 
stable glucose level, thereby determining fasting blood glucose levels. In 
the fasting state, when insulin levels are low, there is lipolysis of 
triglycerides within adipose tissue releasing non-esterified fatty acids 
(NEFA). These NEFA are the primary source of energy through beta-
oxidation in mitochondria, the tricarboxylic acid cycle and the respiratory 
chain. 
In the fed state, metabolism switches to use glucose as the primary fuel 
source. The absorption of glucose and other substrates from the intestine 
exceeds the body’s energy requirements. The maintenance of glucose 
homeostasis depends on storage of glucose as glycogen in the muscles and 
the liver, suppression of hepatic glucose production and an increase in 
glucose oxidation; all of which are facilitated by the actions of insulin. In 
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health, hepatic glucose production is suppressed within 30 minutes of eating 
a meal (Singhal et al., 2002). Under normal physiologic conditions, insulin 
concentrations tightly control the balance between postprandial fatty acid 
storage as triglycerides and their release into plasma during the fasting 
state (Cusi, 2010). Adipose tissue is extremely sensitive to insulin induced 
suppression of lipolysis, inhibiting lipolysis at concentrations much lower 
than those required to suppress hepatic glucose production or stimulate 
glucose uptake in skeletal muscle. Thus, after eating plasma NEFA levels 
fall. 
Glucose released as a monosaccharide in the intestine enters hepatocytes 
from portal blood through glucose transporter 2 (GLUT2). Within 
hepatocytes, glucose is directed towards glycolysis and adenosine 
triphosphate (ATP) production and to replenish glycogen stores. When 
glycogen stores are full, glucose is diverted towards lipid synthesis where it 
serves as a carbon donor for de novo lipogenesis. Fatty acids are esterified as 
triglyceride associated with apolipoprotein B100 and exported as very low 
density lipoproteins (VLDL). When glucose is metabolised to produce ATP 
(through the Krebs cycle) within mitochondria, citrate is formed. Within the 
cytoplasm this inhibits carnitine palmitoyltransferase the transporter of 
long chain fatty acyl coenzyme As into the mitochondria (Cusi, 2010). 
Malonyl CoA therefore acts as the metabolic switch for insulin sensitivity 
between the fasted and fed states.  
1.2.2 Insulin resistance 
Insulin resistance is defined as the inability of insulin to produce its usual 
biological actions at any given concentration. Resistance of target organs to 
the effects of insulin explains the metabolic abnormalities seen in type 2 
diabetes. Hepatic insulin resistance results in decreased hepatic glycogen 
storage in the postprandial state and increased hepatic glucose production 
in both the fasting and the fed state. Skeletal muscle insulin resistance in 
the postprandial state results in less glucose being stored as glycogen. 
Magnetic resonance spectroscopy studies have shown fasting muscle 
glycogen levels to be almost 20% lower in those with type 2 diabetes 
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compared to age and BMI matched non-diabetic controls (Carey et al., 2003), 
and that after day-long eating there is no change in muscle glycogen levels 
in those with diabetes compared to a 17% increase in non-diabetic controls 
(Macauley et al., 2015c). Resistance of adipocytes to insulin results in 
impaired suppression of lipolysis and plasma NEFA levels are typically 
elevated. The cellular mechanisms of insulin resistance are complex. In the 
liver, the mechanism of insulin resistance appears to involve increased 
hepatic diacylglycerol levels, leading to protein kinase–CƐ activation and 
subsequent inhibition of insulin receptor tyrosine kinase activity (Perry et 
al., 2014) (Figure 1-2). 
 
Figure 1-2 Excess diacylglycerol interferes with the insulin signalling 
pathway and results in insulin resistance, which in the liver results in 
decreased glycogen synthesis and increased gluconeogenesis. PKCƐ=protein 
kinase CƐ, DAG=diacylglycerol, IRS2=insulin receptor substrate 2, 
GSK3=glycogen synthase kinase-3, GS=glycogen synthase, 
FOXO1=Forkhead box protein O1, PC=pyruvate carboxylase. Adapted from 
(Perry et al., 2014) 
1.2.3 Insulin secretion 
Insulin is synthesised as pre proinsulin and processed to proinsulin. 
Proinsulin is then converted to insulin and C-peptide and stored in secretory 
granules awaiting release on demand. Insulin synthesis is regulated at both 
the transcriptional and translational level. In vivo approximately 50% of 
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daily insulin production is released in a constant, pulsatile manner to 
achieve control of basal metabolism, with the remainder being released to 
control postprandial metabolism. The release of insulin from pancreatic beta 
cells is coupled to ATP production due to increased substrate supply, most 
notably glucose but also amino acids and fatty acids. Glucose is transported 
into beta cells via GLUT2 receptors. It is then phosphorylated to glucose-6-
phosphate with subsequent glycolysis and oxidation to produce ATP. ATP 
stimulates the closure of ATP-dependent cell membrane potassium 
channels, which depolarises the cell membrane and results in an influx of 
calcium ions. In response to this rise in intracellular calcium levels, the 
insulin containing secretory granules fuse with the cell membrane releasing 
insulin and C-peptide in equimolar amounts. The early response to a 
stimulus lasts about 10 minutes and is defined as the first phase insulin 
response when the stimulus is intravenous glucose. It is this early insulin 
response which suppresses endogenous glucose production at the start of a 
meal (Luzi and DeFronzo, 1989). Defective first phase insulin secretion is a 
characteristic feature of type 2 diabetes (Ferner et al., 1986) and 
impairments in first phase insulin secretion may serve as a marker of risk 
for type 2 diabetes (Pimenta et al., 1995). A study in a population of 
individuals with impaired glucose tolerance found that the absence of the 
peak of first phase insulin secretion was the best predictor of incident type 2 
diabetes (Nijpels et al., 2007). In contrast, the insulin response in 
established type 2 diabetes to the non-glucose secretagogue arginine is only 
mildly reduced (Anello et al., 2005). Using fasting plasma glucose and 
insulin data, beta cell function has been shown to be reduced by about 50% 
at the time of diagnosis of type 2 diabetes and it is widely believed that 
there is an inexorable decline in insulin secretion thereafter (UKPDS, 
1995a). However, a clinical scenario suggests that beta cells can recover and 
in fact can then have the capacity to hyperfunction. That is women who 
have had type 2 diabetes reversed by gastric bypass surgery, then 
subsequently maintain normal glucose tolerance during pregnancy, in the 
face of markedly increased insulin resistance (Steven et al., 2011).  
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Fatty acids are required for normal beta cell function; mice with deletion of 
the fatty acid receptor GPR40 have 50% decreased insulin secretion (Alquier 
et al., 2009). Acute exposure to fatty acids stimulates insulin secretion, 
however, it is well recognised that prolonged exposure in vitro increases 
basal insulin release but decreases glucose stimulated insulin secretion (Lee 
et al., 1994). This seems to relate to endoplasmic reticulum stress, 
mitochondrial dysfunction and initiation of apoptosis (Morgan, 2009). 
Apoptosis is likely to be mediated by chronic exposure to the metabolites of 
fatty acids, such as diacylglycerols and ceramides (Shimabukuro et al., 
1998b). Not all fatty acids are equal in their chronic action to inhibit glucose 
mediated insulin secretion. Saturated fatty acids are particularly potent, 
whereas monounsaturated fatty acids have actually been shown to have 
some protective effects upon beta cells (Diakogiannaki et al., 2007).  
Chronic exposure to glucose and fatty acids contributes to beta cell failure, 
and this is referred to as glucotoxicity and lipotoxicity respectively. 
Lipotoxicity appears to be dependent on hyperglycaemia and elevated levels 
of glucose and fatty acids have a synergistic effect on impairing beta cell 
function. The term glucolipotoxicity is therefore often used. One hypothesis 
is that in the presence of physiological glucose concentrations, excessive 
fatty acids are readily disposed of through mitochondrial β-oxidation. 
However, when both glucose and fatty acids are elevated, there is 
accumulation of metabolites derived from fatty acid esterification which 
impair beta cell function (Robertson et al., 2004). With regards to the 
mechanisms of pancreatic beta cell glucotoxicity specifically, the increased 
flux of glucose places a burden on mitochondrial oxidation, leading to the 
production of reactive oxygen species (Bensellam et al., 2012). Oxidative 
stress can suppress insulin gene expression and can activate mitochondrial 
inner membrane protein uncoupling protein 2 (UCP2) leading to decreased 
ATP production (Fu et al., 2013). The high demand for insulin secretion as a 
result of chronic hyperglycaemia places stress on the endoplasmic reticulum 
of the beta cells. Endoplasmic reticulum stress interferes with the insulin 
secretory pathway and insulin biosynthesis, mainly through excessive 
stimulation of the unfolded protein response (UPR) pathway.  
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Defects in beta cell mass as well as beta cell function contribute to the 
pathophysiology of type 2 diabetes (Marchetti et al., 2004). The interplay 
between these factors is evident when it is recognised that many patients 
undergoing pancreatic surgery can maintain normal glycaemic control after 
resection of large volumes of pancreatic tissue. At 1 year following 
hemipancreatectomy only 25% have abnormal glucose tolerance (Kendall et 
al., 1990). Studies of cadaveric pancreata have shown that beta cell mass is 
decreased by about 50% in individuals with type 2 diabetes (Butler et al., 
2003). It appears that the beta cell mass declines progressively over the 
years in type 2 diabetes (Rahier et al., 2008) and that this decline is more 
pronounced in obese individuals (Hanley et al., 2010). As beta cells turnover 
continuously during adult life, alteration of the balance of apoptosis and 
generation of new cells could restore beta cell function (Menge et al., 2008). 
This understanding of beta cell dynamics may explain the increase in beta 
cell mass seen in adult life in the context of obesity and also during the 
insulin resistance associated with pregnancy (Butler et al., 2010). Even 
more complex is the phenomenon of beta cell dedifferentiation whereby beta 
cells convert to non-beta pancreatic endocrine cell types in response to 
chronic pathophysiologic stress (Weir and Bonner-Weir, 2004; White et al., 
2013). Recent rodent work has suggested that beta cell dedifferentiation and 
reprogramming might explain the association of beta cell dysfunction and 
increased alpha cell function (and therefore hyperglucagonaemia) in early 
type 2 diabetes (Talchai et al., 2012). Reprogramming of beta cells to alpha 
cells has been seen in human ex-vivo pancreata of individuals with recently 
diagnosed type 2 diabetes (White et al., 2013).  Understanding these 
mechanisms gives hope that targeting the inhibition of beta cell apoptosis 
and dedifferentiation, and the promotion of beta cell neogenesis and 
redifferentiation may offer new treatments for type 2 diabetes in the future. 
1.2.4 Dyslipidaemia in type 2 diabetes 
Long chain fatty acids become esterified with glycerol to form triglycerides, 
the major storage form of excess energy (Frayn, 2003). NEFA are the 
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transport form of lipid energy from adipose storage sites to sites of 
utilisation and oxidation. NEFA levels turnover very rapidly and reflect the 
rate of release from adipose tissues, which in turn determines the rate of 
NEFA utilisation by other tissues. Plasma NEFA levels are increased in 
obesity and elevated NEFA levels in experimental studies using lipid 
emulsions and a heparin infusion cause acute insulin resistance and 
activation of proinflammatory pathways (Boden, 2011). However, the direct 
association between elevated NEFA concentrations and insulin resistance in 
vivo has been questioned (Karpe et al., 2011). NEFA are presented to cells 
either bound to albumin, or liberated from triglyceride in the plasma by 
lipoprotein lipase and carried as lipoproteins. Insulin resistance results in 
increased lipoprotein lipase activity in adipose tissue, thus increasing NEFA 
release. Unlike the tight regulation of glucose metabolism, the release of 
fatty acids into plasma is not regulated by substrate requirement, but 
rather by the rate of lipolysis of triglyceride stored in adipose tissue. Plasma 
NEFA are the main substrate for hepatic triglyceride production in the form 
of VLDL and NEFA turnover is a determinant of VLDL-triglyceride 
secretion and plasma triglyceride concentrations (Figure 1-3).  
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Figure 1-3 Sources of fatty acids for liver and VLDL-triglyceride. 
CM=chylomicron, DNL=de novo lipogenesis, TG=triglyceride, FA=fatty 
acids, NEFA=non-esterified fatty acids. Adapted from (Adiels et al., 2008) 
 
Plasma VLDL-triglyceride level is determined by the balance of the hepatic 
secretion of VLDL-triglyceride and its catabolism in peripheral tissues. A 
marked reduction in VLDL-triglyceride export from the liver would limit the 
delivery of fatty acids to peripheral tissues, but would be expected to result 
in accumulation of triglycerides in hepatocytes and the development of fatty 
liver. VLDL-triglyceride is synthesized and secreted by hepatocytes after a 
series of complex intracellular events involving the synthesis of 
apolipoprotein B100 (apoB100) and lipid and their assembly into lipoprotein 
particles. VLDL-triglyceride indicates the rate of lipid production, whereas 
VLDL-apoB100 indicates VLDL1 particle production. Triglyceride is the 
main lipid component of VLDL and VLDL-triglyceride can either be secreted 
from the cell as VLDL2 or can be lapidated to VLDL1, this latter process 
requiring the further addition of triglycerides. VLDL1 levels determine 
plasma triglyceride levels whereas VLDL2 levels determine LDL cholesterol 
levels. VLDL-triglyceride is hydrolysed by lipoprotein lipase at the luminal 
surface of capillaries in peripheral tissues. In healthy individuals, the 
majority of VLDL exported by the liver is in the form of small triglyceride 
poor VLDL2, whereas in conditions such as type 2 diabetes where there are 
large amounts of NEFA and triglyceride, the formation of large triglyceride 
rich VLDL1 is increased (Verges, 2010). Although each VLDL particle has 
one apoB particle it is known that there can be dissociation of VLDL apoB 
and triglyceride secretion rates resulting in VLDL particles with variable 
triglyceride to apoB ratios. Weight loss has been associated with decreased 
VLDL-triglyceride levels; following gastric bypass surgery (Klein et al., 
2006) and following 10% loss in body weight by dietary restriction in women 
with abdominal obesity (Mittendorfer et al., 2003). This is thought to relate 
to a decrease in the contribution of non-systemic fatty acids to VLDL-
triglyceride production, from the lipolysis of intrahepatic and visceral fat. 
The dyslipidaemia of type 2 diabetes is therefore characterised by high 
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serum triglycerides, low HDL cholesterol concentrations and the appearance 
of small dense low density lipoproteins (Adiels et al., 2008).  
1.3 Intra-organ fat accumulation 
1.3.1 Hepatic steatosis 
Fatty liver is physiological in migrating birds as the energy stores are 
required to overcome prolonged fasting (Capeau, 2008). However, in humans 
excess liver fat is pathological and represents the presence of triglyceride as 
lipid droplets in the cytoplasm of hepatocytes. A population study using 
localised proton magnetic resonance spectroscopy showed that a hepatic 
triglyceride content of greater than 5.56% corresponds to the 95th percentile 
in "normal" subjects (Szczepaniak et al., 2005) and above this level is 
considered to be non-alcoholic fatty liver disease (NAFLD) in the absence of 
alternative causative factors. NAFLD is now the most common cause of 
chronic liver disease in the Western world (Bedogni et al., 2005), and can 
progress to non-alcoholic steatohepatitis (NASH) and cirrhosis. Hepatic 
steatosis results from an imbalance between triglyceride synthesis and 
degradation. The primary source of fatty acids (accounting for ~60%) is from 
lipolysis of adipose tissue, which is unsuppressed in insulin resistant states 
(Cusi, 2010). De novo lipogenesis is also increased in conditions of 
hyperinsulinaemia and hyperglycaemia (Adiels et al., 2008). More than 90% 
of obese patients with type 2 diabetes have NAFLD (Tolman et al., 2007). 
The extent of portal hyperinsulinaemia determines how much fatty acid is 
produced from glucose in the liver, hence why despite hyperglycaemia, 
individuals with type 1 diabetes do not develop excess liver fat (Perseghin et 
al., 2005). Approximately 15% of the fatty acid supply comes from lipolysis 
of dietary chylomicrons (Capeau, 2008). These fatty acids can either be 
stored in the liver as triglyceride, undergo β-oxidation in mitochondria, or 
can be exported into the circulation in the form of VLDL-triglyceride (Figure 
1-3). In insulin resistant states, triglyceride is preferentially directed 
towards storage or export because the transport of fatty acid into 
mitochondria for oxidation is inhibited by malonyl Co A produced during 
lipogenesis. Therefore, positive energy balance in the context of portal 
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hyperinsulinaemia in individuals predisposed to insulin resistance results 
in the accumulation of liver fat (Figure 1-4).  
 
 
Figure 1-4 The twin cycle hypothesis on the pathogenesis of type 2 
diabetes. Reproduced with permission (Taylor, 2013). 
Hepatic steatosis correlates with the failure of insulin to suppress hepatic 
glucose production (Seppala-Lindroos et al., 2002), which is the major 
determinant of fasting blood glucose levels. The presence of hepatic steatosis 
can actually predict the development of type 2 diabetes, even when 
adjustments are made for BMI. An ultrasound study of liver fat levels in 
Japanese males showed that a steady increase in liver fat precedes a 
diagnosis of type 2 diabetes with an age adjusted hazard ratio of 4.8 
(Shibata et al., 2007). The West of Scotland Coronary Prevention Study 
demonstrated an increase in the liver enzyme alanine transaminase (ALT) 
in the 18 months prior to a diagnosis of type 2 diabetes, indicating the 
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burden of excess fat on hepatocytes (Sattar et al., 2007). There is a bi-
directional relationship between excess calorie intake and liver fat 
accumulation. Overfeeding obese individuals by 1000kcal/day for 3 weeks 
results in 2% weight gain and 27% increase in hepatic fat content 
(Sevastianova et al., 2012). During calorie restriction it appears that intra-
hepatic fat stores are mobilised rapidly, and before visceral or subcutaneous 
fat stores are affected. Within 7 days of a very low calorie diet in individuals 
with type 2 diabetes, hepatic triglyceride content decreased by 30% and 
simultaneously the suppression of hepatic glucose production by insulin 
infusion improved from 43% at baseline to 74% (Lim et al., 2011). As well as 
caloric restriction (Petersen et al., 2005), increased physical activity 
(Cassidy et al., 2016) and PPAR-γ agonists (Ravikumar et al., 2008) can 
reduce liver fat content in individuals with type 2 diabetes. 
Although the relationship between hepatic steatosis, metabolic syndrome 
and type 2 diabetes is strong, there is considerable interindividual variation. 
Data arising from genome-wide association studies identified that a single 
nucleotide polymorphism in the the adiponutrin (PNPLA3) gene rs738409G 
was associated with NAFLD and plasma levels of liver enzymes. The G 
allele in the PNPLA3 gene results in a missense mutation I148M that 
renders the protein incapable of triglyceride hydrolysis (He et al., 2010). 
This gene mutation has been postulated as an  explanation for the 
dissociation of liver fat and insulin sensitivity in some individuals (Romeo et 
al., 2008; Speliotes et al., 2010). The minor allele frequency of the 148M 
allele is approximately 0.26 in Caucasian populations (Petit et al., 2010). 
Despite increased liver fat content in individuals with the mutation, there 
was no relationship between liver fat content and visceral adiposity, BMI or 
insulin resistance (Kantartzis et al., 2009). It is hypothesised that 
sequestration of diacylglycerols and other fat metabolites as inert 
triglyceride may prevent inhibitory effects on insulin sensitivity in the liver 
in individuals with this mutation.  
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1.3.2 Pancreatic steatosis 
The relevance of excess pancreatic lipid accumulation in the pathogenesis of 
type 2 diabetes in humans is controversial, but a role for excess pancreatic 
fat in causing the islet cell dysfunction has been postulated (Lee et al., 1994; 
Taylor, 2008) (Figure 1-4). Human autopsy studies have reported a 
relationship between pancreatic fat content and BMI but not diabetes status 
(Clark et al., 1988; Saisho et al., 2007) . However, these post-mortem studies 
are limited by the scarcity of pancreatic biopsies, and the fact that 
pancreatic tissue undergoes autolysis by lipases with some fat being 
removed during histological processing. Imaging modalities used to measure 
pancreas fat content in vivo also have limitations; magnetic resonance 
spectroscopy studies are imprecise due to movement of the organ during the 
respiratory cycle and hence inadvertent inclusion of surrounding visceral fat 
in measurements. Finally, determining whether the fat is present within 
beta cells, acinar cells or intra-pancreatic adipocytes is a challenge. Current 
imaging techniques are unable to differentiate beta cells, which constitute 
only 1-2% of pancreatic mass, from non-insulin secreting parenchymal cells. 
Measurement of whole organ pancreas fat content represents parenchymal 
intracellular fat accumulation, including the accumulation of fat in islet and 
acinar cells.  
Despite these caveats, Magnetic Resonance Spectroscopy (MRS) studies in 
obese rodents have shown an increase in pancreatic triglyceride 
accumulation prior to the onset of type 2 diabetes (Lee et al., 2009). Imaging 
studies in humans have suggested increased pancreatic fat content in those 
with type 2 diabetes compared to normal glucose tolerance (Tushuizen et al., 
2007; Lim et al., 2011). Studies looking at the potential relationship between 
pancreatic fat levels and insulin secretion have yielded conflicting results; a 
negative association between pancreatic fat and insulin secretion in some 
(Tushuizen et al., 2007; Heni et al., 2010; Szczepaniak et al., 2012) and only 
a relationship with BMI not beta cell function in others (Saisho et al., 2007; 
van der Zijl et al., 2011) and another with age alone (Begovatz et al., 2015). 
However, interpretation of results and comparisons between studies have 
been complicated by the fact that heterogeneous populations have been 
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studied, with inclusion of some individuals with impaired glucose tolerance 
and impaired fasting glycaemia meaning that some individuals will actually 
have increased insulin secretion compared to those with normal glucose 
tolerance. These studies have also used a variety of imaging modalities (1H-
MRS, MRI and computed tomography (CT)). In one study the poor 
coefficient of variation (14%) for pancreas fat is likely to relate to the use of 
MRS and inclusion of visceral fat due to respiratory motion during the long 
image acquisition time, resulting in insufficient specificity to detect 
differences between subject groups (van der Zijl et al., 2011).  
In vitro studies have established that beta cells avidly import fatty acids 
through CD36 transporters (Noushmehr et al., 2005; Lalloyer et al., 2006) 
and that these can be stored as intra-cellular triglyceride (Diakogiannaki et 
al., 2007). Sustained exposure to elevated NEFA (a mixture of palmitate 
and oleate representative of the in vivo plasma composition of NEFA) 
concentrations has been demonstrated to result in increased triglyceride 
content in human islets and decreased glucose stimulated insulin secretion 
(Dubois et al., 2004). Mice given a high fat diet rapidly accumulate 
adipocytes between pancreatic exocrine cells and close to islet cells (Pinnick 
et al., 2008). In human post-mortem tissue, the degree of adipocyte 
infiltration in the pancreas is correlated with triglyceride content, 
confirming that there is storage of triglyceride in adipocytes within the 
pancreas (Pinnick et al., 2008). During lipolysis of adipocyte triglyceride, 
fatty acids released into the extracellular space would be likely to surround 
the islets at high concentrations which may influence insulin secretion. In 
addition, there may be paracrine effects of adipocyte products, such as 
adipocytokines and leptin, which may influence islet cell function. 
1.3.3 Use of the 3 point Dixon method to measure intra-organ fat 
Principles of Magnetic Resonance (MR) imaging 
Within a strong magnetic field, atomic nuclei align themselves and produce 
a measurable magnetic moment or spin. Also, spinning nuclei precess at a 
characteristic frequency that is proportional to the strength of the external 
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field. Because of the abundance of hydrogen nuclei compared to other nuclei 
in most tissues, the proton signal from hydrogen is used in clinical magnetic 
resonance scanning. Applying radiofrequency energy alters the fraction of 
protons aligned with the magnetic field. When this radiofrequency is 
removed, the protons release the energy they absorbed. This energy is 
released in the form of an oscillating magnetic field detected as an electric 
current in the receiver coil. The density of protons as well as the rate at 
which magnetisation returns to baseline can be measured by the 
radiofrequency signal emitted by the protons as they relax.  
The advantage of using magnetic resonance imaging over CT or positron 
emission tomography (PET) for clinical studies include that it is non-
invasive and there is no exposure to ionising radiation. This allows multiple 
scans to be performed in the same individual over time. The disadvantages 
include the fact that MR scanning is contraindicated in individuals with 
certain implantable metals. Also, as most scanners are enclosed 
claustrophobia can limit tolerability, particularly in obese individuals. In 
this latter group other technical challenges arise, such as increased noise 
resulting in reduced signal to noise ratio, longer scan times due to the larger 
cross-sectional area and this scan time can be detrimental in terms of image 
quality due to movement artefact, particularly in relation to respiratory 
motion (Uppot et al., 2007).  
The 3 point Dixon method  
The power of magnetic resonance is based on small differences in the 
microenvironment of different tissues, which allow different molecules with 
the same nucleus to be differentiated. The resonant frequency of a nucleus 
is modified by the surrounding electrons, called chemical shielding. The fact 
that lipid protons and water protons have different resonant frequencies 
(water slightly faster than fat) is termed chemical shift. The chemical shift 
difference between fat and water is about 3.4ppm: at 3 Tesla this translates 
into a frequency difference of 435Hz. When a radiofrequency pulse is 
applied, the fat and water signals are in-phase (additive signals) but then 
they move out-of-phase (reduced signal as the fat signal subtracts from the 
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water signal) after 1.15ms (=1/(2x435Hz)). Using a subtraction technique fat 
and water only images can be produced from two images with in and out of 
phase echo times on a pixel wise basis (Dixon, 1984). The 3 point Dixon 
technique refers to the correction applied using a third image to correct 
magnet inhomogeneity, that is the fact that a magnetic field is never 
perfectly uniform (Glover and Schneider, 1991). This is because within the 
body, tissues are affected by neighbouring structures of dissimilar magnetic 
susceptibility such as the boundaries between soft tissue and air pockets 
and bone, for example. For measurement of organs which move during the 
respiratory cycle such as the pancreas, the 3 point Dixon method has 
advantages over magnetic resonance spectroscopy. Because of the fast 
acquisition time, images can be acquired during long breath holds, to try to 
prevent any inclusion of surrounding visceral fat in calculations. Also, all of 
the data processing can occur after image acquisition. Therefore 
quantitation of whole pancreas fat content can be performed by manually 
drawing regions of interest in an anatomically defined area within the scan 
slice, rather than analysis of pre-selected volumes in space such as in MR 
spectroscopy (Figure 1-5). The three point Dixon technique has been shown 
to have an inter-scan repeatability co-efficient of 0.5% for the liver and 0.9% 
for the pancreas (Lim et al., 2011). 
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Figure 1-5 Three point Dixon MR method, showing the anatomical image  
and separated fat and water Dixon images, then the derived fat percentage 
image on which regions of interest (shown in dotted white) are drawn to 
measure hepatic and pancreatic triglyceride content.  
 
1.4 Reversal of type 2 diabetes following bariatric surgery 
The first recognition that type 2 diabetes is a reversible condition came from 
observations from bariatric surgery; the Greenville gastric bypass could 
correct glucose metabolism in those with type 2 diabetes (Pories et al., 
1992). Initially it was assumed that the mechanism was through achieving 
significant weight loss, however, two observations suggest that this is not 
the case. Firstly, there is disparity between the resolution rates of obesity 
and diabetes following surgery; the metabolic benefits occur despite many 
patients remaining obese post-operatively. Secondly, the timeframe of 
reversal of diabetes differs from that of weight loss. In a group of superobese 
women undergoing biliopancreatic diversion, it was found that within one 
week of surgery and prior to any significant weight loss, there was 
   
 21 
normalisation of blood glucose levels (Guidone et al., 2006). This 
observation, that glycaemic control occurs prior to any significant weight 
loss associated improvement in insulin sensitivity, prompted further 
investigation into the pathophysiological mechanisms behind the reversal of 
type 2 diabetes after bariatric surgery. The direct association between 
weight loss and improved insulin sensitivity is clear, but the mechanism of 
the early improvement in glucose metabolism requires explanation.  
The effect of the surgery on foregut anatomy and nutrient absorption is an 
important consideration (Figure 1-6): in laparoscopic Roux-en-Y gastric 
bypass surgery (RYGB) the majority of the stomach is stapled off to leave a 
30-50ml gastric pouch. A Roux limb of jejunum measuring 50-70cm is then 
anastomosed to the gastric pouch, with the biliopancreatic limb (100-150cm) 
being re-attached by jejuno-jejunostomy. This results in more rapid delivery 
of nutrients directly to the jejunum following surgery, as demonstrated by 
studies of paracetamol (Falkén et al., 2011) and xylose absorption (Salehi et 
al., 2011). 
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Figure 1-6 Representation of the altered foregut anatomy in a Roux-en-Y 
gastric bypass.  
 
The incretin effect is the increased stimulation of insulin secretion elicited 
by oral compared to intravenous administration of glucose under similar 
plasma glucose levels. This effect is known to be diminished in type 2 
diabetes (Vilsbøll et al., 2001) and secretion of these incretin hormones, 
particularly glucagon-like peptide-1 (GLP-1) and glucose-dependent 
insulinotropic polypeptide (GIP) is markedly altered following manipulation 
of the gut during gastric bypass surgery (Dirksen et al., 2012). The incretin 
hormones have been postulated as key mediators of the beneficial effects of 
gastric bypass surgery on glucose metabolism (Holst and Gromada, 2004). 
GLP-1 exerts glucoregulatory actions by enhancing insulin secretion in 
response to oral glucose stimulation, delaying gastric emptying and 
inhibiting glucagon secretion. 
Gastric pouch 
Roux limb  
Biliopancreatic limb  
Jejuno-jejunostomy 
Gastro-jejunostomy 
Gastric remnant   
Common channel 
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However, various observations suggest that alterations in secretion of these 
secondary glucoregulatory hormones are insufficient to explain the marked 
changes in glucose metabolism seen after surgery. The increase in 
postprandial GLP-1 secretion which occurs without change in fasting GLP-1 
secretion cannot explain the marked changes in fasting physiology (Yousseif 
et al., 2014). In clinical diabetology, GLP-1 receptor agonists can achieve 
supraphysiological circulating levels of hormone with only a modest effect 
on glycaemic control (DeFronzo et al., 2005). Finally, studies using Exendin 
9-39 to specifically antagonise the GLP-1 receptor, have demonstrated a 
blunted maximal insulin secretion rate in response to a meal. However it is 
important to note that this did not negate the beneficial effect of gastric 
bypass surgery on the insulin secretion profile (Salehi et al., 2011; Jimenez 
et al., 2013). 
The major change after bariatric surgery is obligate caloric restriction. The 
effect of different surgical procedures on fasting glucose levels appears to 
correlate with the degree of caloric restriction imposed. A systematic review 
suggested resolution rates of type 2 diabetes of 95.1% for biliopancreatic 
diversion, 80.3% for gastric bypass, 79.7% for gastroplasty and 56.7% for 
laparoscopic adjustable gastric band (Buchwald et al., 2004). Numerous 
studies have tried to directly compare the effects on metabolism of RYGB 
and dietary caloric restriction with the majority demonstrating no difference 
(Jackness et al., 2013; Lingvay et al., 2013; Lips et al., 2014). Other studies 
have been inconclusive due to differences between groups in achieved 
weight loss (Isbell et al., 2010), calorie intake (Laferrere et al., 2008) or 
glucose status (Hofso et al., 2011). Some of these studies have used a non-
representative stimulus for investigating insulin secretion, typically an oral 
glucose tolerance test, which does not reflect the semi-solid high protein diet 
recommended to individuals after bariatric surgery.   
Despite the lack of full understanding regarding the mechanisms 
determining reversal of type 2 diabetes following bariatric surgery, the 
superiority over intensive medical therapy in achieving glycaemic control in 
type 2 diabetes is clear. In a randomised clinical trial the primary outcome 
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of achieving HbA1c <6% (42 mmol/mol) at 12 months post-operatively was 
achieved in 12% of the medical group and 42% of the gastric bypass group 
(Schauer et al., 2012). In the UK gastric bypass surgery is currently the 
most commonly performed procedure (NBSR, 2014). Given the fact that the 
population fulfilling eligibility criteria for bariatric surgery in the UK far 
exceeds capacity from a resource and financial point of view, establishing 
the individuals most likely to benefit from surgery and thereby 
understanding the limitations to complete reversal of type 2 diabetes will be 
crucial.  
1.5 Reversal of type 2 diabetes using calorie restriction 
The first insight into the importance of calorie restriction in the early 
metabolic changes following gastric bypass surgery was actually made in 
one of the original series on the Greenville gastric bypass. An individual 
with type 2 diabetes underwent a ‘sham’ procedure: the procedure had to be 
abandoned due to excess stomach contents at the time of surgery (Pories et 
al., 1995). This individual followed the same post-operative diet as those 
who had undergone successful gastric bypass, and experienced a similar 
rapid reduction in plasma glucose levels as post-surgery individuals. In fact, 
the effect of famine on resolution of glycosuria has been described as far 
back as the 19th century (Bouchardat, 1875). Using a 40 day period of 
330kcal/day dieting in obese individuals with type 2 diabetes, Henry et al. 
demonstrated that although weight reduced gradually over the study period, 
the majority (87%) of the reduction in mean fasting plasma glucose levels 
occurred during the first 10 days of dieting (Henry et al., 1985). The rapid 
improvement in glucose levels during a VLCD prior to significant weight 
loss is a consistent finding (Anderson et al., 2003). A study using a 1200kcal 
diet found that after an average of 7 weeks of dieting and 8kg weight loss, 
fasting plasma glucose dropped significantly, whole body insulin sensitivity 
increased approximately 2 fold and there was a marked increase in the 
suppression of hepatic glucose production associated with an 81% reduction 
in hepatic triglyceride content (Petersen et al., 2005). Using a VLCD 
alongside gold standard tests of beta cell function, a more recent study gave 
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further insight into the mechanisms determining reversal of type 2 diabetes. 
After 7 days of VLCD in individuals with short duration type 2 diabetes, 
fasting plasma glucose levels had normalised, hepatic insulin sensitivity 
had normalised and hepatic triglyceride content decreased by 30% (Lim et 
al., 2011). More gradually, and by the end of the 8 week VLCD first phase 
insulin secretion had increased to become indistinguishable from that of age 
and weight matched glucose tolerant controls. Alongside this, pancreatic 
triglyceride levels had decreased from 8.0±1.6% to 6.2±1.1%, with weight-
matched glucose tolerant control levels being 6.0±1.3%. The normalisation of 
first phase insulin secretion was novel and has been influential in terms of 
understanding the pathophysiology of type 2 diabetes but also in guiding 
clinical management. Following publication of that study there was intense 
interest from people with diabetes and health care practitioners (Steven et 
al., 2013). Previous studies of VLCD have suggested that weight recidivism 
is the norm once calorie restriction is lifted (Paisey et al., 2002). Important 
clinical questions were therefore raised, questioning the durability of the 
reversal of the pathophysiological defects after return to normal eating after 
the VLCD, and the applicability of the findings to the wider type 2 diabetes 
population.   
1.6 Limitations to reversal of type 2 diabetes  
The extent of the improvement in glucose control following bariatric surgery 
in individuals with type 2 diabetes is thought to be influenced by the degree 
of achieved weight loss, subsequent weight regain, duration of diabetes,  
pre-surgery anti-diabetic therapy requirements, and the choice of bariatric 
procedure (Dixon et al., 2011). In addition, poorer pre-operative diabetes 
control, indicated by an elevated HbA1c (Schauer, 2003) or the need for  
insulin therapy (Arterburn et al., 2013), is associated with lower post-
operative diabetes remission rates. It has been suggested that having had 
type 2 diabetes for more than 10 years is associated with less weight loss 
after surgery, less improvement in diabetes control and a lower likelihood of 
diabetes resolution (Renard, 2009). A prospective study on reversibility of 
type 2 diabetes following RYGB showed remission of diabetes, defined as 
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achieving an HbA1c <6.5% (48 mmol/mol) off anti-diabetic medication, was 
seen in 71% if diabetes duration was less than 8 years but only 44% when 
diabetes duration was more than 8 years (Hall et al., 2010). Another group 
investigated obese subjects with and without type 2 diabetes before and 
then at 45 days and 1 year following RYGB (Nannipieri et al., 2011). It was 
found that insulin sensitivity improved in proportion with post-operative 
decrease in BMI whereas beta cell glucose sensitivity improved early then 
levelled off with plasma glucose levels. In that study beta cell sensitivity to 
glucose was the only predictor of remission of diabetes. This information 
concurs with the fact that in individuals who do not achieve diabetes 
reversal following surgery, glucose levels gradually improve over time in 
parallel with weight loss (Kashyap et al., 2011). One hypothesis is that the 
probability of diabetes reversal following bariatric surgery depends on the 
potential for recovery of beta cell function. In contrast, the improvement in 
glucose control post-operatively is determined by the increase in insulin 
sensitivity and therefore the degree of weight loss achieved.  
The influence of diabetes duration on the effect of calorie restriction on 
glycaemic control has also been investigated using a minimum of 4 weeks of 
500kcal/day dieting in individuals with type 2 diabetes of recent onset or 
longer duration (Nagulesparan et al., 1981). Initial mean fasting plasma 
glucose was 14.4mmol/l if type 2 diabetes was of recent onset (≤2 years) and 
14.8mmol/l if of long duration (≥6 years). After the diet period this decreased 
to 6.6mmol/l and 9.7mmol/l respectively. However, there was considerable 
heterogeneity in the long duration group; particularly with regards BMI, 
which ranged from 25.4–56.9kg/m2 with 50% of individuals having a BMI of 
25-30kg/m2. Whether diabetes duration is of importance per se or whether it 
is a surrogate marker for beta cell function is unclear. Two small studies 
have looked at insulin secretion alone in long-standing type 2 diabetes, one 
using C-peptide response to glucagon (Zangeneh et al., 2006) and the other 
C-peptide measurements during oral glucose tolerance testing following 
calorie restriction (Jain et al., 2008). Both concluded that although a decline 
in beta cell function over time is characteristic, it is not inevitable and there 
was much inter-individual variation.  
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1.7 Aims of the studies 
The aims of this thesis are to understand the mechanisms determining the 
improvement in glycaemic control in type 2 diabetes and the limitations to 
complete reversal, through studies using the interventions of gastric bypass 
surgery and very low calorie diet. A specific aim is to understand the 
pathophysiologic processes in the liver and pancreas and the potential 
connection with excess hepatic and pancreatic triglyceride accumulation as 
measured using the non-invasive 3 point Dixon MR technique. The study 
described in Chapter 3 looks at diabetes duration as a potential limiting 
factor in the reversal of type 2 diabetes following bariatric surgery and the 
possible interaction between achieved weight loss and diabetes duration. 
The literature previously discussed challenges the widely held belief that 
type 2 diabetes is an inevitably progressive disease, and laboratory data on 
beta cell replication, neogenesis and redifferentiation gives theoretical 
reasons to believe that reversal of diabetes could be possible at any stage of 
the disease. I postulated that achieving significant weight loss and relieving 
the burden of excess fat on the liver and pancreas might be more important 
than duration of diabetes in terms of achieving remission of diabetes. The 
second study, described in Chapters 4 and 5, relates to the mechanisms 
determining reversal of type 2 diabetes following gastric bypass surgery. In 
Chapter 4, comparison of the effects of bariatric surgery on hepatic and 
pancreatic triglyceride content and metabolic function in individuals with 
type 2 diabetes and those with normal glucose tolerance aims to investigate 
disease specific effects as opposed to consequences of significant weight loss 
alone. In chapter 5 the role of calorie restriction in the early improvement in 
glucose metabolism following gastric bypass surgery is investigated by 
direct comparison of metabolic effects at day 7 after RYGB or VLCD. The 
third study, described in Chapters 6 and 7 was designed to investigate the 
limits of reversibility of type 2 diabetes using an 8 week VLCD and the 
durability of the effect of the VLCD on glucose metabolism after return to 
normal eating. In Chapter 6, the pathophysiological differences between 
short and long duration diabetes and the reversibility of each using an 8 
week VLCD are described. Chapter 7 describes the pathophysiological 
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mechanisms which determine diabetes reversal and what characterises 
those who achieve normalisation of glucose levels following a VLCD 
compared to those who do not. Finally, the durability of the beneficial effects 
of a VLCD after a 6 month period of weight maintenance is described. 
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Chapter 2. Methods 
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2.1 Research participants 
2.1.1 Recruitment 
Participants with an established diagnosis of type 2 diabetes were recruited. 
Detailed history taking was used to clinically exclude individuals with 
alternate diagnoses to type 2 diabetes, such as slow onset type 1 diabetes or 
maturity onset diabetes of the young (MODY). Diabetes duration was 
verified from general practitioner records. Individuals were excluded if they 
had a contraindication to MR scanning, untreated thyroid disease, evidence 
of renal dysfunction (defined as serum creatinine >150µmol/l), if they 
consumed more than 3 units of alcohol per day for women or more than 4 
units per day for men, or if they were taking steroids or atypical anti-
psychotic medication. Participants were recruited from advertisement 
displayed in local hospitals, university, council buildings and retinopathy 
screening clinics. Those who responded to the advert were sent a full 
participant information sheet detailing the purpose, nature and potential 
risks of the study. The potential participant was then invited for a screening 
visit at the Magnetic Resonance Centre. 
Participants with no known personal history or family history (in a first 
degree relative) of type 2 diabetes and with no contra-indication to the study 
were also recruited following confirmation of normal glucose tolerance using 
a standard oral glucose tolerance test.  
For all clinical studies, ethical permission was obtained from the Newcastle 
and North Tyneside Local Research Ethics Committee. All studies were 
explained in detail, through written and verbal explanation, to participants 
who expressed an interest in taking part and all queries were answered. 
Written informed consent was obtained from all participants recruited in 
the studies. After completion of the studies, all participants received 
feedback on personal and overall results.  
2.1.2 Anthropometric measurements 
Body weight was measured to the nearest 0.1kg (wearing indoor clothing 
only after removal of footwear) using a calibrated upright pedestal digital 
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scale (Seca Ltd., Birmingham, UK). Height was measured to the nearest 
0.5cm using a stadiometer (Seca Ltd., Birmingham, UK). Body mass index 
was determined from weight and height measurements [BMI = weight (kg)/ 
height2 (m)].  
Waist and hip circumferences were measured to allow calculation of 
waist:hip ratio. A standard non-distensible tape measure was used for all 
measurements, which were taken with the participants standing and in a 
relaxed posture. The waist was taken as the half way point between the 
anterior superior iliac spine and the lower edge of the rib-cage. Hip 
measurements were taken from the level of the participant’s greater 
trochanter. 
2.1.3 Body composition 
Body composition was determined after an overnight fast by measuring 
whole body impedence using a Bodystat1500 (Bodystat Ltd, Isle of Man, 
UK). Bioelectrical impedence analysis is an indirect measurement of total 
body water volume made by measuring the body resistance to a 
sensationless excitatory current of 500µ root mean square at 50kHz. This is 
calculated from the equation: total body water = specific resistivity of the 
body fluid (ohm-cm) x (height2)/measured impedence (ohm). Four electrodes 
are attached: two placed on the participant’s right hand and two on the 
right foot. This information, along with gender, age, activity level, weight 
and height, are used to calculate body composition.  
2.1.4 Energy balance  
Indirect calorimetry 
Whole body oxygen uptake (VO2) and carbon dioxide production (VCO2) 
were measured using an open circuit calorimeter (Quark RMR; COSMED, 
Rome, Italy) and a canopy hood. The canopy dilution technique is used to 
extract expired gases. A clear plastic canopy is placed over the participant’s 
head and air is drawn through the canopy at a variable but continuously 
monitored flow rate. Carbon dioxide is measured by a non-dispersive 
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infrared sensor and oxygen by a paramagnetic sensor. The precision of the 
Quark monitor used in this study has previously shown to have a 
repeatability coefficient of variation of 1.2% on an ethanol burning test 
(Blond et al., 2011).  
Prior to each study and after a 15 minute warm-up period, the gas analysers 
were calibrated using a certified calibration gas (O2 16% and CO2 5%) to 
ensure precise measurement. Calibration of the digital turbine flowmeter 
was performed using a 3 L calibration syringe. Software uses the Weir 
equation to assess energy expenditure at rest (Weir, 1949).  
Following an overnight fast and avoidance of physical activity, caffeine, 
nicotine and any other stimulants, participants were asked to lie supine on 
a bed and relax (but not sleep) without speaking for 20 minutes. The 
purpose of the test was fully explained to maximise cooperation. The first 5 
minutes were considered the acclimatisation period and excluded from 
analysis.  
Measurements of physical activity 
Physical activity levels were measured objectively using a validated multi-
sensor array (SenseWear Pro3; BodyMedia Inc., Pittsburgh, USA). This 3-
axis accelerometer incorporates a heat flux sensor, galvanic skin response 
sensor, skin temperature sensor, and a near-body ambient temperature 
sensor. Participants were asked to wear this for 5 days, including at least 
one weekend day, removing the armband only for bathing. Participants 
were asked not to change their daily routine while wearing the armband 
and received no feedback from the monitor during use. Data were analysed 
using the InnerView Professional software which contains activity 
detection and lifestyle algorithms to apply appropriate formula to estimate 
energy expenditure from the sensor data as well as gender, age, weight, 
height, smoking status and hand dominance. Parameters reported include 
total energy expenditure, active energy expenditure, resting energy 
expenditure, metabolic equivalent of task (MET), total number of steps, 
sedentary time and physical activity duration (in METs): light (1.5-3.0); 
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moderate (3.0-5.9); vigorous (6.0-9.0); and very vigorous (>9.0). The 
Sensewear armband has been validated for the calculation of energy 
expenditure and quantification of metabolic physical activity on free-living 
individuals (Fruin and Rankin, 2004) and results show reasonable 
concordance with measurement of energy expenditure by doubly labelled 
water (St-Onge et al., 2007).  
Subjective reports of physical activity levels were determined using the 
International Physical Activity Questionnaire (IPAQ) (International 
Physical Activity Questionnaire; Hagströmer et al., 2006). This 
questionnaire asks participants to recall physical activity levels over the 
preceding 7 days encompassing the following domains: job-related physical 
activity, transportation, housework and recreation/leisure time. Participants 
were instructed on how to complete the different sections of the 
questionnaire and were allowed as much time as required to complete it. 
Comparison with accelerometry data has found the long form of the IPAQ to 
have acceptable validity when assessing levels and patterns of physical 
activity in healthy adults (Hagströmer et al., 2006) and reasonable 
consistency across different populations (Craig et al., 2003). 
Calorie intake 
Self-report food diaries were collected; participants were asked to record all 
the food and beverages consumed during 3 consecutive days. This method 
has the advantage over 24hr recall food questionnaires of not relying on 
memory, however, the limitations of food diaries include uncertainty of 
portion size, completeness of diary and whether the 3 day period is 
representative of habitual diet. This method was selected as a compromise 
between precision, researcher burden (time for coding/analysis of diaries) 
and participant compliance. An in-house custom built database using the 
McCance and Widdowson food composition tables was used to analyse data 
(Dr E Foster) (FSA, 2002).  
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2.2 Magnetic resonance imaging  
Magnetic resonance data were acquired using a 3 Tesla Philips Achieva 
scanner (Philips, Best, The Netherlands) with a 6 channel cardiac array 
(Philips) used for imaging by preference, or four large surface coils (large 
and medium, Philips) if required due to body habitus. 
2.2.1 Three point Dixon magnetic resonance imaging 
Three gradient echo scans were acquired with adjacent out-of-phase, in-
phase and out-of-phase echoes. For human studies, the fat-water frequency 
difference at 3 Tesla is 435 Hz, and echo times of 3.45 ms, 4.60 ms and 5.75 
ms were used to acquire adjacent out-of-phase, in-phase and out-of-phase 
images respectively. A repetition time (TR) of 50ms was used with a flip 
angle of 5 degrees for the liver, and 9 degrees for the pancreas.  A breath 
hold time of less than 17 seconds was used to acquire 6 slices to cover the 
liver with slice thickness 10mm and of the pancreas with slice thickness of 
5mm. Participant cooperation was maximised by careful explanation from 
research radiographers. The real and imaginary data (not magnitude 
corrected data) were then uploaded to a custom MATLAB (Mathworks, 
Cambridge, UK) script, following an algorithm to produce separate fat and 
water images (Glover and Schneider, 1991). The fat content of the image 
was then expressed as a percentage of the original signal, composed of both 
the water and fat signals (Figure 2-1). The fat percentage in the visible MR 
signal is referred to as the “fat content”. Region-of-interest (ROI) definition 
was performed using the polygon ROI tool in ImageJ 1.43 software which is 
freely available from NIH (Abramoff et al., 2004).  
a) b) c) 
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Figure 2-1 3 point Dixon technique to measure liver and pancreas fat 
content: (a) fat image, (b) water image, and (c) fat percentage image. 
2.2.2 Hepatic and pancreatic triglyceride 
The anatomical positions of the liver and pancreas were first ascertained by 
axial sections using a single shot balanced turbo-field echo (BTFE) sequence 
(TR = 2.8 ms, TE = 1.4 ms, number of averages = 1, flip angle = 40°, matrix 
of 172 x 192, median field of view (liver) = 420 mm; range 400-450 mm, 
median field of view (pancreas) = 400 mm; range 380-450 mm to suit 
participant size with 70% phase field of view, turbo factor 101, 18 slices, 
slice thickness 5mm and scan duration 6 s. A parallel acceleration factor of 
two was used in the phase direction. After completion of the automated 
reconstruction of the three-point Dixon images, the images were then 
independently analysed. The signal intensity in the images was calculated 
with investigator-defined regions of interest (ROI) using ImageJ (Abramoff 
et al., 2004). A total of five ROIs for the liver and two ROIs for the pancreas 
(on consecutive slices) were acquired and averaged. These ROIs were chosen 
to reflect as closely as possible the same anatomical area across each 
consecutive scan for each individual. ROI placement in the liver was 
carefully performed to avoid contamination from blood vessels, gallbladder, 
falciform ligament and visceral fat. A smaller number of ROIs were used in 
pancreas analysis given the smaller volume of this organ and its lobulated 
structure, and care was taken to place ROI in pancreatic parenchyma rather 
than encroaching adipose tissue. The analysis was performed by a single 
trained investigator (myself). Pancreas image analysis was performed blind 
to both participant identity and visit number. Validation of the three point 
a                                        b                                         c   
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Dixon technique for measuring liver and pancreas fat content by this 
method has been established previously and the inter-scan Bland-Altman 
repeatability coefficients were 0.5% for the liver and 0.9% for the pancreas 
(Lim et al., 2011). The Bland-Altman repeatability for intra-observer 
pancreatic triglyceride analysis in these studies is shown in  
Figure 2-2. To assess the reproducibility of this process, 20% of the pancreas 
scans were independently analysed by another trained investigator (Dr K 
Percival). The Bland-Altman repeatability for inter-observer pancreatic 
triglyceride analysis is shown in Figure 2-3.  
 
Figure 2-2 Bland-Altman plot for intra-observer difference in pancreatic 
triglyceride analysis. Bias is shown as solid line and 95% confidence 
intervals as dotted lines. 
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Figure 2-3 Bland-Altman plot for inter-observer difference in pancreatic 
triglyceride analysis. Bias is shown as solid line and 95% confidence 
intervals as dotted lines.  
2.2.3 Subcutaneous and visceral adipose tissue areas  
Subcutaneous and visceral fat measurements were made by acquiring 
images at the L2/L3 level using a three point Dixon sequence (TR=50 ms, 
TE=3.45/4.60/5.75 ms, number of averages = 1, flip angle = 30° matrix of 160 
x 109, median field of view = 460 mm; range 400-520 mm. Single-slice 
visceral adipose tissue (VAT) areas at 5–10 cm above L4/L5 (approximately 
L2/L3) have been shown in overweight individuals to have a higher 
correlation with VAT volume than does the VAT area at the traditional 
L4/L5 location (Abate et al., 1997; Shen et al., 2004). Also, for participant 
comfort this level is less likely to require repositioning within the scanner 
following the liver/pancreas scans than the L4/L5 level to achieve adequate 
signal. The slice was acquired during a breath hold of 17s and had a slice 
thickness of 10mm. Fat and water were separated, and using ImageJ 
(Abramoff et al., 2004), binary gating was applied to produce a map of 
structures containing more than 50% fat ( 
Figure 2-4). A watershed algorithm was applied to divide the image into 
distinct areas allowing easy identification of subcutaneous and visceral 
compartments. The subcutaneous adipose tissue (SAT) compartment was 
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segmented and measured, and this area was subtracted from the total 
adipose tissue area to give the visceral adipose tissue area. However, in 
cases where the field of view was insufficient to include the entire SAT area, 
a T1 image at the L2/L3 level was used to measure total fat area. A region of 
interest was then manually drawn to measure intra-abdominal fat volume 
and the difference between the total fat area and the intra-abdominal fat 
area was taken to represent SAT area. VAT area in these individuals was 
measured using the three-point Dixon method and watershed algorithm as 
described above. 
 
Figure 2-4 Quantifying subcutaneous and visceral fat: a) Dixon image at 
L2/L3 level, b) binary threshold applied to show structures containing >50% 
fat and total fat area in image measured, c) watershed algorithm applied to 
allow selection and measurement of subcutaneous fat area. Visceral fat area 
is then calculated from total fat area – subcutaneous fat area.  
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2.3 Metabolic studies 
All metabolic studies were performed after an overnight fast. Metformin and 
sulphonylureas were discontinued for 72 hours before the study and DPP-4 
inhibitors for 2 weeks. No rapid-acting insulin was administered within 12 
hours of studies and long-acting insulin was withheld for 36 hours. 
Participants were asked to avoid unusual physical activity, alcohol or 
nicotine for 24 hours prior to the studies.  
2.3.1 Blood sampling 
Venous cannulation for arterialised blood sampling was performed by the 
insertion of an 18-gauge cannula (BD Venflon IV catheter, Oxford, UK) into 
a distal vein of the participants’ dominant arm. The venous blood was 
‘arterialised’ by placing the hand between microwaveable heat packs which 
were regularly reheated to ensure continuous vasodilatation. The 
intravenous line was flushed with 0.9% sodium chloride after taking each 
sample to keep the line patent. Dilution of samples was avoided by 
discarding the initial dead space line volume of blood withdrawn, and by 
using a fresh syringe for each sample. A second cannula was inserted into a 
large antecubital vein in the contralateral arm for administration of 
intravenous glucose, insulin or Intralipid. This line was flushed with 0.9% 
sodium chloride. Whole blood samples were centrifuged at 3000rpm at 4°C 
for 10 minutes (Harrier 18/80, MSE, London, UK), with the supernatant 
separated and then frozen at -40°C at the Magnetic Resonance Centre 
before being transported on ice for assaying.  
2.3.2 Oral glucose tolerance test 
After an overnight fast, blood glucose levels were measured. A standard 75g 
glucose load (Lucozade Original; GlaxoSmithKline, Coleford, UK) was 
consumed within 5 minutes and blood glucose levels were then measured 2 
hours later with the participant relaxing in between with no exercise or 
nicotine. Glucose tolerance was then classified according to the 2006 
WHO/IDF diagnostic criteria (WHO/IDF, 2006). 
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2.3.3 Hepatic glucose production 
Hepatic glucose production was assessed by a primed continuous infusion of 
[6-6-2H]-glucose (dideuterated glucose) over 270 min with priming dose 
adjusted for ambient fasting plasma glucose level (Hother-Nielsen and 
Beck-Nielsen, 1990; Ravikumar et al., 2008). The priming dose is used to 
instantaneously label the whole glucose pool to the steady state level that 
would eventually be reached with a constant infusion alone. Achievement of 
steady state is crucial because at this point, with constant tracer level, the 
tracer disappearance rate (Rd) must equal the tracer infusion rate (Ra).  
6’6’-dideuterated glucose powder (Cambridge Isotope Laboratories; Andover, 
MA) was made up into 10% strength solutions in sterile water using sterile 
technique. The priming dose (10% strength) was given intravenously and 
calculated to the priming dose for a fasting plasma glucose level of 5mmol/l 
being 300mg therefore: 
Bolus dose (10% strength) in (ml)  = fasting plasma glucose (mmol/l) × 300mg5  
After the participant had rested for 30 min the bolus injection was 
administered. Immediately thereafter a continuous infusion of 2% strength 
(20mg/ml) 6’6’-dideuterated glucose at a rate of 0.04 mg/kg/min was 
commenced to achieve equilibrium of 6’6’-dideuterated glucose. 
In order to prevent any fall in atom percent excess (APE) of 6’6’-
dideuterated glucose during the insulin-glucose clamp, the 6’6’-dideuterated 
glucose infusate was continued for the duration of the clamp. In addition, 
the variable 10% glucose infusion used to maintain isoglycaemia during the 
clamp was enriched with 2% 6’6’-dideuterated glucose (Figure 2-5).   










Figure 2-5 Schematic of hyperinsulinaemic isoglycaemic clamp protocol 
showing steady state basal period and steady state hyperinsulinaemic 
period. 
 
Blood samples were taken every 5 min for determining plasma glucose 
concentration and frequently for determining plasma enrichment of 6’6’-
dideuterated glucose, insulin and C-peptide concentration according to a 
schedule (Table 2-1). 1ml samples of 2% strength 6’6’-dideuterated glucose 
infusate (labelled NINF) and 2% 6’6’-dideuterated enriched 10% glucose 
(labelled GINF) were taken at each study for analysis.  
Isoglycaemic-hyperinsulinaemic clamp 
with 2% 6’6’-dideuterated glucose 
enriched 10% dextrose  





-160 -150    -30                       0                       +90                     +120 
Priming dose of 6’6’-dideuterated glucose 












-160 X X X X 
-150 X X   
-90 X X   
-30 X X   
-20 X X   
-10 X X   
0 X X X X 
5 X    
10 X    
15 X    
20 X    
25 X    
30 X X   
35 X    
40 X    
45 X    
50 X    
55 X    
60 X X X  
65 X    
70 X    
75 X    
80 X    
85 X    
90 X X X  
95 X    
100 X X   
105 X  X  
110 X X   
115 X    
120 X X X X 
Table 2-1 Blood sampling schedule for hyperinsulinaemic isoglycaemic 
clamp 
 
Gas chromatography-mass spectrometry analysis 
Frozen samples were allowed to thaw and then underwent a vortex mix (Dr 
A Al-Mrabeh). Approximately 30µl plasma was transferred to an Eppendorf 
tube before 200µl acetonitrile:ethanol (2:1)  (TraceSELECT Fluka Analytical 
Sigma-Aldrich, St. Louis, MO, USA) was added. Following a vortex mix, the 
sample was spun in a micro-centrifuge at 13000 rpm for 5 min. 200µl was 
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then transferred to a 5ml universal glass vial and evaporated to dryness at 
90°C for 45 min under a gentle stream of dry air in a fume hood. 60µl 
pyridine anhydrous 99.8% (Sigma Aldrich, St. Louis, MO, USA) and 20µl 
acetic anhydride (Sigma-Aldrich, St. Louis, MO, USA) were added to dry the 
residue. The vial was capped, gently mixed and heated in an incubator at 
90°C for 30 min. The samples were evaporated to dryness for 5 min at 90°C 
under a gentle stream of dry air. The pentaacetate derivative of glucose was 
then dissolved in 75µl acetonitrile and then a 1 in 4 dilution was prepared 
with acetonitrile. The samples were then analysed using gas 
chromatography-mass spectrometry (GC-MS) analysis.  
GC-MS analysis was carried out on a Thermo ‘Voyager’ single quadruple 
mass spectrometer interfaced to a Thermo ‘Trace’ 2000 version 1.3 GC, with 
automated injection via a Thermo ‘AS2000’ autosampler v1.3 (Thermo 
Scientific, Waltham, MA, USA). Samples for glucose analysis were analysed 
under Electron Ionisation – Single Ion Monitoring (EI-SIM) conditions with 
separation of the pentaacetate derivatives carried out on a Zebron 30m x 
0.25mm x 0.25µm ZB-5 ms capillary column (Phenomenex, Torrance, CA, 
USA). Injections of 3µl were made in the split mode with a 30:1 split and the 
injection port was maintained at a constant 220°C. The carrier gas was 
Helium at a constant flow of 1 ml/min. GC conditions were: 200°C ramping 
to 240°C and 290°C to a maximum of 350°C with a terminal hold of 5 min; 
MS Trace MS Plus 1.0 SPI for Xcaliber version 1.3 (Thermo Finnigan): the 
mass detected were 200 and 202 (6,6-dideuterated glucose). The scanning 
time was 2-8 min with a dwell time of 0.75 and 450 multiplier voltage. The 
CV for the precision of plasma 2H2 APE measurements was 3.3%. The APE 
of the 2H2 infusate was measured similarly and the CV was 0.3%. All 
samples for each study were analysed together along with the corresponding 
NINF and GINF samples and a 6’6’-dideuterated glucose standard was 
derivatised and analysed in addition.  
Calculations 
Hepatic insulin sensitivity can be assessed by the suppression of hepatic 
glucose production by insulin infusion. That is comparing basal hepatic 
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glucose production (under fasting steady state conditions of physiological 
plasma insulin) and clamp hepatic glucose production (under steady state 
supraphysiological insulin concentrations). Under non-steady state 
conditions created by a glucose-insulin clamp hepatic glucose production is 
estimated indirectly using a single compartment model (Steele et al., 1956) 




 V: volume of compartment 
 C: plasma glucose concentration 
 C*: plasma tracer concentration 
 Ra: hepatic glucose production 
 Ra*: tracer infusion rate 
 Rd: rate of glucose disappearance 
 Rd*: rate of tracer disappearance  
Figure 2-6 Single compartment model for estimating hepatic glucose 
production 
 
This assumes that during steady-state glucose infusion, the only source of 
endogenous glucose production is the liver, and thus that HGP represents 
the difference between the rate of glucose appearance in the circulation (Ra) 
and its disappearance (Rd). 
Basal hepatic glucose production was calculated during the last 30 min of 
the 150 min basal period using the following equation (Maggs et al., 1998): 
 Basal HGP = (basal [dideuterated glucose]GIRBSA × �enrichmentinf–  1�  enrichmentplasma       
Basal HGP= Basal hepatic glucose production (mg.m-2.min-1) 
GIR = basal dideuterated glucose infusion rate (mg/min) 
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Enrichment = the fraction of isotope of glucose to naturally occurring glucose (%) 
Enrichment inf = APE of glucose in infusate (%) 
Enrichment plasma = APE of plasma glucose during steady state basal conditions 
 
During the isoglycaemic clamp, clamped hepatic glucose production was 
calculated during the last 30 min of the clamp using the following equation: 
Clamp HGP = GIR𝑚𝑚𝑚𝑚  � mgm2min�  × (enrichment𝑖𝑚𝑖 − 1)enrichment𝑝𝑝𝑚𝑝𝑚𝑚  
Clamp HGP= Clamp hepatic glucose production (mg.m-2.min-1) 
GIRmean = mean glucose infusion rate over the last 30 min of the clamp 
Enrichment inf = APE of glucose in infusate (%) 
Enrichment plasma = APE of plasma glucose during steady state conditions of the clamp (%) 
 
Hepatic insulin sensitivity has also been calculated as the hepatic insulin 
resistance index; the product of the basal rate of hepatic glucose production 
and the fasting insulin concentration (Gastaldelli et al., 2007). This 
measurement is based on the principles that fasting insulin concentration is 
a strong inhibitory stimulus for hepatic glucose production and that the 
insulin infusion rate used in the hyperinsulinaemic clamp suppresses 
hepatic glucose production by 90-95% in the majority of subjects. Use of this 
index of hepatic insulin resistance has been validated against the 
euglycaemic insulin clamp (Groop et al., 1989).   
2.3.4 Peripheral insulin sensitivity 
An isoglycaemic hyperinsulinaemic clamp was used to quantitate peripheral 
insulin sensitivity. Isoglycaemic hyperinsulinaemia was induced using the 
insulin-glucose clamp technique (DeFronzo et al., 1979). Isoglycaemia was 
selected over euglycaemia to avoid the alteration in insulin secretion and 
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hepatic glucose production that would occur over successive studies due to 
the change in the basal condition of each participant and hence fasting 
glucose levels. Human insulin (Actrapid; Novo Nordisk, Bagsvaerd, 
Denmark) was administered as a primed continuous infusion 
(40mU/m2/min) for 120 minutes. Insulin infusions were prepared by 
drawing up the required number of units of Actrapid insulin in 50ml of 0.9% 
sodium chloride. Fasting isoglycaemia was maintained using a 10% dextrose 
infusion 2% enriched with 6’6’-dideuterated glucose to maintain steady the 
plasma atoms percent excess of isotopic enrichment according to the ‘hot 
GINF’ protocol (Finegood et al., 1987).  
A primed constant insulin infusion was calculated according to body surface 
area at 40mU/m2/min to achieve plasma concentrations of ~400pmol/l. Body 
surface area (m2) was calculated according to the Dubois formula: 0.007284 
x (height in cm)0.725 x (weight in kg)0.425 (Dubois and Dubois, 1916).  
The units of insulin required in 50ml 0.9% sodium chloride for a dose of 
40mU/m2/min was determined as follows (Brehm and Roden, 2007): 
Insulin (units) = 0.04 (𝑈)×𝐵𝐵𝐵 (𝑚2) ×60min×50ml (syringe volume) 15𝑚𝑚
ℎ𝑟
(𝑐𝑐𝑚𝑝𝑐𝑚𝑚𝑐 𝑖𝑚𝑖𝑖𝑝𝑖𝑐𝑚 𝑟𝑚𝑐𝑚)  
 
The insulin infusion was primed for 7 min as follows: 0-4 min 60ml/hr (4x 
constant infusion rate); 4-7 min 30ml/hr (2x constant infusion rate) then for 
the rest of the 120 min of the clamp ran at 15ml/hr. Samples for serum 
insulin and C-peptide concentrations were taken according to the schedule 
(Table 2-1) to ensure that steady state hyperinsulinaemia was achieved 
during the final 30 minutes of the clamp and to ensure that endogenous 
insulin secretion was inhibited. Preventing endogenous insulin secretion 
abolishes the usual physiological gradient in insulin concentration between 
the portal and peripheral venous plasma. 
The mean CV of plasma glucose level and glucose infusion rate in the last 30 
min of the 159 clamp studies was 3.2% and 6.5% respectively. 
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Calculation of whole body glucose metabolism 
Whole body glucose metabolism (M) was determined from the glucose 
infusion rate (GIR) in the last 30 min of the clamp corrected for glucose 
space (SC) and urinary loss (UC) (DeFronzo et al., 1979; Rizza et al., 1981). 
Where blood glucose levels were greater than 10 mmol/l at the 
commencement of insulin infusion, urinary glucose was determined. 
Participants were asked to void at the beginning and end of the clamp 
period. The entire urine volume from this 120 min clamp period was 
collected and the urinary glucose mass determined. Whole body glucose 
metabolism is corrected for fat free mass (Mffm) to indicate insulin action on 
glucose uptake in each unit mass of metabolically active tissue. This helps 
to account for gender related differences in fat mass and is more reliable 
than correcting for body weight only in obese individuals. Glucose metabolic 
clearance rates (ml/kgffm/min) were calculated by dividing whole-body 
insulin sensitivity (in mg/kgffm/min) by steady state plasma glucose 
(Ferrannini and Mari, 1998) to correct for the difference in glucose levels for 
isoglycaemia between study timepoints. Muscle insulin sensitivity was 
calculated as the sum of M value and basal hepatic glucose production 
minus the urinary glucose loss (Rothman et al., 1992; Petersen et al., 2005). 
2.3.5 Measuring insulin secretion 
Stepped insulin secretion test with arginine 
In order to characterise first phase insulin response and maximal insulin 
secretory capacity a modified protocol was used (Toschi et al., 2002). Two 
consecutive 30 min square wave steps of hyperglycaemia (at 2.8mmol then 
5.6mmol above fasting glucose) were achieved by a priming 20% dextrose 
bolus followed by a variable 20% dextrose infusion (Figure 2-7). Finally, 
following the second step of hyperglycaemia, the response to a bolus of 5g 
arginine (Amargine L-Arginine Hydrochloride 50% w/v 5g in 10ml; 
Martindale Pharmaceuticals, Essex, UK) was characterised.  








   
    
 
Figure 2-7 Schematic of protocol for stepped insulin secretion test with 
arginine 
 
The priming doses of 20% dextrose for each step were calculated by 
multiplying the desired increments in plasma glucose concentration by the 
body glucose space (150ml per kg body weight). The 20% dextrose boluses 
were administered within 60 seconds. Glucose levels were then maintained 
at the desired plateau using a variable 20% dextrose infusion according to 
the glucose clamp technique (DeFronzo et al., 1979). Blood samples for 
determination of plasma glucose, insulin and C-peptide concentrations were 
obtained every 2 min for 6 min then every 5 min from 10 min until the end 
of each step. After the arginine bolus blood samples were taken at 2, 4 and 6 
min and the test ended after the 10 min blood sample was taken.   
Calculation of insulin secretion rates 
C-peptide concentrations represent insulin secretion more precisely than 
insulin concentrations; C-peptide is excreted in equimolar amounts, it is not 
subject to significant first pass hepatic extraction, and has relatively 
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C-peptide kinetics (Van Cauter et al., 1992) a mathematical modelling 
technique called deconvolution is implemented to calculate insulin secretion 
rates. Each participants’ gender, age, diabetes status, height, weight, body 
surface area and BMI was entered along with C-peptide concentrations into 
ISEC computer program (Hovorka et al., 1996) which implements a 
regularisation method of deconvolution (Twomey, 1965) giving an output of 
insulin secretion rate in nmol/min/m2 of body surface area.  
2.3.6 Incretin meal test 
Each test was performed with the participant semi-reclined at a 45° angle in 
bed to avoid positional change resulting in variable gastric emptying 
between studies. After baseline blood samples at -10 and 0 min (for glucose, 
insulin, C-peptide, glucagon, total glucagon-like peptide-1 [GLP-1] and total 
glucose-dependent insulinotropic polypeptide [GIP]) participants were asked 
to consume the test meal within 3 minutes. A semisolid test meal was 
designed in accordance to the expected volume and consistency of diet 
consumed one week following gastric bypass surgery (10g Mornflake Instant 
Porridge Oats, 64g whole milk and 6g acacia honey: containing 100 kcal; 
57% carbohydrate; 28% fat and 13% protein). Samples were taken every 10 
min for the first 30 min, then every 30 min until the end of the 2 hr study. 
Samples for incretin hormones were taken into chilled tubes containing 
0.25ml aprotinin/EDTA mix (Aprotinin 10,000 KIU/ml Nordic Pharma Ltd.; 
Reading, UK). At all times during processing samples were kept and 
transported on ice. The tubes were immediately centrifuged at 4°C (3000 
rpm for 10 min) and the plasma separated into aliquots and frozen at -40°C 
until analysis. Positive incremental area under the curve was calculated for 
glucose, insulin, GLP-1 and GIP (Wolever et al., 1991).  
2.3.7 PNPLA3 genotyping 
 
To look for the nonsynonymous variant I148M (rs738409 C/G, 
chr22:42656060-42656060) located in human patatin-like phospholipase 
domain containing 3 gene (PNPLA3, also known as adiponutrin) 10ml of 
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whole blood was collected at the final visit for each participant. The sample 
was collected in EDTA and after thorough mixing was then stored at -40°C. 
Genotyping was performed (Dr Yang-Lin Liu) blind to clinical parameters 
using TaqMan SNP Genotyping Analysis (Applied Biosystems, USA) on 
Applied Biosystems StepOne™ Real-Time PCR Systems. Each study was 
executed using the instructions provided and quality controls were included 
in every 48 well plate (duplication of negative controls, wild-type controls, 
mutant controls, and heterozygous controls). 
2.3.8 Very low density lipoprotein-triglyceride production rates 
VLDL1-triglyceride production rates were measured using a validated 
technique which exploits the fact that VLDL accumulates during 
intravenous infusion of a chylomicron-like triglyceride infusion (Intralipid) 
due to competition for lipolysis by lipoprotein lipase (Bjorkegren et al., 1996; 
Al-Shayji et al., 2007). Following an overnight fast, two 18G intravenous 
cannulae were inserted: one for blood sampling and one for administration 
of Intralipid (purified soybean oil emulsion; Fresenius Kabi Ltd, Runcorn, 
UK). Two baseline blood samples were taken 10 min apart. For each sample, 
9ml of whole blood was collected into EDTA tubes and kept at ambient 
temperature. A bolus of 20% Intralipid (0.1g/kg body mass) was injected 
within 60 seconds and was immediately followed by a continuous infusion of 
10% Intralipid at 0.1g/kg/hr. At 5 min, 15 min, 30 min, 45 min, 60 min and 
75 min further samples were collected and the infusion was stopped at 75 
min. Samples were stored at ambient room temperature and were analysed 
within 72 hours of collection. Firstly, the plasma was separated from the cell 
pellet by centrifugation at 3000 rpm (Mrs J Cooney). Chylomicrons were 
separated from plasma by a short ultracentrifugation at density 1.006g/ml. 
The same method was used for the separation of Intralipid. Then a further 
ultracentrifugation step was used to separate VLDL1 and VLDL2. The 
VLDL1 was then characterised using centrifugal analysis for full 
compositional analysis. Triglyceride and apoB concentrations were then 
measured in these fractions.  
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VLDL1-triglyceride production rates (PR) were calculated from the gradient 
of the linear increase in their concentrations over time as follows:  
 
VLDL1TG PR (mg/hr) = Gradient (mg/dl) ×  plasma volume (dl) × 60Time (min)  
 
VLDL1TG PR (mg/kg/day) = VLDL1TG production rate (mg/hr) × 24Body weight (kg)  
          Where plasma volume (dl) = 4% of body mass 
 
2.3.9 Metabolic and hormone assays 
Blood samples for glucose measurement were taken into fluoride oxalate 
preservative. Whole blood and plasma glucose were measured by the glucose 
oxidase method (Yellow Springs glucose analyzer YSI 2300 STAT Plus; 
Yellow Springs Inc., Yellow Springs, OH: CV for measurement of glucose= 
2%). Serum insulin was measured using ELISA kits (DAKO; Ely, 
Cambridge, UK: inter-assay CV [insulin range 36.9 - 47.3 pmol/l]: 6.2%). 
Serum C-peptide was initially measured using ELISA kits (DAKO; Ely, 
Cambridge, UK: CV for measurement [C-peptide range 1.20-2.00 nmol/l]: 
7.1%) then by ELISA kits (Mercodia; Uppsala, Sweden: inter-assay CV for 
measurement [C-peptide range 1.16 – 1.40 nmol/l]: 4.4%). Mercodia results 
were adjusted to be in-line with DAKO results based on an in-house method 
evaluation of the correlation between the 2 assays: R2 = 0.9466 therefore C-
peptide (Dako) = C-peptide (Mercodia) + 0.0345)/0.7824. Plasma NEFA 
concentration was measured using a FLUOstar Omega microplate reader 
(BMG labtech; Ortenberg, Germany) by a commercially available enzymatic 
calorimetric kit (NEFA HR Reagent 1 and 2; Alpha laboratories, Eastleigh, 
Hampshire, UK: CV using 1mmol standard = 6.7%).  Plasma glucagon 
concentration was measured by radioimmunoassay (Millipore Corporation; 
Billerica, MA, USA). The intra-assay CV and inter-assay CV at a mean 
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concentration of 111pg/ml were 2.9% and 7.1% respectively. β- 
Hydroxybutyrate levels were measured using an Optium Exceed ketone 
meter (Abbott Diabetes Care; Oxfordshire, UK). HbA1c, liver function tests, 
γ glutamyl-transferase, thyroid function, full blood count and lipid profile 
were measured at a Clinical Pathology Accredited laboratory (Newcastle 
upon Tyne Hospitals NHS Foundation Trust, Department of Clinical 
Biochemistry). Incretin assays were batch assayed at the end of the study to 
reduce inter-assay variability (Dr A Pucci). All samples were run in 
duplicate and all of one participant’s samples were run on the same plate. 
Human Total GLP-1 (7-36, 9-36) was measured using ELISA kits (Alpco 
Diagnostics; Salem, NH, USA) with intra-assay variation 4.1% and inter-
assay variation 5.0%. Human Total GIP was measured using ELISA kits 
(Merck Millipore; Watford, UK). Intra-assay and inter-assay variability 
were 3.0% and 3.5% respectively.
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Chapter 3. Effect of Diabetes Duration & Achieved Weight 
Loss on Reversal of Type 2 Diabetes Following 
Bariatric Surgery




Duration of disease is considered to be an important clinical parameter 
which influences treatment selection and glycaemic outcomes in type 2 
diabetes. The published data suggest that 2-3 years of type 2 diabetes does 
not usually result in irreversible beta cell damage, but it is widely believed 
that long duration disease results in an inevitable and irreversible decline 
in insulin secretion with the inevitable requirement for insulin therapy after 
an average of 10 years (UKPDS, 1998). Treatment guidelines for type 2 
diabetes are based on this seemingly inevitable deterioration in glucose 
control, with algorithms of sequential addition of oral agents or non-insulin 
injectable therapies prior to commencement of insulin therapy (NICE, 
2015). Diabetes duration has also been shown to be an important factor in 
determining remission of type 2 diabetes following bariatric surgical 
procedures (Schauer, 2003; Renard, 2009). This is acknowledged in the most 
recent UK guideline for obesity management which recommends expedited 
assessment for bariatric surgery for individuals with a BMI>35 kg/m2 who 
have recent onset type 2 diabetes, considered to be within 10 years of 
diagnosis (NICE, 2014 ). A prospective study found that remission rates 
following gastric bypass surgery were 71% if diabetes duration was 8 years 
or less and 44% if diabetes duration was greater than 8 years (Hall et al., 
2010). However, a prediction model found that low pre-operative HbA1c and 
no requirement for insulin therapy were the pre-operative variables with 
the highest independent predictive value for resolution of type 2 diabetes 
after gastric bypass surgery (Hayes et al., 2011). Other factors such as the 
extent of weight loss, weight regain and pre-surgery anti-diabetic therapy 
requirements have been postulated as predictors of outcomes. A randomised 
prospective study comparing remission of type 2 diabetes following gastric 
banding or intensive medical treatment found that remission was associated 
with the degree of weight loss and therefore was achieved more effectively 
in the surgery group (Dixon et al., 2008). Another study of individuals 
undergoing gastric bypass surgery with less severe obesity showed a much 
higher remission rate at 88% in a group with relatively longstanding 
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diabetes, mean duration 12.5±7.4 years (Cohen et al., 2012) suggesting that 
diabetes duration per se may not limit the reversibility of type 2 diabetes. 
It is recognised that hyperglycaemia in type 2 diabetes is determined by 
impaired insulin secretion (Tabák et al., 2009) on a background of 
longstanding insulin resistance (Martin et al., 1992). Alongside the 
impairment in acute insulin secretion, characteristically a loss of first phase 
insulin response, there is also a reduction in beta cell mass in type 2 
diabetes. In obese individuals with type 2 diabetes, relative beta cell volume 
is decreased by approximately 60% compared to obese people without 
diabetes (Butler et al., 2003). This loss of beta cell mass seems to increase as 
duration of diabetes increases (Rahier et al., 2008). The mechanism is likely 
to be due to apoptosis of beta cells induced by prolonged exposure to the 
toxic metabolites of fatty acids such as ceramides (Shimabukuro et al., 
1998a; Shimabukuro et al., 1998b). In vitro work suggests that the 
functional impairment in insulin secretion can be reversed (Boucher et al., 
2004), and beta cell replication and neogenesis continue into adult life, 
suggesting the potential for recovery of both beta cell function and mass 
(Butler et al., 2003; Butler et al., 2010). The relative contribution of beta cell 
dysfunction and true decrease in beta cell mass is not clear. Recent rodent 
work has suggested that beta cell dedifferentiation and reprogramming 
might explain the association of beta cell dysfunction and increased alpha 
cell function in early type 2 diabetes (Talchai et al., 2012). In human beta 
cells obtained from individuals with type 2 diabetes, the presence of 
mesenchymal cells and alpha cell phenotypic markers support this theory 
(White et al., 2013).  
Recently it has been demonstrated that reversal of type 2 diabetes can be 
achieved by acute calorie restriction alone through the use of a very low 
calorie diet (Lim et al., 2011). In this study, recovery of first phase insulin 
response commenced after 7 days of a very low calorie diet and continued to 
improve, becoming indistinguishable from obese non-diabetic control 
subjects at 8 weeks. The participants all had a diabetes duration of less than 
4 years. A differential effect of acute calorie restriction (minimum of 4 weeks 
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of 500kcal/day) on glycaemic control between individuals with short (≤2 
years) and long duration (≥6 years) diabetes has been demonstrated, with a 
much more modest effect on fasting glucose in the long duration group 
(Nagulesparan et al., 1981). However, this was a very heterogenous cohort, 
particularly regarding BMI which ranged from 25.4 to 56.9 kg/m2. Whether 
diabetes duration is of importance per se or whether it is a surrogate marker 
for beta cell function is unclear.  
Both duration of type 2 diabetes and extent of achieved weight loss are thus 
likely to influence the chance of diabetes reversal following bariatric 
surgery. However, the interaction between these two factors requires 
definition. The hypothesis that the degree of weight loss achieved after 
surgery is more important than disease duration in determining reversal of 
diabetes was tested in a heterogenous cohort representative of the bariatric 
surgery population in the UK.  
3.2 Study design 
3.2.1 Participants 
148 individuals undergoing any bariatric surgical procedure in a specialist 
bariatric centre in North East England between 2009 and 2011 were 
identified through consecutive referrals to the diabetes team. All 
participants were seen by a member of the diabetes team, with clinical 
verification of the diagnosis of type 2 diabetes. Inclusion criteria were pre-
operative HbA1c of ≥6.1% (43 mmol/mol) and a further HbA1c value 
measured 3 or more months after surgery. 
3.2.2 Experimental protocol 
This study was a retrospective data collection. Follow-up information on 
post-operative HbA1c was requested from the participants’ primary care 
doctor. Post-operative HbA1c and weight data were taken at the furthest 
available time point from surgery. Post-operative HbA1c values are all from 
within the first 2.5 years following surgery, median 11 months (3-29). 
HbA1c is known to remain stable over this period (Mingrone et al., 2012; 
Schauer et al., 2012). Diabetes duration was pre-defined as the time 
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between diagnosis of type 2 diabetes and the pre-operative assessment. 
Reversal of diabetes was defined stringently as achieving a post-operative 
HbA1c <6.1% (43 mmol/mol) (Buse et al., 2009). Diabetes duration was 
grouped as follows: short: <4 years; medium: 4-8 years; long: >8 years.  
3.2.3 Statistical analysis 
Parametric data are presented as mean ± SD or SEM and non-parametric as 
median and range apart from  
 
Figure 3-2 where median and interquartile range is displayed. Statistical 
analyses were performed using Minitab 16 Statistical Software (Minitab 
Inc.;State College, PA: www.minitab.com). Parametric data were analysed 
using Student’s t-test and non-parametric data were analysed using Mann 
Whitney U, Spearman rank correlation coefficient or Kruskal-Wallis.  
3.3 Results 
3.3.1 Clinical characteristics 
Complete data on diabetes duration, achieved HbA1c and achieved post-
operative weight loss were available for 89 eligible individuals. There was 
no statistically significant difference in baseline age, weight, BMI, or 
diabetes duration in those excluded from the analysis (n=59). The cohort 
consisted of 26 individuals with short, 36 with medium and 27 with long 
duration type 2 diabetes (Table 3-1). Pre-operative anti-diabetic treatments 
were: metformin: 75; sulphonylurea: 32; GLP-1 agonist: 19; 
thiazolidinedione: 18; insulin: 15; diet control only: 5; DPP-4 inhibitor: 4. 
The commonest surgical procedure was Roux-en-Y gastric bypass: n=57. 
Other procedures were laparoscopic adjustable gastric band (LAGB): n=16; 
sleeve gastrectomy (SG): n=8; and gastric balloon: n=8. 
   
 
  
 Short duration 
diabetes (<4 yr) 
Medium duration 
diabetes (4-8 yr) 
Long duration 
diabetes (>8 yr) 
Overall 
n 26 36 27 89 
M:F 6:20 13:23 9:18 28:61 
Age (yr) 45.5 (32.0-62.0) 46.0 (18.0-64.0) 55.5 (37.0-74.0) * 49.0 (18.0-74.0) 
Weight (kg) 136.3 ± 27.6 136.0 ± 27.4 133.0 ± 21.6 135.2 ± 25.9 
Median BMI (kg/m2) 47.0 (39.3-66.8) 45.9 (37.7-67.1) 46.4 (37.2-75.6) 46.4 (37.2-75.6) 
Median diabetes duration  2yr (1mo–3yr) 5yr (4yr–8yr) 12yr (9yr–31yr) * 5yr (1mo–31yr) 
Median HbA1c (%) 









Diabetes treatment: n (%) 
     Diet control: 
     OHA only: 
     Insulin:  
 
4 (15.4) 














Primary surgery: n (%) 
     RYGB: 
     LAGB: 
     SG: 






















Table 3-1 Pre-operative participant characteristics. Results are displayed as mean ± SD or median and (range). * = p<0.05 
comparing short and long duration diabetes.
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3.3.2 Effect of degree of weight loss on achieved blood glucose control 
Overall 48% (43/89) of this cohort achieved a post-operative HbA1c of <6.1% 
(43 mmol/mol). The median post-operative weight loss was 21.8kg (-4.2 - 
64.7) and the mean percentage weight loss was 17.6 ± 1.1%. For the group 
achieving >25kg weight loss, there was a 61% (20/33) diabetes reversal rate 
compared to 41% (23/56) in the group achieving <25kg weight loss. The 
relationship between weight loss (%) and achieved HbA1c (Figure 3-1) 
showed a clear effect of greater weight loss bringing about lower HbA1c (Rs 
=-0.53; p<0.0001). In the group achieving weight loss of >25kg there was a 
modest difference between the short and long duration groups in achieved 
HbA1c (5.5±0.2 vs. 6.7±0.5 %; p=0.096) (37 vs. 50 mmol/mol) ( 
 
Figure 3-2, panel e) compared to those who achieved <25kg weight loss 
(6.1±0.3 vs. 7.5±0.4 %; p=0.004) (43 vs. 58 mmol/mol) ( 
 
Figure 3-2, panel f). In those who achieved HbA1c <6.1% (43 mmol/mol), 
post-operative weight loss was 29.4±2.4 kg (21.8±1.4 %) vs. 18.6±2.1 kg 
(13.6±1.5 %) in those who remained in the diabetic range (p=0.001).  




Figure 3-1 The relationship between achieved post-operative weight loss 
(%) and achieved HbA1c (%) in short (closed circles), medium (open circles) 
and long (triangles) duration type 2 diabetes. The solid line represents an 
HbA1c of 6.1 % (43 mmol/mol) and the cut-off for defining diabetes reversal. 
 





Figure 3-2 Change in HbA1c in each individual according to diabetes 
duration and achievement of more/less than 25 kg weight loss following 
bariatric surgery (panels a-d). Median and IQR HbA1c for long duration 
diabetes (triangles) and short duration diabetes (circles) (panels e-f). (n=11 
for >25 kg short, n=13 for >25 kg long, n=17 for <25 kg short, n=14 for <25 
kg long). 
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The characteristics of individuals who achieved >25kg weight loss in 
relation to post-operative HbA1c of less than or greater than 6.1% (43 
mmol/mol) are shown in Table 3-2. There were no significant differences 
between the two groups at baseline. 






n 20 13 
M:F 10:10 5:8 
Age (yr) 49.0 (18.0-74.0) 47.0 (38.0-63.0)  
Weight (kg) 145.9 ± 22.0 143.2 ± 22.2 
Median BMI (kg/m2) 49.5 (39.7-67.1) 50.7 (40.1-75.6) 
Median diabetes duration 5.5 yr (6 mo – 15 yr) 10.0 yr (2 yr – 19 yr) * 
Median pre-operative HbA1c 
                               (%) 







Median achieved HbA1c          
                               (%) 





6.5 (6.1-12.3) * 
48 (43-111) 
Mean achieved weight loss   
                               (kg) 
                               (%) 
 
41.5 ± 12.2 
28.3 ± 6.7 
 
37.2 ± 10.0 
26.3 ± 7.1  
Diabetes treatment [n (%)] 
     Diet controlled: 
     Non-insulin agents only: 









Diabetes medications [n (%)]  
     0 
     1 
     2 











Primary surgery [n (%)] 
     RYGB: 
     LAGB: 
     SG: 












Table 3-2 Characteristics of individuals who achieved >25kg weight loss 
according to achieved post-operative HbA1c. RYGB = Roux-en-Y gastric 
bypass surgery; LAGB = laparoscopic adjustable gastric band; SG = sleeve 
gastrectomy. Results are shown as mean ± SD or median (range). *=p<0.05 
for between group difference.
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3.3.3 Effect of duration of diabetes on achieved blood glucose control 
HbA1c <6.1% (43mmol/mol) was achieved in 62% (16/26), 56% (20/36) and 
26% (7/27) of the short, medium and long duration groups respectively. The 
diabetes durations in individuals who achieved a post-operative HbA1c 
<6.1% (43mmol/mol) overlapped with those who did not but was shorter 
[median 4 years (range: 1 month – 18 years) vs. median 6½ years (range: 9 
months – 31 years); p=0.010]. The degree of achieved weight loss appeared 
to be more important in those with long duration compared to short 
duration diabetes (Figure 3-2, panels e and f). There was a notable lack of 
achievement of normoglycaemia in those individuals who had long duration 
diabetes and also lost less than 25kg (Figure 3-2, panel f). The relative 
effects of duration of type 2 diabetes and degree of achieved weight loss are 
shown in Figure 3-3. Despite increasing degrees of weight loss there is a 
plateau of diabetes reversal above about 20% post-operative weight loss.  
 
Figure 3-3 Reversal of diabetes according to duration of diabetes and 
degree of achieved post-operative weight loss following any bariatric 
procedure.   
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3.3.4 Predictors of achieved blood glucose control 
Using regression analysis, it was found that maximum percentage achieved 
weight loss (β=0.013, p<0.0001) and baseline HbA1c (β=0.093, p=0.014) were 
significant predictors of achieved HbA1c. Diabetes duration (β=0.028, 
p=0.118), age (β=0.015, p=0.770) and initial BMI (β=0.014, p=0.496) were 
not significant predictors.  
3.4 Discussion 
The study demonstrates that degree of achieved weight loss is the major 
determinant of reversal of diabetes and that in long duration diabetes, 
greater weight loss is required to achieve reversal. In this cohort, the 
longest duration of diabetes in which a post-operative HbA1c of <6.1% (43 
mmol/mol) was achieved was 18 years. This individual was treated with 
insulin therapy pre-operatively with an HbA1c of 9.1% (76 mmol/mol) and 
achieved a post-operative HbA1c of 5% (31 mmol/mol) off insulin therapy 
after losing 21.4kg (17.4% of body weight) following RYGB. The results of 
the study challenge the widely held belief that as duration of type 2 diabetes 
increases, there is a steady, inexorable and irreversible decline in beta cell 
function. The data provide further evidence that it is the removal of fat that 
allows return of normal metabolic function.   
A prospective study on reversibility of type 2 diabetes reported that 
remission of type 2 diabetes was seen in 68% following RYGB with a trend 
towards reduced remission rates as diabetes duration increased (Hall et al., 
2010). The higher remission rate in this study compared to the present 
study is likely to relate to two main differences: only participants 
undergoing RYGB were included and the definition of remission was 
achieving an HbA1c <6.5% (48 mmol/mol). More recently, diabetes remission 
was investigated in a group of 66 individuals with type 2 diabetes 
undergoing RYGB with a relatively low BMI at 30-35 kg/m2 (Cohen et al., 
2012). In this study 88% of individuals achieved a post-operative HbA1c of 
<6.5% (48 mmol/mol) off anti-diabetic therapies, with the mean diabetes 
duration in those who achieved diabetes remission being 8.0±2.5 years. A 
recent retrospective study devised a scoring system to aid patient selection 
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for bariatric surgery incorporating pre-operative age, BMI, C-peptide and 
diabetes duration (Lee et al., 2015). Similar to our study they concluded that 
weight loss has the dominant effect on type 2 diabetes remission.  
The mechanisms determining the reversal of type 2 diabetes following 
bariatric surgery are becoming clear (Knop and Taylor, 2013). Calorie 
restriction alone can reverse type 2 diabetes (Lim et al., 2011), and the acute 
negative calorie balance must be the primary driver for the early rapid 
improvement in glucose levels (Taylor, 2008). Studies directly comparing the 
change in glycaemic control following RYGB compared to calorie restriction 
have demonstrated no additive effect of surgery over calorie restriction 
suggesting that alterations in incretin hormones (the foregut or hindgut 
hypotheses) are not a primary mechanism (Isbell et al., 2010; Lingvay et al., 
2013). In the first seven days of hypocaloric intake liver triglyceride content 
falls and hepatic insulin sensitivity increases (Guidone et al., 2006). 
Although an improvement in peripheral insulin sensitivity may be expected 
with sustained weight loss, the majority of individuals remain clinically 
obese following surgery and the published data suggest that changes in beta 
cell function underlie the reversal of type 2 diabetes. The present study 
involves use of different surgical procedures. However, when the RYGB 
group are looked at separately (short duration: n=18; medium: n=22; long: 
n=17) the correlation between achieved HbA1c and percentage weight loss 
remains (Spearman rank -0.324; p=0.014) and mean post-operative weight 
loss was 31.1±2.7 kg in those who achieved a post-operative HbA1c of <6.1% 
vs. 23.6±2.3 kg in those who remained in the diabetic range. In this group, 
the mean duration of diabetes was 3.7±0.4 yr in those who achieved a post-
operative HbA1c <6.1% (43 mmol/mol). A recent paper found no significant 
difference between RYGB and sleeve gastrectomy in terms of improvement 
in HbA1c (Schauer et al., 2012). Overall, there is no convincing evidence for 
a specific effect of bypassing the duodenum separate from induction of 
negative calorie balance.   
The recovery in beta cell function is likely to relate to removal of the burden 
of the toxic metabolites of saturated fatty acids with or without decrease in 
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beta cell apoptosis (Taylor, 2013). The demonstration that new beta cells can 
be developed from adult exocrine pancreatic ducts (Butler et al., 2003) and 
the possibility that beta cell dedifferentiation is reversible (White et al., 
2013) suggests that recovery of insulin secretion in long duration diabetes is 
at least possible. Clinical observations suggest that beta cell function can 
recover and even hyperfunction; for example women who have had type 2 
diabetes reversed by RYGB who do not develop gestational diabetes in 
subsequent pregnancies despite the increased insulin resistance associated 
with pregnancy (Steven et al., 2011). Two studies have looked at insulin 
secretion in long-standing type 2 diabetes, using C-peptide response to 
glucagon (Zangeneh et al., 2006) or fasting C-peptide measurements (Jain et 
al., 2008). Both concluded that although a decline in beta cell function over 
time is characteristic, this is not inevitable and is highly variable between 
individuals. In our cohort, individuals who did not achieve a post-operative 
HbA1c of <6.1 % (43 mmol/mol) despite weight loss of more than 25 kg had a 
longer diabetes duration and were more likely to be on insulin or GLP-1 
agonist therapies than those who did achieve a post-operative HbA1c of 
<6.1% (43 mmol/mol). 
In the current study, there was a notable lack of normoglycaemia in 
individuals with long duration diabetes achieving <25 kg weight loss. 
Individuals with long duration disease are likely to have gained more 
weight since the time of diagnosis, partly due to the natural history of the 
disease but also compounded by the use of medications such as 
sulphonylureas and insulin (UKPDS, 1998). It is hypothesised that these 
individuals with long duration diabetes need to lose more weight than those 
with short duration disease in order to reach a weight at which beta cell 
function can return with normalisation of blood glucose levels. The negative 
correlation between duration of type 2 diabetes and beta cell function has 
previously been reported to be more apparent in obese individuals than in 
lean individuals (Funakoshi et al., 2008; Saisho et al., 2012).  
Of note, one individual in the current study with diabetes duration of 9 
years ( 




Figure 3-2, panel c) demonstrated a marked deterioration in diabetes 
control post-operatively despite achieving 26.8kg (20.2%) weight loss 9 
months after RYGB. Pre-operative HbA1c was 8.4% (68 mmol/mol) on 
metformin, gliclazide and pioglitazone therapies, and then 9 months post-
operatively this was 12.3% (111 mmol/mol) on metformin and gliclazide. No 
specific cause for this paradoxical deterioration in control could be 
identified. 
Limitations of the current study must be considered. The date of onset of 
diabetes is notoriously inaccurate, with the potential for a long period of 
unrecognised hyperglycaemia preceding a diagnosis. This would have the 
effect of underestimating diabetes duration, which if anything would 
increase the reversal rates in the long duration group. As fasting glucose 
levels were not available in this study the ADA Consensus criteria for 
defining diabetes remission (Buse et al., 2009) were not used, although our 
criterion for defining diabetes reversal was consistent and stringently 
applied. In this study, as all individuals were reviewed as in-patients by the 
diabetes team, the risk of inclusion of individuals with alternate diagnoses 
including slow-onset type 1 diabetes and maturity onset diabetes of the 
young (MODY) has been minimised. Inclusion of such individuals would 
have the effect of reducing remission rates in general. As the type of 
bariatric procedure performed is decided by the surgeon, a possible 
confounder is that higher risk patients (such as those with poor diabetes 
control) were selected to have lower risk but less “effective” procedures. This 
could result in the association between lower achieved weight loss and less 
improvement in glucose control. However, the association between achieved 
weight loss and achieved HbA1c seen in the whole group was also evident 
when the RYGB cohort was examined separately.   
This study demonstrates that degree of achieved weight loss is the major 
determinant of reversal of diabetes. Reversal to normoglycaemia can be 
achieved in long duration type 2 diabetes following bariatric surgery, but 
greater weight loss is required to achieve reversal compared to short 
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duration disease. A minority of individuals appear not to achieve diabetes 
reversal despite achieving significant weight loss even with short duration 
diabetes. The pathophysiologic limitations to complete reversal of type 2 
diabetes require investigation.  
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Chapter 4. Comparison of the Effects of Bariatric Surgery 
on Glucose Metabolism in Type 2 Diabetes & Normal 
Glucose Tolerance 
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4.1 Introduction 
Bariatric surgery is currently the most effective treatment for reversal of 
type 2 diabetes; a randomised trial of intensive medical therapy alone 
versus medical therapy plus bariatric surgery demonstrated an HbA1c <6% 
after 12 months in 12% of those medically treated compared to 42% of those 
having gastric bypass surgery (Schauer et al., 2012). We do not fully 
understand the pathophysiologic mechanisms which define diabetes 
reversal, and this is crucial to understanding the aetiology of the disease 
and overcoming the limits to full reversibility. Major changes in incretin 
hormones occur after Roux-en-Y gastric bypass surgery (RYGB) which could 
potentially contribute to the observed increase in meal related insulin 
secretion (Guidone et al., 2006). In type 2 diabetes, there is a diminished 
glucagon-like peptide-1 (GLP-1) response to food ingestion (Vilsbøll et al., 
2001), and some believe that RYGB exerts a specific effect in type 2 diabetes 
which differs from that in subjects with normal glucose tolerance. Some 
studies have supported this concept (Jorgensen et al., 2013; Bojsen-Møller et 
al., 2014; Manning et al., 2015) although similar restoration of 
normoglycaemia has been observed after calorie restriction alone (Isbell et 
al., 2010; Lingvay et al., 2013). Previously, an 8 week very low calorie diet 
(VLCD) was used to test the hypothesis that acute negative calorie balance 
alone reverses type 2 diabetes by normalising both beta cell function and 
insulin sensitivity. In that study, over the first week of calorie restriction, 
hepatic insulin sensitivity normalised and hepatic triglyceride content 
decreased by 30% (Lim et al., 2011). After 8 weeks of calorie restriction, first 
phase insulin secretion and pancreatic triglyceride content had normalised.  
These observations have confirmed some aspects of the twin cycle 
hypothesis of the aetiology of type 2 diabetes (Taylor, 2013).  
The importance of hepatic triglyceride in the pathogenesis of type 2 diabetes 
is clear (Perry et al., 2014). In contrast, it remains uncertain whether the 
change in pancreatic triglyceride seen during a VLCD is specific to diabetes 
itself, reflecting a disease related abnormality or whether it simply reflects 
decrease in whole body fat content that would occur during substantial 
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weight loss irrespective of the metabolic state. Human studies have yielded 
conflicting results; a negative association between pancreatic fat and insulin 
secretion in some (Tushuizen et al., 2007; Heni et al., 2010; Szczepaniak et 
al., 2012); only a relationship with BMI not beta cell function in others 
(Saisho et al., 2007; van der Zijl et al., 2011); and another with age alone 
(Begovatz et al., 2015). However, these studies have used a variety of 
imaging modalities, some of which are likely to have included visceral fat in 
the measurement of pancreatic fat. Also the use of heterogeneous 
populations in terms of glucose tolerance, including some subjects with 
impaired glucose tolerance and impaired fasting glycaemia who are likely to 
have increased insulin secretion, makes interpretation of the correlation 
with beta cell function challenging.  
Investigation of intracellular pancreatic fat content from autopsy specimens 
has been limited by potential post-mortem pancreatic lipase activity. 
However, mechanistically, the importance of fat to beta cells is clear: in vitro 
studies have demonstrated that acute exposure of beta cells to fatty acids 
acts as a stimulus for insulin secretion, however, chronic exposure results in 
decreased glucose stimulated insulin secretion (Lee et al., 1994). This seems 
to relate to endoplasmic reticulum stress, mitochondrial dysfunction and 
initiation of apoptosis (Morgan, 2009). Inhibition by excess intracellular 
fatty acids or their metabolites is a potential mechanism (Lee et al., 1994; 
Lalloyer et al., 2006; Diakogiannaki et al., 2007). Currently available 
imaging techniques are unable to specifically measure triglyceride within 
beta cells, and it is likely that most pancreatic fat measured is present 
within adipocytes in exocrine tissue or in adipose tissue in the interlobular 
space. However, in animal models, islet fat content correlates with whole 
organ fat content (Lee et al., 2009). Although the triglyceride measured is 
actually an inert storage form of fat, it may serve as a biomarker for the 
toxic metabolites of fat that are in the close environment of the beta cell.  
Comparison of changes in pancreatic triglyceride in type 2 diabetes and 
normal glucose tolerance during acute weight loss could define those 
changes specific to the recovery of insulin secretory capacity. Achieving 
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equivalent dietary weight loss in normal glucose tolerant individuals who do 
not have the motivation of potentially reversing their diabetes to normal 
would be challenging. Bariatric surgery, specifically RYGB for obesity 
produces reliable weight loss and permits detailed comparison of the 
pathophysiologic changes in these two groups. The aim of this study was to 
compare groups of individuals with type 2 diabetes and normal glucose 
tolerance before and 8 weeks after RYGB; specifically the changes in 
pancreas triglyceride content, incretin-independent intravenous glucose 
mediated insulin secretion, and physiologic incretin secretion. Changes in 
hepatic triglyceride content and hepatic insulin sensitivity were also 
assessed. 
4.2 Study Design 
4.2.1 Participants 
Individuals listed for laparoscopic RYGB were identified from two regional 
bariatric surgery centres. Individuals with type 2 diabetes (n=18) were 
recruited with diabetes duration <15 yr, aged 25-65 yr, BMI up to 45 kg/m2 
(due to scanner constraints), and no significant renal or hepatic dysfunction 
(creatinine <150 µmol/l; ALT <2.5-fold above upper limit of normal). 
Exclusion criteria were: contraindication to magnetic resonance scanning; 
alcohol consumption >14 units/wk; previous bowel surgery; or treatment 
with steroids. At the time of study enrolment, 4 participants were taking 
metformin only, 6 participants were treated with metformin and a 
sulphonylurea, 2 participants were on metformin and insulin, 1 participant 
was taking metformin, a sulphonylurea and a GLP-1 agonist, 1 metformin, 
sulphonylurea and a DPP-4 inhibitor, 1 metformin and GLP-1 agonist, 1 
metformin, sulphonylurea and a thiazolidinedione, 1 metformin and a 
thiazolidinedione, 1 metformin, GLP-1 agonist and insulin. Participants 
were asked to discontinue DPP-4 and thiazolidinediones at least 1 month 
prior to starting the study and GLP-1 agonists 2 weeks prior. Metformin 
and sulphonylureas were stopped 72 hours prior to studies. No insulin was 
given within 24 hours of the first study. Statin therapy was continued 
throughout the study. The type 2 diabetes group (n=18) consisted of 11 
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females and 7 males, aged 49.1±7.0 years with diabetes duration 6.9±1.0 
years. A group with normal glucose tolerance and no family history of type 2 
diabetes in a first degree relative (n=9) was also studied, and were similar 
in age and weight. Glucose tolerance was confirmed by a standard 75g oral 
glucose tolerance test (section 2.3.2). This group consisted of 7 females and 2 
males, aged 46.3±2.1 years. The groups were recruited by invite letter from 
the surgical team and participants understood that they were free to 
withdraw from the study at any point. The study protocol was approved by 
the Newcastle upon Tyne 1 Research Ethics Committee. All participants 
provided written informed consent. One individual in the normal glucose 
tolerance group did not undergo surgery following baseline studies due to 
the diagnosis of an unrelated medical problem.  
4.2.2 Experimental protocol 
All participants were studied just before surgery and at 8 weeks post-
operatively. Pre-operatively all participants were on a liver reduction diet, 
as advised by their surgeon, based on low dietary fat and carbohydrate 
intake, with an approximate overall energy intake of 1200 kcal/day for 7-10 
days. At both time points, fasting anthropometry and assessments of first 
phase insulin secretion, pancreatic and hepatic triglyceride content, insulin 
sensitivity and incretin response to a semi-solid meal test were made. All 
metabolic studies were performed after an overnight fast. Individuals were 
asked to avoid intensive physical activity or unusual alcohol or caffeine 
intake in the 48 hours prior to each study and to avoid nicotine intake on 
the day of studies. Studies took place over one full day (assessments of 
insulin sensitivity and insulin secretion) and one half day (assessment of 
body composition and meal test). On the morning of the first day, a cannula 
was inserted into an antecubital vein for infusions and a second cannula 
inserted into the contralateral wrist for blood sampling. A 4.5 hr 
isoglycaemic hyperinsulinaemic clamp study was performed with stable 
isotope dilution technique to assess basal hepatic glucose production and 
hepatic and peripheral insulin sensitivity (sections 2.3.3 and 2.3.4). 
Following the clamp study, participants rested for a minimum of 60 min (or 
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until steady state fasting glucose levels were achieved) before undergoing 
the stepped insulin secretion test with arginine to assess first phase insulin 
response and maximal insulin secretory capacity (section 2.3.5). The 
following morning, participants underwent measurement of body 
composition using electrical bioimpedence (Bodystat1500; Bodystat Ltd., 
Isle of Man, UK) and then had hepatic and pancreatic triglyceride content 
(section 2.2.2) and visceral adipose tissue (VAT) and subcutaneous adipose 
tissue (SAT) areas (section 2.2.3) measured using the three point Dixon 
magnetic resonance method on a 3 Tesla Achieva scanner (Philips; Best, The 
Netherlands). Waist and hip circumferences were measured using a 
standard non-distensible tape measure, taken with the participants 
standing and in a relaxed posture by one observer (SS). Following this the 2 
hour semi-solid meal test was performed with the participant semi-reclined 
at a 45° angle in bed to avoid positional change affecting gastric emptying 
(section 2.3.6). Baseline blood samples were taken at -10 and 0 min (glucose, 
insulin, C-peptide, glucagon, glucagon-like peptide-1 (GLP-1) and glucose-
dependent insulinotropic polypeptide (GIP)). Participants were then asked 
to consume a semi-solid meal within 3 minutes (10g Mornflake Instant 
Porridge Oats, 64g whole milk and 6g acacia honey: 100 kcal; 57% 
carbohydrate; 28% fat; 13% protein), designed in accordance with the 
expected volume and consistency of diet consumed in the initial post-RYGB 
phase. Whole blood samples were collected for PNPLA3 genotyping (section 
2.3.7).  
4.2.3 Surgery 
RYGB was performed laparoscopically in all patients. A gastric pouch (30-
50ml) was fashioned on the lesser curve of stomach using an ETS 45 mm 
linear stapler firing blue (6R45B) cartridges (Ethicon Endosurgery; 
Cincinnati, OH). A biliopancreatic limb of 50-70cm from the duodenojejunal 
flexure was anastomosed to the gastric pouch. An alimentary limb of 100-
150cm was then measured and a side to side antimesenteric jejuno-
jejunostomy carried out. The roux construction was completed by dividing 
the omega loop close to the gastrojejunostomy. At the time of operation, 2 
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participants with type 2 diabetes underwent sleeve gastrectomy instead of 
RYGB due to the presence of significant intra-abdominal adhesions. The 
data from these 2 participants have been excluded from the incretin 
analyses.  
4.2.4 Statistical analysis 
Data are presented as mean ± SEM for parametric and median (range) for 
non-parametric data. Data was tested for normality using Kolmogorov 
Smirnov test. Insulin secretion rates are given as median with 25th and 75th 
percentile. Comparisons between the type 2 diabetes group and the normal 
glucose tolerance group were made using Student’s unpaired t-test or Mann 
Whitney U test. Within group differences between baseline and week 8 were 
determined using Student’s paired t-test or Wilcoxon Rank. Correlations 
were examined using Pearson or Spearman rank test. Minitab 16 statistical 
program was used (Minitab Inc.; State College, PA: www.minitab.com). 
Statistical significance was accepted at p<0.05.  
4.3 Results 
4.3.1 Weight loss and body composition 
Pre-operative weight did not differ between the type 2 diabetes and normal 
glucose tolerance groups (121.1±3.0 vs. 114.5±5.0 kg; p=0.244). There was no 
difference in VAT or SAT areas between the two groups at baseline (Table 
4-1). The VAT:SAT ratio at baseline was higher in the diabetes group but 
this did not reach statistical significance (p=0.084). At 8 weeks post-
operatively weight loss was similar in the two groups (13.6±0.7 and 12.8±0.8 
% respectively; p=0.286) as was change in total body fat content (Table 4-1). 
There was a significant decrease in SAT and VAT areas in both groups after 
surgery. The VAT:SAT ratio did not change in either group after surgery. 
The waist:hip ratio was lower in individuals with normal glucose tolerance 
at baseline and after surgery.
   










Weight (kg) 121.1±3.0 104.5±2.7 <0.001 114.5±5.0 99.7±4.6 <0.001 
BMI (kg/m2) 42.7±0.7 36.9±0.7 <0.001 41.3±1.0 36.4±0.8 <0.001 
Fat mass (kg) 56.6±2.4 43.0±2.4 <0.001 56.7±3.3 45.4±2.3 <0.001 
Waist:Hip ratio 0.97±0.02 0.94±0.02 0.006 0.90±0.03 * 0.87±0.03 # 0.066 
VAT area (cm2) 300.4±17.5 241.3±11.0 <0.001 244.5±28.4 187.9±28.3 0.010 
SAT area (cm2) 453.8±28.9 393.2±26.8 <0.001 496.4±16.0 409.7±26.0 0.016 
VAT:SAT ratio 0.74±0.09 0.70±0.09 0.213 0.50±0.07 0.47±0.07 0.159 
Plasma glucose (mmol/l) 9.4±0.8 6.4±0.4 <0.001 5.2±0.2 * 4.9±0.1 # 0.089 
Serum insulin (mU/l) 15.3 (4.3-61.2) 11.3 (2.9-27.0) <0.001 11.0±1.6 6.7±0.7 # 0.008 
ALT (U/l) 37.7±4.1 25.7±2.4 0.009 24.3±2.8 * 22.1±3.7 0.542 
GGT (U/l) 33 (13-148) 15 (7-69) 0.002 23 (8-39) 11 (5-122) 0.234 
NEFA (mmol/l) 0.85±0.08 0.77±0.05 0.207 0.72±0.09 0.80±0.07 0.263 
Glucagon (ng/l) 74.6±9.8 58.0±8.3 0.001 49.4±5.0 48.1±5.0 0.865 
Triglycerides (mmol/l) 1.5 (0.6-3.7) 1.1 (0.5-2.2) 0.011 1.2±0.2 1.1±0.2 0.156 
Table 4-1 Anthropometric and fasting metabolic data before and at 8 weeks post-operatively in the type 2 diabetes (T2DM) and 
normal glucose tolerance (NGT) groups. * indicates a statistically significant difference between the 2 groups at baseline. #  
indicates a statistically significant difference between the 2 groups at week 8. 
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4.3.2 Plasma glucose, insulin, glucagon and metabolites 
Fasting plasma glucose decreased from 9.4±0.8 to 6.4±0.4 mmol/l in the 
diabetes group (p<0.001) and from 5.2±0.2 mmol/l to 4.9±0.1 mmol/l in the 
normal glucose tolerance group (p=0.196). HbA1c decreased from 7.6±0.4 % 
(59±4 mmol/mol) at baseline to 6.2±0.2 % (45±2 mmol/mol) at week 8 in 
those with diabetes (p<0.001) compared to 5.4±0.1 % (35±1 mmol/mol) to 
5.2±0.1 % (34±1 mmol/mol) in those without (p=0.010). Fasting insulin levels 
fell in both groups (T2DM: 15.3 (4.3-61.2) to 11.3 (2.9-27.0) mU/l (p<0.001); 
NGT: 10.7±1.4 to 6.7±0.7 mU/l (p=0.008). There were significant decreases 
in fasting plasma glucagon, triglyceride, ALT and GGT in the diabetes 
group following surgery but not the normal glucose tolerance group (Table 
4-1). There was no significant change in fasting NEFA concentration after 
surgery in either group.  
4.3.3 Pancreatic triglyceride content 
Pancreatic triglyceride content was higher at baseline in those with type 2 
diabetes compared to normal glucose tolerance (6.6±0.5 vs. 5.1±0.2 %; 
p=0.009). After surgery, pancreatic triglyceride content had decreased in the 
diabetes group to levels similar to the normal glucose tolerance group 
(6.6±0.5 to 5.4±0.4 %; p=0.007). Pancreatic triglyceride content did not 
change after surgery in those without diabetes (5.1±0.2 to 5.5±0.4 %; 
p=0.437) (Figure 4-1) despite a comparable decrease in whole body fat mass 
(Table 4-1).  




Figure 4-1 Change in pancreatic triglyceride content (shown as mean and 
SEM) in the diabetes (T2DM) and normal glucose tolerance (NGT) groups at 
baseline (grey) and then at 8 post-operative weeks (chequered).  
4.3.4 Change in insulin secretion 
The planned stepped increases in plasma glucose during the insulin 
secretion test were achieved (Figure 4-2A). At baseline, the first phase 
insulin response (baseline to 6 min insulin secretion rate) in the diabetes 
group was severely impaired compared to those with normal glucose 
tolerance (0.08 (-0.01-0.10) vs. 0.24 (0.13-0.46) nmol min-1 m-2; p=0.011; 
Figure 4-2B). There was marked restoration of the first phase insulin 
response in those with diabetes after surgery: increasing to 0.22 (0.07-0.30) 
nmol min-1 m-2; p=0.005; Figure 4-2C). There was no change in first phase 
insulin response in those with normal glucose tolerance: 0.24 (0.13-0.46) at 
baseline and 0.23 (0.19-0.37) nmol min-1 m-2 after surgery (p=0.464; Figure 
4-2B&C). The first phase insulin response was not significantly different in 
the diabetes group compared to the normal glucose tolerance group at week 
8 (p=0.453). Arginine induced maximal insulin secretory capacity (baseline 
to peak insulin secretion rate) did not change after surgery in the diabetes 
group (0.68 (0.61-0.84) at baseline to 0.64 (0.48-1.11) nmol min-1 m-2 after 
surgery; p=0.663) or in the normal glucose tolerance group (0.96 (0.81-1.16) 
and 0.70 (0.63-1.25) nmol min-1 m-2 respectively; p=0.834). 
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Figure 4-2 Stepped insulin secretion test with arginine, showing (A) the 
induced change in plasma glucose at baseline (open circles) and week 8 
(closed circles), (B) baseline insulin secretion rates (median and 25th-75th 
percentile), and (C) 8 week post-operative insulin secretion rates (median 
and 25th-75th percentile) for the diabetes group (T2DM) and the normal 
glucose tolerance group (NGT). 
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4.3.5 Hepatic triglyceride content and hepatic enzymes 
At baseline, hepatic triglyceride content was over 2-fold higher in those with 
diabetes compared to the normal glucose tolerance group (9.3±1.5 vs. 4.2±1.4 
%; p=0.022) (Figure 4-3A). After surgery, hepatic triglyceride content 
decreased to a greater extent in those with diabetes (9.3±1.5 to 5.2±0.8 %; 
p=0.018) compared to those with normal glucose tolerance (4.2±1.4 to 
2.3±0.6 %; p=0.059). These changes were reflected in the fall in serum ALT 
and GGT following surgery in the diabetes group only (Table 4-1). There 
was marked variability in baseline hepatic triglyceride content in both 
groups, but particularly those with diabetes (Figure 4-3B & C). There was 
no correlation between baseline hepatic triglyceride and pancreatic 
triglyceride contents in those with diabetes (Pearson=-0.096; p=0.714) or 
those with normal glucose tolerance (Pearson=-0.320; p=0.484). Likewise 
there was no correlation between the change in hepatic and pancreatic 
triglyceride contents in those with diabetes (Pearson=-0.224; p=0.387) or 
without (Pearson=-0.504; p=0.249).  




Figure 4-3 Effect of weight loss on change in hepatic triglyceride content in 
the diabetes (T2DM) and normal glucose tolerance (NGT) groups at baseline 
(grey) and at 8 post-operative weeks (chequered) (A). The change in 
individual hepatic triglyceride content between baseline and 8 post-
operative weeks in participants with type 2 diabetes (B) and normal glucose 
tolerance (C).  
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4.3.6 Hepatic insulin sensitivity 
Basal hepatic glucose production in the diabetes group decreased after 
surgery (3.60±0.24 to 2.69±0.12 mg/kgffm/min; p<0.001). There was no 
significant change in those with normal glucose tolerance (2.60±0.08 to 
2.51±0.20 mg/kgffm/min; p=0.555). Hepatic insulin sensitivity improved in 
both groups but the change was only significant in those with diabetes: 
hepatic IR index 2.76±0.41 to 1.33±0.23 mmol.min-1.kgffm-1.pmol.l-1 
(p=0.002); normal glucose tolerance group: 1.18±0.19 to 0.70±0.07 mmol.min-
1.kgffm-1.pmol.l-1 (p=0.062). The insulin induced suppression of hepatic 
glucose production was greater in the type 2 diabetes group at 8 post-
operative weeks: 67±4 to 85±3 %; p<0.001, with no change in the normal 
glucose tolerance group: 84±4 to 77±8 %; p=0.339. 
4.3.7 Peripheral tissue insulin sensitivity 
Insulin stimulated glucose disposal decreased in the type 2 diabetes group 
after surgery (3.23±0.34 to 2.51±0.32 mg/kgffm/min; p=0.020) and was 
unchanged in those with normal glucose tolerance (3.47±0.50 to 3.58±0.52 
mg/kgffm/min; p=0.784). Insulin stimulated glucose metabolic clearance rates 
(to correct for the difference between clamp glucose levels between studies) 
did not change in either group: 2.46 (0.86-8.80) to 2.69 (0.45-10.07) 
ml/kgffm/min in the diabetes group (p=0.223) and 4.51±0.63 to 4.79±0.70 
ml/kgffm/min in those with normal glucose tolerance (p=0.572). Both before 
surgery (p=0.033) and after surgery (p=0.024) peripheral insulin sensitivity 
was significantly lower in the diabetes group. 
4.3.8 Change in meal tolerance test 
The rise in plasma glucose over the first 20 min of the meal test was greater 
in both the diabetes and normal glucose tolerance groups following surgery 
(0.6±0.1 at baseline to 1.8±0.1 mmol/l post-operatively; p<0.001 and 0.5±0.1 
to 1.7±0.2 mmol/l; p=0.004, respectively) ( 
Figure 4-4A). The positive incremental area under the curve for glucose 
increased after surgery only in the diabetes group (Table 4-2). 2 hour post-
meal glucose was lower following surgery in both groups: 9.4±0.8 to 6.4±0.3 
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mmol/l in the diabetes group (p<0.001) and 5.5±0.2 to 5.0±0.0mmol/l in the 
normal glucose tolerance group (p=0.022). 
The incremental rise in plasma insulin over the first 20 minutes increased 
in both groups after surgery, with a higher and earlier peak plasma insulin 
being achieved. In the diabetes group the peak insulin at baseline was 
35.2±4.9 mU/l achieved at 60 (10-120) min compared to 47.7±5.8 mU/l at 20 
(10-30) min post-operatively; p=0.010. In those with normal glucose 
tolerance the peak insulin at baseline was 37.0±5.0 mU/l achieved at 60 (30-
120) min compared to 58.1±10.0 mU/l at 20 (20-30) min 8 weeks post-
operatively; p=0.032 ( 
Figure 4-4B). The positive area under the curve for insulin increased in both 
groups after surgery but this was only significant in the diabetes group 
(Table 4-2). 
Peak GLP-1 levels during the meal test increased from 5.0±0.3 at baseline to 
12.7±1.3 pmol/l after surgery in the type 2 diabetes group (p<0.001) and 
from 5.1±0.6 to 12.9±1.2 pmol/l in the normal glucose tolerance group 
respectively (p=0.001) ( 
Figure 4-4C). There was a five-fold increase in positive incremental area 
under the curve (iAUC) of GLP-1 following surgery in those with diabetes 
and four-fold increase in those with normal glucose tolerance (Table 4-2). 
Peak GIP levels increased from 197.6±18.1 to 246.2±24.4 pg/ml in the type 2 
diabetes group (p=0.051) but did not change in those with normal glucose 
tolerance: 206.7±28.6 to 231.2±32.6 pg/ml (p=0.482). There was an earlier 
rise in GIP in both groups post-operatively ( 
Figure 4-4D). There was no significant change in positive iAUC of GIP 
following surgery in either group (Table 4-2).




Figure 4-4 Glucose (A), insulin (B), total GLP-1 (C) and total GIP (D) levels 
(mean ± SEM) during the 2 hour meal test in the diabetes (T2DM) and 
normal glucose tolerance (NGT) groups at baseline (open circles) and week 8 
(closed circles). Inset graph displays fasting (open bars) and 20 min (hatched 
bars) levels at baseline compared to week 8. 
    
   
 Type 2 Diabetes Normal Glucose Tolerance 
 Baseline Week 8 p Baseline Week 8 p 
Glucose  
(mmol.l-1 .min) 







0.005 1183.8±103.7 1578.1±172.9 0.082 
GLP-1 
 (pmol.l-1 .min) 
62.6±12.7 324.1±43.4 <0.001 101.6±28.1 409.1±64.2 <0.001 
GIP  
(pg.ml-1 .min) 
7136.5±749.2 8444.1±1042.5 0.265 10417.2±1544.1 10489.2±1656.3 0.972 
 
Table 4-2 Positive incremental area under the curve during the semi-solid meal test at baseline then at 8 post-operative weeks in 
individuals with type 2 diabetes and normal glucose tolerance. 
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4.3.9 PNPLA3 
In the whole group (n=26), the rs738409 C to G adiponutrin/PNPLA3 
genotype (coding for I148M) was found in 9 individuals: 8 were heterozygous 
for the SNP: CG (148I/M) and 1 homozygous: GG (148M/M), 6 of whom had 
type 2 diabetes and 3 of whom were glucose tolerant ( 
Figure 4-5). In the diabetes group, mean baseline hepatic triglyceride 
content was 8.7±1.9 % in CC wild type compared to 10.6±2.3 % (p=0.590) in 
those a mutation (CG/GG). At 8 weeks post-operatively this was 3.9±0.5 and 
8.2±1.9 % respectively (p=0.006). The GG homozygous individual with type 2 
diabetes had a hepatic triglyceride content of 4.1% at baseline and 6.1% 
post-operatively. 
 
Figure 4-5 Allelic discrimination plot from Taqman using RT-PCR. 







wild type (CC) 
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4.4 Discussion 
Despite similar achieved weight loss following bariatric surgery in groups of 
well-matched individuals with type 2 diabetes or normal glucose tolerance, 
pancreatic triglyceride content decreased uniquely in those with diabetes. 
This was associated with normalisation of first phase insulin secretion in 
the diabetes group.  There was no change in pancreatic triglyceride in the 
normal glucose tolerance group despite a 5 unit decrease in BMI. Hepatic 
insulin sensitivity both fasting and during insulin stimulation normalised in 
those with diabetes in step with a greater decrease in liver triglyceride 
compared to those with normal glucose tolerance. The meal-related rise in 
glucose and insulin was faster in both groups after surgery and there was a 
similarly enhanced GLP-1 response. 
Type 2 diabetes develops as a consequence of positive calorie balance over 
many years and ectopic fat storage appears to be central to the disease 
process (Taylor, 2013). The importance of pancreatic triglyceride in the 
pathogenesis of the disease was initially demonstrated by a study in obese 
rodents (Lee et al., 2009). In humans significantly greater pancreatic 
triglyceride content in individuals with type 2 diabetes compared to glucose 
tolerant individuals has been demonstrated (Tushuizen et al., 2007).  
Histological studies show no adipose tissue expansion within the limiting 
membrane of the pancreas (Saisho et al., 2008) and exposure to even modest 
concentrations of fatty acids causes marked triglyceride accumulation in 
human islets in vitro (Lalloyer et al., 2006). The change in pancreas fat 
content demonstrated in type 2 diabetes is small in absolute terms (1.2% in 
56ml pancreas volume, or less than 700mg) and consistent with change in 
intracellular triglyceride content. The difficulty in demonstrating these 
modest differences in cross sectional studies has been identified and ethnic 
differences in pancreatic triglyceride content may exist (van der Zijl et al., 
2011; Szczepaniak et al., 2012). Some of the variability in results may come 
from the variety of methods used to quantify pancreatic triglyceride content. 
Using the 3 point Dixon method to measure pancreatic triglyceride should 
overcome some of the disadvantages of using MR spectroscopy by using the 
image post-acquisition to guide definition of the region of interest. However 
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the technique must be carefully applied to avoid serious errors such as 
deriving negative values for percentage triglyceride (Begovatz et al., 2015; 
Hollingsworth et al., 2015). 
In this study we have demonstrated that the increased pancreatic 
triglyceride is specifically decreased in type 2 diabetes after bariatric 
surgery whereas no change in pancreatic triglyceride occurred despite 
equivalent weight loss in those with normal glucose tolerance. The relative 
changes shown in Figure 4-1 are striking. After surgery there was a 15% 
decrease in pancreatic triglyceride content such that the 8 week post-
operative levels in the diabetes group were the same as those with normal 
glucose tolerance, demonstrating that the increase in the fat content of the 
pancreas is specific to the condition rather than being a reflection of obesity 
per se. These data are in keeping with a previous study which demonstrated 
reduction in pancreatic fat content, as measured by magnetic resonance 
spectroscopy at 6 months after bariatric surgery and also dissociation of the 
reduction in hepatic and pancreatic triglyceride contents with weight loss 
(Gaborit et al., 2015). This post-surgery decrease in pancreatic triglyceride 
content occurred at the same time as the recovery in first phase insulin 
secretion, similar to that previously observed following an 8 week very low 
calorie diet (Lim et al., 2011). It is likely that in type 2 diabetes local 
lipolysis of pancreatic triglyceride brings about interstitial and intracellular 
concentrations of fatty acids sufficient to inhibit beta cell function. Recently 
it has been shown that fatty acid receptors are expressed in mouse and 
human pancreatic beta cells and when knocked out allow recovery of insulin 
secretion (Tang et al., 2015).  
Fasting plasma glucose concentration is determined by the rate of hepatic 
glucose production (Ravikumar et al., 2008) which in turn is controlled by 
insulin (Prager et al., 1986). Hepatic insulin sensitivity is known to be 
impaired by increased hepatic triglyceride content (Seppala-Lindroos et al., 
2002; Gastaldelli et al., 2007). Short term carbohydrate overfeeding can 
induce hepatic triglyceride accumulation (Sevastianova et al., 2012) and 
furthermore, weight loss with consequent reduction in liver fat by dietary 
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means or medication is associated with improvements in insulin sensitivity 
and fasting plasma glucose levels (Petersen et al., 2005; Ravikumar et al., 
2008). The present study demonstrates a greater reduction in hepatic 
triglyceride content post-surgery in individuals with type 2 diabetes 
compared to normal glucose tolerance. Prior to surgery, hepatic triglyceride 
in those with diabetes was higher and hepatic insulin sensitivity lower 
compared with the glucose tolerant, and the post-surgery decrease in 
hepatic triglyceride content from 9.3 to 5.2% was associated with 
normalisation of hepatic insulin sensitivity. The toxic burden of fat within 
the hepatocytes is represented by the elevated hepatic enzymes (ALT and 
GGT) in the diabetes group and these normalise alongside the reduction in 
hepatic triglyceride content following surgery. In participants with normal 
glucose tolerance, hepatic glucose production was normal and the observed 
decrease in hepatic triglyceride from 4.2 to 2.3% may be assumed to be 
below the threshold for inhibition of insulin sensitivity by fat. A recent 
study reported similar reductions in endogenous glucose production in 
diabetes and glucose tolerant groups after bariatric surgery, but the latter 
group was heavier and also had higher hepatic triglyceride pre-operatively 
(Immonen et al., 2014).  
The range of baseline hepatic triglyceride in both groups is likely to reflect 
individual differences in susceptibility to the adverse metabolic effects of 
hepatic fat. Data from the UKPDS on individuals with normal BMI supports 
the concept of a variable personal fat threshold of susceptibility (Taylor and 
Holman, 2015). As one specific and known underlying factor, it appeared in 
the current study that the PNPLA3 polymorphism blunted the weight-loss 
associated decrease in hepatic triglyceride content. The G allele is thought 
to code for a lipase that is ineffective at hydrolysing triglyceride. In 
individuals with the mutation, it may be that sequestration of triglyceride in 
the liver despite weight loss might actually prevent the deleterious effects of 
metabolites of triglyceride such as diacylglycerol on the insulin signalling 
pathway.  
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The markedly increased nutrient-stimulated secretion of GLP-1 after RYGB 
is well recognised, and the present observations confirm this. However, data 
are lacking to indicate that this is the major mechanism underlying the 
improved blood glucose control. In the present study we observe 
normalisation of the first phase insulin response to a controlled intravenous 
infusion of glucose, demonstrating that the improvement was independent 
of acute incretin stimulation. This is consistent with a recent study in 
individuals with type 2 diabetes at 3 months after RYGB which observed a 
marked (2.6-fold) increase of insulin secretion in response to intravenous 
glucose as reflected by disposition index (Bojsen-Møller et al., 2014). One of 
the major changes after RYGB is that the usual function of the stomach to 
retain and process food is lost and nutrients pass rapidly into the mid-
jejunum. The dramatic extent of this change is demonstrated by studies of 
acetaminophen absorption (Falkén et al., 2011) and more rapid and 
complete absorption of simple sugars after RYGB has also been 
demonstrated (Salehi et al., 2011). A recent study compared beta cell 
function following comparable weight loss achieved by VLCD or RYGB. 
Acute insulin secretion increased similarly in both groups despite a marked 
increase in GLP-1 in the RYGB group only (Jackness et al., 2013). A specific 
GLP-1 receptor antagonist, Exendin 9-39, has been shown not to affect the 
change in post RYGB insulin secretion profile (Salehi et al., 2011; Jimenez et 
al., 2013). Most studies examining the incretin effect of RYGB have used an 
oral glucose challenge (Guidone et al., 2006; Bojsen-Møller et al., 2014) or a 
liquid mixed meal (Isbell et al., 2010) although an oral glucose load passes 
immediately into the small intestine via the gastroenterostomy, producing 
both rapid absorption and a non-physiological incretin stimulus (Salehi et 
al., 2011). The present study used a semi-solid meal to minimise the rapid 
entry of nutrients into the jejunum, but even so a more rapid rise in glucose 
levels was observed after surgery in both those with and without type 2 
diabetes. The GIP peak after the test meal was earlier and greater in both 
groups post-RYGB. Overall, it appears that acute post-meal enhanced 
incretin secretion does not explain the improved beta cell function in type 2 
diabetes following bariatric surgery. A possible longer term impact of the 
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augmented nutrient stimulated GLP-1 response upon beta cell function 
requires specific study. 
The limitations of the study must be discussed. Use of gold standard, 
validated methods for measuring hepatic triglyceride, pancreatic 
triglyceride and detailed insulin secretion studies have allowed detailed 
comparisons of the early changes in glucose metabolism after surgery in 
response to experimental conditions designed to reflect usual dietary intake. 
The group sizes were sufficient to achieve clear statistical significance, and 
although smaller numbers of normal glucose tolerant individuals were 
studied the range of responses within this group was small. Although the 
diabetes group were unselected in terms of diabetes duration and 
treatments, this is representative of the truly heterogeneous population 
undergoing bariatric surgery. Although there may have been heterogeneity 
between individuals in the exact nature of the liver reduction diet and how 
stringently this was followed, a significant variation between those with 
type 2 diabetes or normal glucose tolerance would not be expected. We 
measured total rather than active GLP-1, although the responses of active 
and total GLP-1 are tightly correlated (Heijboer et al., 2011). 
In summary, this study has demonstrated that individuals with severe 
obesity and type 2 diabetes exhibit an attenuated first phase insulin 
response and increased pancreatic triglyceride compared to BMI-matched 
glucose tolerant individuals. 8 weeks after bariatric surgery both first phase 
insulin response and pancreatic triglyceride normalise uniquely in the 
diabetes group. GLP-1 response after a semi-solid meal improved equally in 
both groups. These observations support the concept of pancreatic 
triglyceride and the resulting metabolites being central to the aetiology of 
type 2 diabetes. Understanding that type 2 diabetes is a disease of fat 
accumulation above a personal threshold lays the foundation for more 
appropriate clinical management.  
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Chapter 5. Comparison of the Early Metabolic Changes 
Following RYGB vs. VLCD in Individuals with Type 2 
Diabetes 
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5.1 Introduction 
It has been recognised since the 1950s that the metabolic derangements in 
type 2 diabetes can be ameliorated by bariatric surgery (Friedman et al., 
1955; Buchwald et al., 2004). The defects in beta cell function and insulin 
sensitivity are reversed after biliopancreatic diversion (Camastra et al., 
2007). The variable remission rates following different surgical procedures 
was initially thought to relate to the relative degrees of restriction to calorie 
intake and nutrient malabsorption induced by the procedure, and therefore 
ultimately determined by the degree of weight loss achieved (Buchwald et 
al., 2004). However, two observations suggest that this is not the case. 
Firstly, there is disparity between the resolution rates of obesity and type 2 
diabetes following surgery. Secondly, the timeframe of reversal of diabetes 
differs from that of weight loss. In a group of superobese women undergoing 
biliopancreatic diversion, it was found that the major improvement in 
metabolism occurred within one week of surgery (Guidone et al., 2006). The 
observation that glycaemic control occurs prior to any significant weight loss 
prompted further hypotheses regarding the pathophysiological mechanisms 
behind the reversal of type 2 diabetes by bariatric surgery. The major 
changes in incretin hormone secretion which occur after Roux-en-Y gastric 
bypass surgery (RYGB) became widely believed to result in the observed 
increase in meal related insulin secretion which thereby normalises glucose 
levels (Laferrere et al., 2008; Knop, 2009). The hindgut hypothesis 
postulated that rapid exposure of the distal small intestine to nutrients 
enhances the secretion of incretin hormones such as glucagon-like peptide-1 
(GLP-1). GLP-1 is released from L-cells in the ileum when stimulated by 
glucose, lipids or protein and levels have been shown to increase 
substantially after RYGB (Roux et al., 2006; Korner et al., 2007; Laferrere et 
al., 2007). The foregut hypothesis postulated that duodenal exclusion of 
nutrients suppresses secretion of anti-incretin hormones. Studies on the 
effect of gastric bypass on glucose-dependent insulinotropic polypeptide 
(GIP), secreted by K-cells in the duodenum, have shown inconsistent results 
(Rubino et al., 2004; Laferrere et al., 2008).  Several observations suggest 
that changes in incretin hormone secretion are insufficient to adequately 
   
 95  
explain the dramatic change in glucose metabolism which occurs early after 
gastric bypass surgery. Firstly, the lack of change in fasting GLP-1 secretion 
after surgery cannot explain the marked improvements in fasting glucose 
metabolism (Falkén et al., 2011). Secondly, the supraphysiological levels of 
GLP-1 achieved in clinical practice using GLP-1 receptor agonists result in 
only a modest effect on glucose levels (DeFronzo et al., 2005). Thirdly, 
although studies have shown that the use of GLP-1 receptor antagonists is 
associated with a blunting of insulin secretion after bariatric surgery, the 
antagonists do not negate the beneficial effect of surgery on the insulin 
secretion profile or glucose tolerance (Salehi et al., 2011; Jiménez et al., 
2014).  
An alternative hypothesis to explain the profound change in metabolism 
following bariatric surgery, is that it is primarily a result of obligate calorie 
restriction enforced by the surgery (Knop and Taylor, 2013). This would be 
consistent with the original observations on the Greenville bypass (Pories et 
al., 1995). One individual, in whom the procedure was abandoned due to a 
full stomach at the time of surgery, followed the same post-operative dietary 
restrictions as those who had undergone the procedure and achieved the 
same dramatic improvement in blood glucose levels. It has now been 
demonstrated that 7 days of calorie restriction alone, using a very low 
calorie diet (VLCD), can normalise fasting glucose levels in individuals with 
short duration type 2 diabetes (Lim et al., 2011). Alongside the 
normalisation of glucose levels, in the first 7 days of calorie restriction, there 
was a marked reduction in hepatic triglyceride content and a normalisation 
of hepatic insulin sensitivity. Over the 8 week VLCD there was restoration 
of first phase insulin secretion alongside a reduction in pancreatic 
triglyceride content. Several studies have attempted to directly compare the 
early metabolic effects of acute caloric restriction and bariatric surgery 
(Isbell et al., 2010; Jackness et al., 2013; Lingvay et al., 2013; Lips et al., 
2014); however the use of indirect measurements of insulin secretion and 
insulin sensitivity, use of tests involving non-physiological incretin 
stimulus, and heterogenous populations in terms of beta cell function has 
meant that no consensus has been reached.  
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This study aimed to directly compare the immediate metabolic responses to 
very low calorie diet and gastric bypass surgery in individuals with type 2 
diabetes. Specifically, it aimed to directly compare the impact of GLP-1 
secretion following a semi-solid meal 7 days after bariatric surgery with that 
after 7 days of a VLCD. Hepatic insulin sensitivity, hepatic triglyceride 
content, insulin secretion (both first phase and in response to a mixed meal) 
and pancreatic triglyceride content were also quantified.   
5.2 Study design 
5.2.1 Participants 
Individuals with type 2 diabetes listed for laparoscopic RYGB were 
identified from two regional bariatric surgery centres. Inclusion criteria 
were: diabetes duration <15 yr; aged 25-65 yr; BMI up to 45 kg/m2; and 
listed for laparoscopic gastric bypass surgery. Exclusion criteria were: 
contraindication to MR scanning; alcohol consumption >14 units per week; 
previous bowel surgery; steroid treatment, or significant renal or hepatic 
dysfunction (creatinine <150 µmol/l; ALT <2.5-fold above the upper limit of 
normal). The study protocol was approved by the Newcastle upon Tyne 1 
Research Ethics Committee. The groups were recruited by invitation letter 
from the surgical team and participants understood that they were free to 
withdraw from the study at any point. All participants provided written 
informed consent. Participants were asked to discontinue DPP-4 and 
thiazolidinediones at least one month prior to starting the study and GLP-1 
agonists at least 2 weeks prior. Metformin and sulphonylureas were stopped 
72 hours prior to studies. No insulin was given within 24 hours of the first 
study. Participants were asked to avoid intensive physical activity and 
excess alcohol or caffeine intake in the 48 hours prior to each study. 
Participants were also asked to avoid nicotine on study days. All metabolic 
studies were performed after an overnight fast. The baseline participant 
characteristics and anti-diabetic medications at recruitment are shown in 
Table 5-1. 
.
   
 97  




p value  
Gender 3M:6F 4M:5F  
Age (yr) 45.9±2.5 52.3±1.6 0.046 
Weight (kg) 120.8±5.0 121.2±3.7 0.946 
BMI (kg/m2) 43.0±1.1 42.3±0.9 0.604 
HbA1c (mmol/mol) 53 (38-92) 58 (40-103) 0.427 
Diabetes duration (yr) 7.1±1.4 6.7±1.4 0.828 
Diabetes medications: 
MF only 
MF + SU 
MF + Insulin 
MF + GLP-1 
MF + TZD 
MF + SU + GLP-1  
MF + SU + TZD 
MF + SU + DPP-4 























Table 5-1 Baseline characteristics of the surgery and VLCD groups 
5.2.2 Experimental protocol 
At recruitment, participants were randomised using online software 
(www.sealedenvelope.com) into two groups: Surgery or VLCD. Participants 
randomised to VLCD were seen prior to the first study with spouse as 
appropriate to discuss the dietary requirements in detail. All participants 
were asked to follow their surgical pre-operative liver reduction diet plans 
up to the first study point, based on a low fat and low carbohydrate diet of 
approximately 1200 kcal per day, thus all were in modest negative calorie 
balance at the time of the first study. Both groups had assessments at 
baseline and then after 7 days of intervention; Surgery group (studied before 
and then 7 days after surgery) or VLCD group (studied before and after a 7 
day VLCD, just prior to surgery). The post-operative diet was as advised by 
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the surgical team: liquids on day 1, then a semi-solid diet for the rest of the 
first post-operative week. At each study time point, a semi-solid meal test 
was used to assess metabolic and incretin responses. Hepatic and peripheral 
insulin sensitivity were also quantified using an isoglycaemic 
hyperinsulinaemic clamp with tracer studies, first phase and maximal 
insulin secretory capacity were measured using a stepped insulin secretion 
test, and pancreatic and hepatic triglyceride content were quantified by 
magnetic resonance imaging. Studies took place over 1 full day (assessment 
of insulin sensitivity and insulin secretion) and one half day (assessment of 
body composition and meal test). On the morning of the first day, after an 
overnight fast, a cannula was inserted into an antecubital vein for infusions 
and a second cannula was inserted into the contralateral wrist vein for blood 
sampling. An isoglycaemic clamp study was performed (sections 2.3.3 & 
2.3.4); isoglycaemia was chosen over euglycaemia due to the anticipated 
change in fasting glucose levels over the two study time points, and as it 
was intended to study individuals in their current metabolic state. 
Following the clamp study, participants rested for at least 60 minutes, or 
until stable fasting glycaemia had resumed. The stepped insulin secretion 
test with arginine was then performed (section 2.3.5). On day 2, after an 
overnight fast, participants underwent assessment of body composition 
using electrical bioimpedence (section 2.1.3), had an MR scan using the 3 
point Dixon technique (section 2.2.2) and then had a cannulae inserted into 
an antecubital fossa for blood sampling during the incretin meal test 
(section 2.3.6).   
5.2.3 Surgery 
RYGB was performed laparoscopically in all patients. A gastric pouch (30-50 
ml) was fashioned on the lesser curve of stomach using an ETS 45 mm 
linear stapler firing blue (6R45B) cartridges (Ethicon Endosurgery; 
Cincinnati, OH). A biliopancreatic limb of 50-70 cm from the duodenojejunal 
flexure was anastomosed to the gastric pouch. An alimentary limb of 100-
150 cm was then measured and a side to side antimesentericjejuno-
jejunostomy carried out. The roux construction was completed by dividing 
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the omega loop close to the gastrojejunostomy. At the time of operation, 2 
patients with type 2 diabetes underwent sleeve gastrectomy instead of 
RYGB due to the presence of significant intra-abdominal adhesions. These 2 
patients have been excluded from the incretin analyses (Yousseif et al., 
2014). 3 day food diary analyses calculated that calorie intake in the first 
post-operative week was 449±53 kcal/day.  
5.2.4 Very low calorie diet 
Following baseline assessments the VLCD group commenced a prescribed 7 
day VLCD using a liquid meal replacement product (Optifast; Nestle 
Nutrition, Croydon, UK) providing 624 kcal/day (2∙6 MJ/day); 43% 
carbohydrate, 34% protein and 19.5% fat plus the recommended daily intake 
of vitamins, minerals and trace elements. In addition, participants were 
encouraged to take up to 240g of non-starchy vegetables to add fibre and 
variation with the intention of aiding compliance with the diet. A list of 
appropriate vegetables and recipe ideas was provided. Participants were 
also encouraged to drink at least 2L of calorie free beverages per day and to 
continue usual levels of physical activity. Support was provided to all 
participants by means of daily contact via e-mail/telephone call or text 
message.   
5.2.5 Statistical analysis 
Data are presented as mean ± SEM for parametric and median (range) for 
non-parametric data. Insulin secretion rates are given as median with 25th 
and 75th percentile. Statistical analysis used Student’s t-test, paired t-test, 
Mann-Whitney U test, Wilcoxon Rank and Spearman Rank correlations as 
appropriate using Minitab 16 statistical program (Minitab Inc.; State 
College, PA: www.minitab.com). 
5.3 Results 
5.3.1 Weight loss, body composition and fat distribution 
Weight loss was greater 7 days following surgery compared to after 7 days of 
VLCD (6.2±0.7 kg (5.1±0.5 %) vs. 4.3±0.5 kg (3.5±0.4 %); p=0.030). The 
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components of weight loss were notably different in the surgery vs. VLCD 
groups ( 
Table 5-2), with the additional weight loss in the surgery group consisting of 
lean mass (-2.5±0.3 vs. -1.3±0.6 kg; p=0.108). Decrease in fat mass was 
almost identical after surgery vs. VLCD (3.0±0.3 vs. 3.0±0.7 kg). Waist and 
hip circumference decreased significantly in both groups. There was no 
significant change in either subcutaneous or visceral adipose tissue areas at 











7 days after 
Surgery 
p 
Weight (kg) 121.4±3.7 117.1±3.6 <0.001 120.8±5.0 114.6±4.7 <0.001 
BMI (kg/m2) 42.3±0.9 40.9±0.9 <0.001 43.0±1.1 40.9±1.2 <0.001 
Fat mass (kg) 55.7±4.0 52.8±4.2 0.002 57.5±3.3 54.5±3.3 <0.001 
Lean mass (kg) 65.6±3.7 64.3±3.7 0.075 62.1±4.6 59.6±5.1 <0.001 
Body water (L) 49.4±2.4 47.8±2.1 0.012 46.7±3.3 44.3±3.1 <0.001 
Waist circ (cm) 128.6±3.1 125.8±3.0 0.010 127.5±3.1 124.1±2.8 <0.001 
Hip circ (cm) 132.0±2.1 129.9±2.2 0.021 131.9±3.5 129.4±3.6 <0.001 
Waist:Hip ratio 0.97±0.02 0.97±0.02 0.612 0.97±0.04 0.97±0.04 0.287 
VAT area (cm2) 313.2±24.1 303.5±19.2 0.371 283.0±30.0 272.6±21.9 0.437 
SAT area (cm2) 403.8±26.5 410.9±30.6 0.587 510.2±48.0 496.5±48.8 0.361 
 
Table 5-2 Anthropometric data before and then after 7 days of VLCD or 7 days after Surgery. There were no significant 
differences in any parameters between the groups either at baseline or at day 7. Values are shown as mean ± SEM. VAT = visceral 






5.3.2 Plasma glucose, insulin, glucagon and metabolites 
Fasting plasma glucose levels fell modestly and similarly in both groups 
(1.2±0.6 mmol/l following VLCD and 0.9±0.5 mmol/l following Surgery; 
p=0.739). The decrease in 2 hour glucose during the meal test was only 
significant in the Surgery group (Table 5-3). Fasting and 2 hour insulin 
levels were higher at baseline in the VLCD group, but appeared to decrease 
in both groups after intervention although this was not statistically 
significant. Fasting β-hydroxybutyrate levels increased almost 3-fold in both 
groups at day 7. There was no significant change in fasting NEFA or 
glucagon in either group. Serum ALT appeared to increase in both groups 
after 7 days of intervention, however, GGT decreased only following the 
VLCD. The change in serum triglycerides was divergent and this difference 
was significant: after surgery (0.3 (-0.3-0.8) mmol/l and after VLCD (-0.1 (-





 Before VLCD 7 days after 
VLCD 
p Before Surgery 7 days after 
Surgery 
p 
Fasting glucose (mmol/l) 10.5±1.4 9.4±1.2 0.078 8.0±0.7 7.1±0.6 0.105 
2hr glucose (mmol/l) 10.4±1.4 9.5±1.0 0.175 8.4±0.7 7.3±0.6 0.040 
Fasting insulin (mU/l) 18.5 (13.5-44.6) 14.8 (10.6-38.8) 0.813 13.5 (4.3-61.2) * 9.8 (5.2-23.2) # 0.076 
2hr insulin (mU/l) 22.3 (18.3-78.9) 19.5 (10.1-76.2) 0.363 14.4 (5.2-70.5) * 11.0 (5.6-28.3) 0.124 
Fasting β-
hydroxybutyrate (mmol/l) 
0.22±0.07 0.63±0.17 0.005 0.29±0.06 0.86±0.18 0.019 
Fasting NEFA (mmol/l) 0.85 ± 0.13 0.91 ± 0.08 0.402 0.85 ± 0.11 0.96 ± 0.08 0.087 
Fasting glucagon (ng/l) 63.9 (27.3-117.4) 51.0 (37.7-129.3) 0.636 61.3 (33.3-203.8) 58.5 (40.3-124.7) 0.124 
Fasting triglycerides 
(mmol/l) 
1.7 (0.6-3.7) 1.3 (0.8-2.4) 0.193 1.3 (1.0-2.0) 1.8 (0.9-2.0) 0.124 
Fasting ALT (U/l) 34.7 ± 6.4 39.9 ± 7.2 0.020 40.8 ± 5.2 61.4 ± 9.9 0.108 
Fasting GGT (U/l) 33 (20-113) 27 (15-81) 0.014 39 (13-148) 40 (29-241) 0.155 
 
Table 5-3 Metabolic response to 7 days of either VLCD or Surgery. Values are mean ± SEM or median (range). * p<0.05 for 







5.3.3 Incretin meal test 
Following surgery, the gastroenterostomy caused a significantly greater 
early rise in post-meal plasma glucose (Figure 5-1A & Figure 5-2A). This 
was associated with a greater early rise in insulin (4.5±2.2 to 22.5±6.9 mU/l; 
p=0.063) which was unchanged after VLCD (5.7±2.3 to 3.8±2.3 mU/l; 
p=0.493). The early rise in insulin correlated with the rise in plasma glucose 
(Spearman rank=0.867; p=0.002). The resulting greater early insulin 
secretion did not fully compensate as shown by the overall glucose AUC, and 
indeed there was a modest increase in glucose AUC in the surgery group 
(Figure 5-1B). There was no significant change in insulin AUC in either 
group. If GLP-1 was driving the insulin response, then it would be expected 
to be directly proportionate to the change in insulin/glucose ratio. No such 
relationship was observed (Spearman rank: Surgery: =-0.214; p=0.610; 
VLCD: -0.190; p=0.651; Whole group: 0.365; p=0.165). The considerable 
extent and duration of the postprandial rise in GLP-1 can be appreciated 
from the plasma hormone profile (Figure 5-2C). The GIP response to the 
meal test appeared to increase at 7 days after Surgery but the change in 
AUC was not significant. The AUC for GIP was not altered by VLCD 







Figure 5-1 Incremental change in glucose, insulin, total GLP-1 and total 
GIP from fasting to 20 minutes (A) and change in positive incremental area 
under the curve (B) during the semi-solid meal test before (pale) and 7 days 
after (dark) intervention (VLCD or Surgery). Data are shown as mean ± 






Figure 5-2 Glucose (A), insulin (B), total GLP-1 (C) and total GIP (D) levels 
(mean ± SEM) during the 2 hour meal test in the VLCD and Surgery groups 





5.3.4 Insulin response to intravenous stimulus 
First phase insulin secretion (baseline to 6 min increment in insulin 
secretion rate in response to an intravenous glucose challenge) was 
unchanged at day 7 compared to baseline in both groups: 0.08 (0.07-0.10) to 
0.06 (0.00-0.13) nmol min-1 m-2 in the Surgery group (p=0.722) and 0.04       
(-0.03-0.10) to 0.10 (0.08-0.14) nmol min-1 m-2 in the VLCD group (p=0.155). 
There was no change in maximal insulin secretory capacity in response to 
an arginine bolus (baseline to peak insulin secretion rate) in either the 
Surgery group (0.80 (0.63-0.84) to 0.67 (0.54-1.46) nmol min-1 m-2; p=0.906) 
or the VLCD group (0.67 (0.53-0.70) to 0.54 (0.43-0.72) nmol min-1 m-2; 
p=0.477).  
5.3.5 Hepatic insulin sensitivity 
Concordant with the modest change in fasting plasma glucose levels, basal 
hepatic glucose production did not change significantly in either group: 
3.48±0.32 to 3.43±0.63 mg/kgffm/min in the VLCD group (p=0.906) compared 
to 3.71±0.36 to 3.16±0.33 mg/kgffm/min in the Surgery group (p=0.083). 
Hepatic insulin sensitivity did not change significantly in either the VLCD 
or Surgery group although there was a trend toward improvement; 
measured either as hepatic IR index: 2.38 (1.07-4.62) to 1.97 (0.60-6.98) 
mmol.min-1.kgffm-1.pmol.l-1  (p=0.427) and 2.15 (0.61-8.02) to 1.25 (0.20-3.14) 
mmol.min-1.kgffm-1.pmol.l-1 (p=0.077) respectively, or percentage suppression 
of hepatic glucose production induced by insulin: 61.7±5.5 to 73.0±5.7 % 
(p=0.173) and 73.2±4.6 to 78.9±7.2 % (p=0.448) respectively.  
5.3.6 Peripheral tissue insulin sensitivity  
There was no significant change in peripheral insulin sensitivity expressed 
as glucose disposal rates during either 7 day intervention. Insulin-
stimulated glucose disposal was 3.48±0.54 then 3.21±0.83 mg/kgffm/min 
(p=0.594) in the VLCD group and 2.97±0.43 then 2.37±0.37 mg/kgffm/min 
(p=0.186) in the Surgery group. Glucose metabolic clearance rate (MCR) was 
calculated to correct for the difference in fasting plasma glucose between the 





either intervention; VLCD: 2.21 (0.91-8.80) to 1.83 (1.10-13.79) ml/kgffm/min 
(p=0.791) and Surgery: 2.55 (0.86-5.15) to 2.40 (0.59-3.94) ml/kgffm/min 
(p=0.724). 
5.3.7 Intra-organ triglyceride content 
Hepatic triglyceride content decreased in both groups; VLCD by 18.6±4.0 % 
and Surgery by 29.8±3.7 % (p=0.058) (VLCD: 11.8±2.2 to 9.8±1.9 %; p=0.003 
and Surgery: 6.5±1.6 to 4.5±1.0 %; p=0.029). However, there was a strikingly 
different relationship to weight loss within each group. After VLCD, the fall 
in hepatic triglyceride was directly related to the extent of weight loss 
(Pearson r=0.798; p=0.010), whereas after surgery the greatest reduction in 
hepatic triglyceride occurred in participants with modest weight loss 
(Pearson r=-0.833; p=0.010) (Figure 5-3). This effect was not explained by 
PNPLA3 genotype: the rs738409 C to G adiponutrin/PNPLA3 genotype 
(coding for I148M) was found in 4 individuals in the VLCD group (one 
homozygous and 3 heterozygous; change in hepatic triglyceride 4.1 to 3.2% 
and 13.9±1.8 to 12.2±1.7% respectively) and 1 individual in the Surgery 
group (heterozygous; change in hepatic triglyceride 7.2 to 4.8%). There was 
no correlation between the reduction in hepatic triglyceride content and the 
reduction in lean mass in the Surgery group (Spearman rank=-0.094; 
p=0.840). There was no correlation between the change in hepatic 
triglyceride content and change in either serum triglycerides or serum ALT 
in either group. There was no change in pancreatic triglyceride content after 
7 days of either VLCD or Surgery (6.4±0.6 to 6.5±0.7 %; p=0.781 and 6.7±0.7 






Figure 5-3 Relationship between achieved weight loss and reduction in 
hepatic triglyceride content after 7 days of VLCD or 7 days after Surgery. 
 
5.4 Discussion 
This study demonstrates that despite greater weight loss at 7 days after 
surgery, the improvement in fasting plasma glucose was modest and not 
significantly greater than 7 days after VLCD. After surgery, a greater early 
rise in plasma glucose after the test meal was associated with a greater 0-20 
minute rise in both plasma insulin and GLP-1. The latter was 7 fold greater 
in the surgery group compared to the VLCD group and plasma levels 
remained higher throughout the test meal period. Despite this, the 
incremental AUCs for insulin and glucose were not significantly different 
between the VLCD and Surgery groups. There was no association between 
the extent of GLP-1 rise and insulin secretion independent of the glucose 
stimulation and the marked increase in GLP-1 did not confer a clear benefit 
on post-meal glucose levels or insulin secretion. There was no change in 
non-incretin dependent beta cell function as assessed by the stepped 
intravenous insulin secretion test in either Surgery or VLCD groups. 
Differences were observed between the 7 day response to RYGB or VLCD in 
components of body weight change and also in the relationship between 





The increased meal stimulated GLP-1 noted only in the surgery group did 
not seem to be accompanied by any additional benefits over the diet group. 
This is not in keeping with the widespread acceptance that GLP-1 has a 
determinant role in improving postprandial insulin secretion after RYGB 
(Holst, 2011; Naslund and Hellstrom, 2013; Vella, 2013; Goldfine and Patti, 
2014). It may be that the changes in GLP-1 secretion are secondary to the 
rapid rerouting of nutrients through the gut. Studies have demonstrated 
that d-xylose (Salehi et al., 2011) and acetaminophen (Falkén et al., 2011) 
are absorbed more rapidly and reach higher peak levels following gastric 
bypass surgery. The alterations in insulin and incretin hormone secretion 
may be secondary phenomena related to change in post-operative glucose 
profile. The greatest metabolic change seen after bariatric surgery is 
decreased fasting glucose, which would not be expected to be affected by 
postprandial secretion of GLP-1. A previous comparison of a matched group 
of obese individuals with type 2 diabetes before and one month after RYGB 
and a matched group undergoing 10kg dietary weight loss demonstrated 
that stimulated GLP-1 and GIP levels increased after surgery but not after 
diet induced weight loss (Laferrere et al., 2008). There was a similar 
reduction in fasting glucose, insulin, C-peptide and HOMA-IR in both 
groups. The authors concluded that the incretin effect explained the 
improvement of glucose control after RYGB, however the data show that the 
peak plasma glucose was higher after surgery and the calculated incretin 
effect did not differ after surgery or diet.  
In contrast to the lack of definitive data on the role of GLP-1 in the post 
RYGB improvement in glycaemic control, several studies have 
demonstrated the greater improvement in fasting plasma glucose by calorie 
restriction alone (Isbell et al., 2010; Lingvay et al., 2013). The earlier effects 
of RYGB on glucose metabolism, that is within 4 days of surgery, have been 
compared to calorie restriction using replication of the post-RYGB diet in a 
group which included some individuals with type 2 diabetes (Isbell et al., 
2010). The increase in meal stimulated GLP-1 after surgery was not 
accompanied by any additional benefits over the diet group. Another study 





diabetes due to have RYGB in a paired design using individuals as their 
own controls (Lingvay et al., 2013). After 10 days of VLCD there was a 
significant improvement in fasting glucose, peak glucose and glucose AUC 
during a mixed meal challenge test but not in the early post RYGB phase 
despite a greater GLP-1 response after surgery. These studies, together with 
the present data, indicate that the major mechanism underlying the change 
in glucose control in the early post-operative period is severely restricted 
oral calorie intake. This does not preclude a role for the ongoing cumulative 
effects of markedly increased postprandial GLP-1 in the more extended 
post-operative period, which could include augmentation of beta cell mass 
and/or function. This requires further investigation.  
This study has demonstrated some differences in the metabolic state at 7 
days after RYGB compared to VLCD. There were similar differences in the 
decrease in fat mass, but surgery appeared to induce a larger decrease in 
lean mass, which may represent a catabolic response to the surgery. The 
differing relationship between fall in hepatic triglyceride and achieved 
weight loss following VLCD and bariatric surgery has not, to my knowledge, 
been demonstrated previously. At 7 days after surgery, participants with 
the greatest weight loss had the smallest reduction in hepatic triglyceride 
content. Exacerbation of fatty liver disease following jejuno-ileal bypass has 
been reported, ranging from transient worsening of inflammation and 
fibrosis to steatosis and rarely to fulminant hepatic failure (Peters et al., 
1975) and it is possible that the underlying mechanism for this could disturb 
the relationship. One hypothesis would be that this is due to massive fatty 
acid mobilisation from visceral stores, reaching the liver through the portal 
vein, which would also fit with the elevated NEFA and triglycerides 
resulting in a metabolic insult to hepatocytes and an elevated ALT. Another 
possibility is that the GLP-1 peak after every meal might produce a 
cumulative effect on liver fat content. A decrease in liver fat has been seen 
with therapeutic use of both GLP-1 agonists (Cuthbertson et al., 2012) and 
DPP-4 inhibitors (Macauley et al., 2015a). In view of this possible 
relationship, the extent of post-meal GLP-1 elevation and fall in liver fat in 





0.590; p=0.016) between peak GLP-1 and fall in hepatic triglyceride content 
is suggestive of a causal relationship and this requires further examination.  
Ectopic fat storage is central to the pathophysiology of type 2 diabetes 
(Taylor, 2013). The importance of pancreatic triglyceride in the pathogenesis 
of diabetes was suggested by a study in obese rodents showing an increase 
in triglyceride accumulation in the pancreas prior to the onset of type 2 
diabetes (Lee et al., 2009). In humans significantly greater pancreatic fat 
content in individuals with type 2 diabetes compared to those with normal 
glucose tolerance has been demonstrated (Tushuizen et al., 2007). However, 
the data on the relationship between pancreatic triglyceride content and 
beta cell function in humans is discordant (Tushuizen et al., 2007; Heni et 
al., 2010; van der Zijl et al., 2011). Pancreatic triglyceride content has been 
shown to correlate with hepatic triglyceride content and hepatic insulin 
resistance (Hannukainen et al., 2011). A previous study demonstrated a 
significant improvement in first phase insulin secretion after 8 weeks of 
VLCD alongside a reduction in pancreatic triglyceride content, with no 
meaningful change after 7 days (Lim et al., 2011). The present data confirm 
this for VLCD and show that the same is true following bariatric surgery. 
Similarly, a decrease in pancreatic triglyceride content and improvement in 
first phase insulin secretion has been demonstrated at 8 weeks after 
bariatric surgery (data in chapter 4). It may be that although hepatic 
triglyceride stores are utilised early during calorie restriction, pancreatic 
triglyceride stores may decrease more gradually.  
In this study, change in beta cell function does not explain the early 
improvement in glucose control seen after bariatric surgery. In contrast, 
both hepatic triglyceride content and hepatic insulin sensitivity improve 
rapidly during calorie restriction. Fasting plasma glucose concentration is 
determined by the rate of hepatic glucose production (Ravikumar et al., 
2008) and elevated liver fat concentration is associated with decreased 
insulin sensitivity to suppression of hepatic glucose production (Seppala-
Lindroos et al., 2002; Gastaldelli et al., 2007). Short term carbohydrate 





and furthermore, weight loss with consequent reduction in liver fat by 
dietary means (Petersen et al., 2005) or by Pioglitazone (Ravikumar et al., 
2008) is associated with improvements in insulin sensitivity and fasting 
plasma glucose levels. The design of this study, with pre-operative calorie 
restriction due to surgical requirements, minimised change in hepatic 
insulin resistance, but it is known that liver fat content continues to fall 
beyond the first week of calorie restriction (Lim et al., 2011). In the latter 
study, all eleven participants achieved a fasting glucose level of <7mmol/l 
after 7 days of VLCD. The lower rates of achieving a normal fasting glucose 
level seen in the current study (33% (3/9) of the VLCD and 44% (4/9) of the 
Surgery group) is likely to relate to the difference in the populations 
studied. The cohort reported by Lim et al. had less severe obesity (mean 
BMI 33.6 vs. 42.7 kg/m2), a shorter diabetes duration (all < 4yr vs. median 
6.25 yr), and required less anti-diabetic treatment at baseline (Metformin 
and Sulphonylurea only vs. insulin and triple oral therapy).  
The limitations of the study must be discussed. There was baseline 
heterogeneity between the VLCD and Surgery groups; both groups were in 
negative calorie balance prior to their surgery but the degree of compliance 
with the pre-operative diet advised by the surgical teams was not able to be 
quantified and may have been highly variable. The baseline heterogeneity 
does not preclude comparison of the changes in the first 7 days of either 
intervention. The fact that body water content decreased similarly in the 2 
groups after 7 days suggests both groups were in a similar phase of calorie 
restriction, with glycogen stores being utilised first (Henry and Gumbiner, 
1991). The lack of change in peripheral insulin sensitivity in the surgery 
group and the similar changes between the surgery and VLCD groups 
makes it very unlikely that there has been any significant blunting of the 
effect of surgery by a temporary post-operative insulin resistance. The 
potential effect of the different macronutrient content of the dietary intake 
of the two groups during the 7 day interventions must be considered. This 
could be a potential explanation for the greater loss of lean mass in the 
surgery group. However, over this short period of time, any effect is likely to 





intake, which was similar with the meal replacement product and the high 
protein semi-solid post-operative diet advised by the surgical dieticians. In 
this study, the unselected population in terms of diabetes duration and 
treatments is representative of the truly heterogeneous population 
undergoing bariatric surgery. The small numbers in each group were 
necessary given the practical time constraints of this study and the complex 
physiological studies undertaken. The potential carry-over effect of anti-
diabetic medications is a possibility; however, this would be the same in 
both the Surgery and VLCD group and is unlikely to have significantly 
influenced the baseline results. The study design differs from the majority of 
studies after RYGB in that an oral glucose challenge was not used and this 
must be borne in mind when comparing with results from earlier studies. 
However, the use of a semi-solid test meal allows assessment of post-meal 
physiology following RYGB in response to experimental conditions designed 
to reflect usual dietary intake. 
This study suggests that the more rapid entry of food into the small 
intestine causes both a more rapid rise in plasma glucose and a more rapid 
rise in insulin. No relationship of this with the large postprandial rise in 
plasma GLP-1 could be detected. There were similar reductions in glucose 
levels and hepatic triglyceride content achieved by 7 days of VLCD and at 7 
days after RYGB. No change was observed in either beta cell function or 
pancreatic triglyceride content at 7 days after either intervention.
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Chapter 6. Pathophysiology & Reversibility of Long 
Duration Type 2 Diabetes Compared to Short Duration 
Disease
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6.1 Introduction 
The landmark UK Prospective Diabetes Study demonstrated that glucose 
control in type 2 diabetes steadily worsened towards an inevitable 
requirement for insulin treatment despite best possible therapy (UKPDS, 
1995a). Since this study the progressive and irreversible nature of type 2 
diabetes has been widely accepted. Moreover, the approach to management 
has developed around this concept with guidelines laying out the sequential 
addition of therapies prior to initiation of insulin therapy (NICE, 2015). It 
has been recognised for over 3 decades that normalisation of glucose control 
can occur following bariatric surgery. More recently it has been 
demonstrated that a very low calorie diet can also reverse the 
pathophysiological defects of type 2 diabetes and normalise glucose control 
(Lim et al., 2011). This latter study selected individuals with type 2 diabetes 
of duration less than four years. Studies investigating the factors associated 
with diabetes remission following bariatric surgery have identified duration 
of diabetes of more than 10 years as a potential limiting factor (Renard, 
2009; Hall et al., 2010). In line with this, the most recent NICE guidance on 
bariatric surgery has recommended expedited assessment for surgery in 
individuals with a BMI in excess of 35kg/m2  or who have recent onset type 2 
diabetes, which was considered to be within 10 years from diagnosis (NICE, 
2014 ). In chapter 3, a retrospective data collection showed that reversal to 
normoglycaemia can be achieved in long duration type 2 diabetes following 
bariatric surgery, but that greater weight loss is required to achieve 
reversal compared to short duration disease. 
There is compelling evidence that of the multiple pathophysiological defects 
seen in type 2 diabetes, it is beta cell dysfunction that determines the onset 
of hyperglycaemia and whether or not blood glucose control can be achieved 
(Ferrannini et al., 2004). Studies investigating C-peptide response to 
glucagon (Zangeneh et al., 2006) or during oral glucose tolerance testing 
following calorie restriction (Jain et al., 2008) in long duration type 2 
diabetes concluded that although a decline in beta cell function over time is 
characteristic, it is not inevitable and there was much variation between 
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individuals. A recent study on outcomes of gastric bypass surgery at 2 years 
in individuals with short duration (<5 yr) and long duration (>10 yr) 
diabetes demonstrated that the better glycaemic outcomes in the former 
group were related to greater improvement in beta cell function post-
operatively (Khanna et al., 2015).  
In vitro work suggests a key role for fat in causing beta cell dysfunction in 
type 2 diabetes, in particular, the metabolites of triglyceride such as 
ceramides and diacylglycerol. Lipid-induced reversible inhibition of glucose 
sensitive insulin secretion has been demonstrated (Lee et al., 1994; Cnop, 
2008). Furthermore, it appears likely that the toxic effects of lipid 
metabolites on beta cells could explain both the onset and reversibility of 
beta cell dysfunction (Kashyap et al., 2003; Morgan et al., 2008; Taylor, 
2013). These same inhibitory molecules can induce beta cell apoptosis 
(Shimabukuro et al., 1998a). As well as beta cell dysfunction, a time-
dependent reduction of functional beta cell mass could limit the capacity to 
return to normal glucose control in longer duration type 2 diabetes (Rahier 
et al., 2008). Recent work demonstrating ongoing beta cell replication and 
neogenesis in adult life gives theoretical hope of diabetes reversal at any 
stage of the disease. Removal of the toxic milieu caused by ectopic lipid 
deposition could allow existing beta cells to recover function and then with 
downregulation of apoptotic pathways there is potential for beta cell mass 
expansion and redifferentiation (White et al., 2013).  
The pathways by which fat metabolites can impair insulin sensitivity in 
liver and muscle have now been defined. Activation of protein kinase C 
epsilon type inhibits the signalling pathway from the insulin receptor to 
insulin receptor substrate 1 (Samuel et al., 2010). There is a clear 
relationship between liver fat and hepatic insulin sensitivity, and weight 
loss achieved either by diet (Petersen et al., 2005) or bariatric surgery 
(Immonen et al., 2014) reduces liver fat and improves hepatic insulin 
sensitivity, the latter being the major determinant of fasting glucose levels.  
There is now accumulating evidence that pancreatic fat content could be a 
biomarker for beta cell dysfunction. Pancreatic fat levels rise prior to the 
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development of type 2 diabetes in rodents (Lee et al., 1994). In humans 
supranormal pancreas triglyceride content has been associated with beta 
cell dysfunction (Tushuizen et al., 2007).  More recently normalisation of 
first phase insulin secretion has been seen alongside a reduction in 
pancreatic triglyceride content induced by weight loss (Lim et al., 2011) 
Identification of the location of triglyceride within the pancreas has been 
hampered by rapid post-mortem autolysis, but study of pancreata retrieved 
but not used for pancreas transplantation has provided clear information 
(Pinnick et al., 2010). Intracellular fat droplets are widely distributed within 
the exocrine pancreatic cells, in addition to widely scattered isolated 
adipocytes. Recently it has been shown that fatty acid receptors are 
expressed in human pancreatic beta cells (Tang et al., 2015) and in vitro 
exposure of human islet cells to fatty acids causes marked triglyceride 
accumulation (Lalloyer et al., 2006). It is hypothesised that the export of 
excess fat from the liver in the form of VLDL-triglyceride may be one of the 
mechanisms by which excess fat accumulates in and around beta cells 
causing dysfunction (Taylor, 2013). It is likely that local lipolysis could 
result in interstitial and intracellular concentrations of fatty acids sufficient 
to inhibit beta cell function. 
The aims of this study were to establish the pathophysiological differences 
between long and short duration type 2 diabetes, and to establish how 
effectively a VLCD could improve glucose control in long duration compared 
to short duration type 2 diabetes.  This has not previously been investigated 
and the results could have important implications for the management of 
type 2 diabetes in everyday clinical practice. 
6.2 Study design 
6.2.1 Participants 
Individuals with type 2 diabetes were identified in response to local 
advertisement; 15 with short duration disease (defined as <4yr duration) 
and 15 with long duration disease (defined as >8yr duration) were recruited. 
Inclusion criteria were age 25-80 years; type 2 diabetes treated by diet, 
metformin, sulphonylurea, DPP-4 inhibitors and/or insulin; and BMI 27-45 
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kg/m2. Exclusion criteria were loss of more than 5kg body weight in the 
preceding 6 months, treatment with thiazolidinediones, GLP-1 agonists, 
steroids or atypical anti-psychotic medications, untreated thyroid disease, 
renal dysfunction (serum creatinine >150 µmol/l) or alcohol consumption >3 
units per day for women and >4 units per day for men. The history of the 
diagnosis of diabetes was taken carefully to clinically exclude alternate 
diagnoses than type 2 diabetes. Date of diagnosis of type 2 diabetes was 
confirmed from primary care medical records. The study protocol was 
approved by Newcastle and North Tyneside 2 Ethics Committee and all 
participants gave informed written consent. Participants were asked to 
remain on their usual dose of lipid lowering treatment throughout the 
study. Anti-hypertensive medications were decreased as necessary 
throughout the study. Participants were asked to discontinue all anti-
diabetic therapy prior to the baseline study: metformin and sulphonylureas 
for 72 hours; long acting insulin for >36 hours and short acting insulin for 
>12 hours. Dietary adherence was assessed using blood ketones. As in a 
previous study, participants were excluded if they were unable to achieve 
weight loss targets of 3∙8% body weight at week one of the VLCD and 9∙3% 
at week four (Lim et al., 2011). Only one participant in the long duration 
group did not meet the weight loss target and left the study after week one. 
Hence the final numbers were 15 in the short duration group and 14 in the 
long duration group. The baseline characteristics for the participants who 
completed the VLCD are shown in Table 6-1. 
.









Gender 15M:14F 7M:8F 8M:6F  
Age (yr) 56.7±1.8 52∙1±2∙6 61∙6±2∙0 0∙007 
Weight (kg) 98.0±2.6 99∙0±3∙7 96∙9±3∙8 0∙683 
BMI (kg/m2) 34.2±0.7 34∙1±0.8 34.3±1.2 0∙862 
Fat mass (kg) 39.1±1.9 38.8±2.3 39.4±3.3 0.881 
Body water (L) 43.8±1.5 44.4±2.2 43.2±2.1 0.705 
Lean mass (kg) 58.9±2.3 60.2±3.2 57.5±3.3 0.549 
Diabetes duration (yr) 7.3±1.1 2∙3±0∙3 12∙7±1∙2 <0∙001 
Fasting plasma glucose 
(mmol/l) 































Anti-hypertensives (n) 17 6 11  
Statins (n) 19 9 10  
Table 6-1 Baseline participant characteristics and anthropometrics for the short and long duration groups. Data are mean ± SEM. 
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6.2.2 Experimental protocol 
Participants were asked to continue their habitual pattern of eating until 
the start of the study. They were seen prior to the first study with 
family/friends as appropriate to discuss the very low calorie diet 
requirements in detail. They were asked to avoid intensive physical activity 
and excess alcohol or caffeine intake in the 48 hours prior to each study and 
to avoid nicotine on study days. Assessments of body composition, beta cell 
function, hepatic and peripheral insulin sensitivity, hepatic and pancreatic 
triglyceride content, and hepatic VLDL1-triglyceride production were carried 
out at baseline. Assessments took place over 1 half day then 1 full day. All 
studies were performed after a 12 hour overnight fast. On the morning of 
the half day, anthropometric and body composition measurements were 
made using electrical bioimpedence (section 2.1.3)  and hepatic and 
pancreatic triglyceride measured using the 3 point Dixon MR method 
(section 2.2.2). Resting metabolism was assessed using indirect calorimetry 
(section 2.1.4). A cannula was then inserted into an antecubital fossa for 
infusion of Intralipid to measure VLDL1-triglyceride production rate, and a 
second cannula was inserted in the contralateral arm for blood sampling 
(section 2.3.8). On the morning of the full day, a cannula was inserted into 
an antecubital fossa for infusions and a second cannula inserted into the 
contralateral wrist for arterialised blood sampling. Assessments of hepatic 
and peripheral insulin sensitivity were made using an hyperinsulinaemic 
isoglycaemic clamp study (sections 2.3.3 & 2.3.4). Following the clamp, 
participants rested for a minimum of 60 min and until stable fasting glucose 
levels were re-established. Insulin secretion was then assessed using a 
stepwise insulin secretion test with arginine (section 2.3.5).   
6.2.3 Very low calorie diet 
Following completion of baseline assessments, all participants commenced 
an 8 week very low calorie diet. This was provided using a meal replacement 
liquid formula diet (43% carbohydrate, 34% protein and 19.5% fat; vitamins, 
minerals and trace elements; 2∙6 MJ/day [624 kcal/day]); Optifast; Nestlé 
Nutrition, Croydon, UK). In addition, participants were asked to consume 
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up to 240g of non-starchy vegetables per day, such that the total energy 
intake per day was 624-700 kcal. Participants were provided with detailed 
information on vegetable and recipe ideas. They were also encouraged to 
drink at least two litres of calorie-free beverages per day and to maintain 
their habitual levels of physical activity. In order to maximise adherence to 
the protocol, one-to-one support was provided weekly by telephone, e-mail, 
text or face-to-face contact. Additional face-to-face contact was provided if 
requested, but this was rare and similar between the groups. Participants 
were seen at week 1, week 4 and then at the end of the 8 week diet for 
fasting blood tests, anthropometry and blood pressure measurement.  
Statistics 
Statistical analyses were performed using Minitab 16 Statistical Software 
(Minitab Inc.; State College, PA: www.minitab.com). Data are presented as 
mean ± standard error of the mean, or median (range) for non-parametric 
data. Insulin secretion rates and hepatic insulin resistance indices are 
presented as median with 25th and 75th percentile. Statistical comparisons 
between the short and long duration groups were performed using the two-
tailed Student’s t-test or Mann Whitney U test, while within-group 
differences before and after the VLCD were determined using a two-tailed 
Student’s paired t-test or Wilcoxon rank test if non-parametric. Correlations 
were examined using the Spearman rank test. Statistical significance was 
accepted at p<0∙05.  
6.3 Results 
6.3.1 Pathophysiological differences between long and short 
duration type 2 diabetes 
Fasting metabolism 
Individuals with long duration type 2 diabetes had poorer baseline 
glycaemic control represented by a higher fasting plasma glucose and 
HbA1c (Table 6-1). There was a wide and overlapping range of baseline C-
peptide levels but the long duration group had significantly lower fasting 
insulin and C-peptide levels along with elevated plasma NEFA levels, 
   
123 
 
suggestive of a relatively insulin deficient state (Table 6-2). There were no 
differences in resting fasting metabolism between the short and long 
duration groups; resting energy expenditure: 2008.1±96.8 vs. 1958.4±80.3 
kcal/day; p=0.696 respectively and respiratory quotient: 0.78±0.01 vs. 







Insulin (mU/l) 17.4 (3.9-48.9) 7.0 (4.1-31.9) 0.006 
C-peptide (nmol/l) 1.1 (0.4-2.8) 0.6 (0.4-1.2) 0.006 
β-hydroxybutyrate (mmol/l) 0.1 (0.1-0.3) 0.2 (0.1-1.1) 0.371 
NEFA (mmol/l) 0.55±0.04 0.69±0.05 0.044 
Serum triglycerides 
(mmol/l) 
1.5 (0.7-8.1) 1.3 (0.5-3.3) 0.348 
Total cholesterol (mmol/l) 4.6±0.2 4.8±0.3 0.589 
Non-HDL cholesterol 
(mmol/l) 
3.5±0.2 3.4±0.3 0.925 
HDL cholesterol (mmol/l) 1.1±0.1 1.4±0.1 0.042 
ALT (U/l) 27 (11-118) 23 (12-151) 0.472 
GGT (U/l) 31 (11-185) 31 (11-62) 0.407 
Table 6-2 Fasting metabolites in short and long duration diabetes. Values 
are mean ± SEM or median (range). 
Liver 
Hepatic triglyceride content was 11.8±2.2 % in those with short duration 
diabetes and 8.2±1.4 % in those with long duration diabetes (p=0.182). 
There was no correlation between diabetes duration and hepatic triglyceride 
content (Spearman rank -0.281; p=0.139). Hepatic triglyceride content and 
fasting insulin levels were strongly positively correlated (Spearman 
rank=0.636; p<0.001). Hepatic insulin sensitivity was lower at baseline in 
those with short duration compared to long duration diabetes: hepatic IR 
index: 2063 (1202-2389) vs. 1219 (888-1409) µmol.min-1.kgffm-1.pmol.l-1 
respectively; p=0.034. There was no difference in hepatic VLDL1-triglyceride 
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production rate between the groups (136.5±19.3 vs. 145.4±14.0 mg/kg/day; 
p=0.719).  
Pancreas 
There was no difference between first phase insulin response (baseline to 6 
min increment in insulin secretion rate) between short and long duration 
diabetes (0.02 (0.00-0.18) and 0.01 (0.00-0.03) nmol min-1 m-2; p=0.230). The 
difference in maximal insulin secretory capacity (baseline to peak increment 
in insulin secretion rate) following arginine bolus was not significant (0.41 
(0.20-0.67) and 0.23 (0.18-0.33) nmol min-1 m-2; p=0.102). Pancreatic 
triglyceride content was greater in those with long duration compared to 
short duration disease: 5.7% (3.8-15.9) vs. 4.7% (3.3-8.0); p=0.043). 
6.3.2 Effect of a VLCD in individuals with short vs. long duration 
type 2 diabetes 
Weight loss 
At baseline the groups were well matched for weight and BMI (Table 6-1). 
Weight loss during the first week for the short duration vs. long duration 
group was 4∙0±0∙2 % vs. 3∙7±0∙2 % (p=0.384) and at week four was 9∙0±0∙5 % 
vs. 8∙4±0∙4 % (p=0.355). The mean weight loss over the eight week diet 
period was very similar in the two groups at 14∙8±0∙8 % and 14∙4±0∙7 % 
respectively (p=0∙662). Absolute weight loss and changes in waist and hip 
circumference are shown in  
Table 6-3. Body mass index decreased from 34∙1±0∙8 to 29∙1±0∙9 kg/m2 in the 
short duration group (p<0∙001) and from 34∙3±1∙2 to 29∙4±1∙1 kg/m2 in the 
long duration group (p=0∙001). Overall, the conditions were established to 
allow direct comparison of the glucose response to weight loss in short and 
long duration type 2 diabetes.
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 Baseline Week 1 Week 4 Week 8 
Weight (kg)                 Short 
                                      Long 
99∙0±3∙7 95∙1±3∙6 90∙2±3∙6 84∙5±3∙5 
96∙9±3∙8 93∙2±3∙6 88∙6±3∙4 83∙0±3∙2 
 
Waist circ. (cm)          Short 
                                      Long 
110∙0±2∙3 107∙6±2∙2 102∙9±2∙4 98∙0±2∙5 
113∙8±3∙0 112∙3±2∙9 107∙0±2∙9 101∙4±2∙9 
 
Hip Circ. (cm)             Short 
                                      Long 
115∙7±2∙4 114∙3±2∙5 112∙2±2∙5 107∙9±2∙4 
117∙3±3∙0 115∙8±3∙1 113∙1±3∙2 109∙9±3∙1 
 
Waist:Hip Ratio         Short 
                                      Long 
0∙95±0∙02 0∙94±0∙02 0∙93±0∙02 0∙91±0∙02 
0∙97±0∙02 0∙97±0∙02 0∙95±0∙02 0∙92±0∙02 
 
Table 6-3 Change in anthropometry over the 8 week VLCD in both short 
and long duration type 2 diabetes.  
Glucose control  
Over the eight week VLCD fasting plasma glucose decreased from 9∙6±0∙7 to 
5∙8±0∙2 mmol/l in the short duration group (p<0∙001) and 13∙4±0∙8 to 8∙4±1∙1 
mmol/l in the long duration group (p<0∙001). The glucose response to acute 
calorie restriction was strikingly heterogeneous in long duration diabetes 
(Figure 6-1B), with some responding within one week just as in the short 
duration group (Figure 6-1A) and some not at all. In 3/14 (21%) of the long 
duration group, a slow, steady return to non-diabetic fasting plasma glucose 
levels occurred and this was not observed in any of the short duration group. 
This is reflected in the difference in the fall in fasting glucose levels between 
week one and week eight of the VLCD between the groups; this being 
significantly greater in the long duration group compared to the short 
duration group: 2∙6±0∙6 vs. 1∙1±0∙3 mmol/l (p=0∙039).  




Figure 6-1 Change in fasting plasma glucose levels over the eight week 
VLCD for each individual with short duration type 2 diabetes (A) and long 
duration type 2 diabetes (B). 
At week 8, 87% of the short duration group and 50% of the long duration 
group achieved a fasting plasma glucose level of <7 mmol/l. The baseline 
differences in those with long duration diabetes between responders and 
non-responders are shown in  
Table 6-4. The non-responders had higher baseline fasting plasma glucose 
levels and lower maximal insulin secretory capacity.  
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HbA1c (mmol/mol) 67.3 ± 6.8 73.3 ± 4.7 0.483 
Baseline FPG (mmol/l) 11.8 ± 1.2 14.9 ± 0.6 0.048 
ALT (U/l) 26.0 (12.0-151.0) 22.0 (19.0-61.0) 0.277 
Triglycerides (mmol/l) 1.3 ± 0.1 1.7 ± 0.3 0.263 
Insulin (mU/l) 12.0 ± 3.5 7.1 ± 1.2 0.212 
C-peptide (nmol/l) 0.77 ± 0.08 0.67 ± 0.10 0.426 
Β-hydroxybutyrate 
(mmol/l) 
0.2 (0.1-0.2) 0.2 (0.1-1.1) 0.482 
NEFA (mmol/l) 0.61 ± 0.07 0.77 ± 0.06 0.113 
Hepatic triglyceride (%) 9.6 ± 2.0 6.8 ± 1.9 0.338 
Pancreatic triglyceride 
(%) 
7.0 ± 1.5 6.0 ± 0.6 0.534 
Hepatic IR index 
(mmol.min-1.kgffm-
1.pmol.l-1) 
1.45 ± 0.26 1.01 ± 0.15 0.160 
Basal HGP 
(mg/kgffm/min) 




147.8 ± 22.9 143.4 ± 18.7 0.882 
First phase insulin 
response (nmol min-1 m-2) 
0.037 ± 0.026 0.005 ± 0.003 0.234 
Maximal insulin 
secretory capacity 
 (nmol min-1 m-2) 
0.352 ± 0.055 0.169 ± 0.042 0.022 
 
Table 6-4 Baseline differences in the long duration group between those 
achieving a fasting plasma glucose <7 mmol/l following the VLCD 
(responders) and those achieving a fasting plasma glucose >7 mmol/l (non-
responders). 
Diabetes duration correlated with fasting plasma glucose at week 8 
(Spearman rank 0∙501; p=0∙006;  
Figure 6-2). If diabetes duration was <4 yr, mean achieved fasting plasma 
glucose level at week eight of the VLCD was 5∙8±0∙2 mmol/l; for diabetes 
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duration 8-12 yr this was 6∙2±0∙7 mmol/l; and for diabetes duration ≥12 yr 
this was 10∙6±1∙7 mmol/l.  
 
Figure 6-2 Achieved fasting plasma glucose levels at the end of the 8 week 
VLCD according to type 2 diabetes duration. 
HbA1c decreased from 55±2 mmol/mol (7.2±0.2 %) to 44±2 mmol/mol 
(6.1±0.2 %) in the short duration group (p<0∙001) and from 70±4 mmol/mol 
(8.6±0.4 %) to 64±6 mmol/mol (8.0±0.5 %) in the long duration group 
(p=0∙276). Although the HbA1c levels would not completely reflect change 
over the relatively short period of the study, non-diabetic levels (<43 
mmol/mol) were achieved at week eight in 6/15 (40%) of the short duration 
group and 2/14 (14%) of the long duration group. Fasting beta-
hydroxybutyrate levels increased from 0.1 (0.1-0.3) to 0.8 (0.2-4.6) mmol/l; 
p=0.001 in those with short duration disease and from 0.2 (0.1-1.1) to 1.0 
(0.2-4.6) mmol/l; p=0.001 in those with long duration disease. There was no 
difference between the fasting beta-hydroxybutyrate levels in the groups at 
week 8 (p=0.300). 
Basal energy expenditure decreased in both groups after the VLCD (Short: 
2008.1±96.8 to 1708.2±93.2 kcal/day; p<0.001 and Long: 1958.4±80.3 to 
1587.5±39.6 kcal/day; p<0.001). There was no change in respiratory quotient 
in either group (Short: 0.78±0.01 to 0.77±0.01; p=0.795 and Long: 0.79±0.01 
to 0.78±0.02; p=0.393).   
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Blood pressure control 
Blood pressure improved markedly and similarly in both groups (short vs. 
long duration): systolic: 144±5 to 125±5 mmHg (p=0∙003) vs. 160±7 to 133±6 
mmHg (p<0∙001); and diastolic: 91±2 to 82±3 mmHg (p=0∙007) vs. 90±2 to 
80±3 mmHg (p=0∙003). This improvement was sufficient to allow 
antihypertensive dose reduction in 1/6 (17%) and 7/11 (64%) of the short 
duration and long duration groups respectively who were on anti-
hypertensives at baseline. 
Serum lipid profile 
Total cholesterol improved from 4∙6±0∙2 to 3∙6±0∙2 mmol/l (p=0∙004) and 
4∙8±0∙3 to 3∙7±0∙3 mmol/l (p<0∙001) in the short and long duration groups 
respectively. The reduction was due to a decrease in non-HDL cholesterol 
from 3∙5±0∙2 to 2∙5±0∙2 mmol/l (p=0∙004) and from 3∙4±0∙3 to 2∙4±0∙3 mmol/l 
(p<0∙001) in the short and long duration groups respectively. There was no 
change in HDL cholesterol in either group (1∙1±0∙1 to 1∙1±0∙1 mmol/l; 
p=0∙322 and 1∙4±0∙1 to 1∙3±0∙1 mmol/l; p=0∙187). Triglycerides improved 
from 1.5 (0.7-8.1) to 0.9 (0.6-1.9) mmol/l (p=0∙002) and 1∙3 (0.5-3.3) to 1∙0 
(0.6-2.1) mmol/l (p=0∙005). There was no correlation between decrease in 
fasting triglycerides and glucose response in either the short duration 
(Pearson 0∙371; p=0∙174) or long duration groups (Pearson 0∙077; p=0∙793).  
6.4 Discussion 
Long duration type 2 diabetes is characterised by higher fasting glucose 
levels and pancreatic triglyceride content, and lower fasting insulin and C-
peptide levels, hepatic triglyceride content and hepatic insulin resistance 
compared to short duration type 2 diabetes. The glucose response to a VLCD 
correlated with diabetes duration, and at week 8, 50% of people with long 
duration and 87% with short duration type 2 diabetes returned to non-
diabetic fasting glucose levels despite withdrawal of all anti-diabetic 
therapies. The glucose response to acute calorie restriction in long duration 
diabetes was heterogeneous in contrast to the uniformly early fall in plasma 
glucose levels seen in those with short duration diabetes. Irrespective of 
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diabetes duration, clinically important improvements in blood pressure and 
lipid profile occurred. In those with long duration type 2 diabetes, lack of 
glucose response was characterised by higher baseline fasting glucose levels 
and decreased maximal insulin secretory capacity compared to those who 
responded.  
The observation of steady loss of beta cell function in the UK Prospective 
Diabetes Study was made during the usual natural history of type 2 
diabetes, that is during progressive weight gain (UKPDS, 1995a). Reports of 
normalisation of blood glucose control after bariatric surgery raised the 
possibility that negative calorie balance could restore normal physiology, 
however this was widely assumed to be surgery-specific and related to 
change in gut hormone profiles (Guidone et al., 2006; Laferrere et al., 2007; 
Bradley et al., 2012). Direct comparison of gastric bypass with negative 
calorie balance alone has suggested that the latter is primarily responsible 
for the improvement in glucose handling (Jackness et al., 2013; Lingvay et 
al., 2013). The Counterpoint study was designed to test the hypothesis that 
negative calorie balance would decrease fat levels in liver and pancreas and 
that this would be associated with normalisation of liver insulin sensitivity 
and beta cell insulin secretion (Lim et al., 2011). A return to normal of both 
parameters was observed in step with a fall in intra-organ fat levels, with 
complete normalisation of liver within seven days and return of beta cell 
function gradually over eight weeks. However, that study had been designed 
to examine the pathophysiological mechanisms underlying reversibility of 
type 2 diabetes, and to ensure a homogenous study group all were selected 
to have diabetes duration of less than four years. The clinical question of 
whether the observations may have more widespread applicability was 
raised immediately on publication (Yki-Järvinen, 2011). The present 
therapeutic study was therefore carried out to determine how people with 
longer term type 2 diabetes would respond to a very low calorie diet.  
In keeping with the findings from the Counterpoint Study, the current study 
demonstrated a rapid fall in fasting plasma glucose in all participants with 
short duration type 2 diabetes. This is in contrast with the variable response 
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in those with long duration diabetes, ranging from rapid normalisation of 
fasting glucose levels to no glucose response to acute calorie restriction. 
Four individuals with long duration diabetes showed a distinct, 
intermediate response of a slow steady decrease in glucose levels over the 8 
week VLCD which ultimately entered non-diabetic levels. The 
demonstration of potential for diabetes reversal using a VLCD in 
approximately half of those with longstanding disease is in keeping with 
observations following bariatric surgery. A study of 110 individuals with 
type 2 diabetes undergoing Roux-en-Y gastric bypass found a remission rate 
of 44% for those with diabetes duration of more than eight years (Hall et al., 
2010).    
Beta cell dysfunction and relative insulin deficiency (demonstrated by lower 
fasting insulin and higher NEFA levels and reduced maximal insulin 
secretory capacity) seem to be the key features defining both longer duration 
type 2 diabetes and individuals less likely to achieve non-diabetic fasting 
glucose levels after VLCD. In non-diabetic humans senescence has been 
associated with a progressive decline in basal insulin release (Iozzo et al., 
1999). However, small studies of stimulated C-peptide response in diabetes 
of longer duration have suggested significant inter-individual variation 
(Zangeneh et al., 2006; Jain et al., 2008). It may be that diabetes duration is 
simply a surrogate and insensitive marker for insulin secretory capacity, 
which is the major determinant of the potential therapeutic utility of a 
VLCD from a glucose perspective.  
A previous  post-mortem study on human pancreata demonstrated that 
adipose tissue content was positively correlated with age (Schmitz-
Moormann et al., 1981). Another study using multidetector-row CT scanning 
with measurement of Hounsfield units demonstrated that as duration of 
type 2 diabetes increases, pancreatic volume decreases and pancreatic fat 
content increases, with mean age being the same in all groups at 53 years 
(Lim et al., 2014). In the current study, the long duration group had higher 
pancreatic triglyceride content and lower hepatic triglyceride content when 
compared with the short duration group. This is in keeping with a previous 
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study using the same 3 point Dixon method, which showed that hepatic and 
pancreatic triglyceride content were positively correlated in those with 
normal glucose tolerance but that this association was lost in type 2 
diabetes (Macauley et al., 2015b). As diabetes duration increases and insulin 
secretory capacity declines, lower portal insulin levels are likely to result in 
diminution of hepatic de novo lipogenesis. In this situation, ongoing export 
of VLDL1-triglyceride from the liver could result in this divergence of 
hepatic and pancreatic triglyceride levels. Higher pancreatic triglyceride 
content coupled with decreased beta cell mass in individuals with long 
duration diabetes may be an explanation for variable gradual glucose 
response to the VLCD in some individuals in the long duration group. It 
could be hypothesised that it would take longer to mobilise the increased fat 
content in the pancreata of those with long duration disease. If this were to 
relieve the toxic burden on the beta cells, and if there was sufficient 
remaining beta cell mass, a critical level of insulin secretion necessary to 
regain normal fasting glucose levels could be recovered.  
Although a VLCD strategy has been incorporated into NICE guidelines on 
obesity, this has not yet been widely taken up despite demonstration of 
efficacy and durability when applied in routine primary care (Ross et al., 
2008; NICE, 2014 ). This apprehension in using a VLCD may relate to 
perceived low adherence, concerns about sustainability of effects and 
theoretical concerns about detrimental effects on lipid profile (RCGP, 2002). 
The use of nutritionally complete diet products has been extensively 
reviewed and are considered safe (Mustajoki and Pekkarinen, 2001). The 
present study provides clear information on acceptability and metabolic 
state. Compliance with the VLCD is high, at least in motivated individuals, 
as judged by the hard end-point of substantial weight loss, with only one of 
30 participants unable to complete the study. Follow-up of the Counterpoint 
study at three months after completing the VLCD showed that 7 of the 11 
participants were not diabetic on oral glucose tolerance testing despite 
weight gain of 4kg (Lim et al., 2011). That study had not been designed as a 
therapeutic study and no follow up support had been provided. Following 
publication of the Counterpoint study the extent of the enthusiasm of some 
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people with type 2 diabetes to take major steps to escape from diabetes 
became clear in the very large scale email feedback (Steven et al., 2013). 
Amongst the email cohort of those who lost weight and returned to normal 
glucose tolerance, duration of normal glucose control in some now 
approaches three years (Peters et al., 2015). Provided that weight loss is 
maintained, there is hope that diabetes will not return at least over several 
years and it is now important to establish the durability of the effect on 
glucose control. 
The overall health benefits of the VLCD were both striking and appreciated 
by all participants. These included lower blood pressure, improvement in 
lipid profile, enhanced general wellbeing, and better mobility. The 19-27 
mmHg improvement in systolic blood pressure and 9-10 mmHg 
improvement in diastolic blood pressure is comparable to addition of two 
antihypertensive agents at usual dose (Arauz-Pacheco et al., 2002). The 
improvement in total cholesterol seen in this study is similar to that 
observed with full dose statin therapy (MRC/BHF, 2003). Together these 
improvements in blood pressure and lipids are likely to make a consequent 
major reduction in cardiovascular events in individuals with diabetes. 
The limitations of the current study must be considered. Diabetes duration 
is an imprecise entity and some individuals may have a prolonged period of 
unrecognised hyperglycaemia preceding a diagnosis. The best information 
suggests that fasting glucose levels rise only gradually over many years 
preceding a diagnosis, but in the final 12-24 months increase rapidly (Sattar 
et al., 2007; Tabák et al., 2009). In the current study, the date of diagnosis 
reported by participants was verified from medical records and any 
subclinical period would be equally likely in each group and would if 
anything, underestimate duration. Secondly, the diagnosis of type 2 diabetes 
itself depends upon exclusion of other possible diagnoses. Participants were 
recruited if diabetes was detected through a routine test and excluded if 
diagnosis was precipitated by severe osmotic symptoms. Thorough history 
taking was used to exclude those with clinical features suggestive of latent 
autoimmune diabetes in adults (LADA) or maturity onset diabetes of the 
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young (MODY). Thirdly, the baseline levels of fasting plasma glucose were 
necessarily different in the groups defined by duration of type 2 diabetes. 
Additional matching for glycaemic control or treatment for diabetes would 
have resulted in an atypical group as defined by duration of diabetes. 
Finally, the proportion of these research participants successfully 
completing the VLCD cannot be extrapolated to the general population with 
the condition. Individuals in the study were highly motivated to succeed in 
losing weight and a selection bias will have operated. However, even if only 
a modest proportion of the affected population was able to follow this 
treatment, the impact upon health service budgets would be substantial.  
In conclusion, in individuals with type 2 diabetes of duration greater than 
eight years, a therapeutic trial of very low calorie diet may be undertaken 
with a 50% chance of achieving non-diabetic fasting plasma glucose levels 
off all anti-diabetic therapies. For those who do not achieve non-diabetic 
plasma glucose levels, blood pressure, lipids and general wellbeing, will be 
considerably improved. These insights provide quantitative evidence for the 
potential for use of a VLCD in long duration type 2 diabetes and carry 
implications for everyday clinical practice. The critical factor which seems to 
differentiate long duration from short duration type 2 diabetes, and 
determine reversibility in the long duration group is baseline glucose control 
and insulin secretory capacity. Individuals with long duration diabetes have 
higher pancreatic triglyceride content compared to short duration disease 
and the potential relationship of this to beta cell function requires further 
investigation. 
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7.1 Introduction 
The benefits of significant weight loss achieved through an intensive 
lifestyle intervention on glycaemic control in type 2 diabetes are well 
recognised (Henry et al., 1985; Pi-Sunyer et al., 2007; Gregg et al., 2012). 
However, the major challenge to most patients and clinicians is long-term 
maintenance of weight loss rather than achieving initial significant weight 
loss. It is thought that only 20% of individuals manage to lose 10% of body 
weight and maintain this for at least 1 year (Wing and Hill, 2001). One 
advantage of bariatric surgery over a very low calorie diet (VLCD) in the 
management of type 2 diabetes is the increased propensity for maintenance 
of long term weight reduction. There are now long term studies going out to 
15 years demonstrating only slight weight gain and that although diabetes 
remission rates decrease over time, bariatric surgery has superior sustained 
benefit compared to conventional lifestyle and pharmacological treatment 
with an odds ratio of 6.3 (Sjostrom et al., 2014). Previously there has been 
clear demonstration of recidivism of weight loss following VLCD in 
individuals with type 2 diabetes (Paisey et al., 2002). However, more recent 
reports suggesting the potential widespread applicability (Steven et al., 
2013) and durability of the benefit of a VLCD to at least 3 years (Peters et 
al., 2015) have renewed interest in their potential role in the therapeutic 
armamentarium for the treatment of type 2 diabetes.  
The rapid beneficial effect of a very low calorie diet on metabolism has been 
recognised for decades (Henry et al., 1985), however, they have never been 
incorporated into routine diabetes clinical practice. Use of VLCD has 
recently become part of national guidance regarding obesity management in 
specific clinical scenarios, as part of a multidisciplinary weight management 
strategy (NICE, 2014 ). Initial safety concerns are no longer applicable with 
modern nutritionally complete VLCD products (Basciani et al., 2015). There 
is now a clear understanding of the pathophysiological changes occurring 
during acute calorie restriction in individuals with type 2 diabetes (Lim et 
al., 2011). Within 7 days, hepatic triglyceride content decreases markedly. 
Within the liver, the close relationship between triglyceride content and 
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hepatic glucose output, the primary determinant of fasting blood glucose, is 
well established (Petersen et al., 2005; Ravikumar et al., 2008) and within 7 
days of VLCD hepatic insulin sensitivity improves to that of weight matched 
glucose tolerant controls. By the end of an 8 week VLCD recovery of first 
phase insulin secretion is seen alongside a reduction in pancreatic 
triglyceride content. However, these changes were demonstrated in the 
metabolic milieu of ongoing calorie restriction (Lim et al., 2011). Also, this 
study involved 11 individuals with short duration, well controlled type 2 
diabetes. Of great clinical relevance and import is the wider applicability of 
a VLCD as a treatment strategy in the wider, heterogeneous type 2 diabetes 
population. Also, whether the effect of the VLCD on metabolism is 
maintained after normal eating resumes, and crucially whether the benefit 
is maintained in the longer term with successful maintenance of weight loss.  
The twin cycle hypothesis of type 2 diabetes links excess hepatic triglyceride 
and exposure of beta cells to excess fatty acid through the export of VLDL1-
triglyceride from liver to pancreas (Taylor, 2008). NEFA are major 
substrates for hepatic VLDL1-triglyceride production and this may be a 
substrate driven process. Weight loss has been shown to reduce the 
secretion of VLDL1-triglyceride from the liver (Klein et al., 2006). However, 
this effect is variable suggesting that weight loss induced alterations in 
hepatic VLDL1-triglyceride secretion are regulated by factors other than 
weight loss alone. There is now strong evidence for the detrimental effect of 
metabolites of triglyceride, namely diacylglycerol, on both insulin secretion 
and insulin action directly and via ceramide activation of novel and/or 
atypical protein kinase C’s which affect insulin signalling and apoptosis 
(Samuel et al., 2010; Stretton et al., 2010). 
Studies in bariatric surgery have identified clinical characteristics which 
are associated with reversal or persistence of diabetes, but understanding 
the pathophysiologic limitations to diabetes reversal is crucial in furthering 
our understanding of the pathophysiology of type 2 diabetes. Moreover, 
understanding the limitations to diabetes reversal will help to individualise 
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therapy in type 2 diabetes and target use of a VLCD and/or bariatric 
surgery towards those most likely to benefit. 
The aim of this study was to test the hypothesis that individuals who 
achieve non-diabetic fasting blood glucose levels after a VLCD will remain 
normoglycaemic in the long term provided that weight regain is avoided. 
The physiological parameters defining reversibility of type 2 diabetes will be 
investigated along with the durability of these changes.  
7.2 Study design 
7.2.1 Participants 
30 individuals with type 2 diabetes were identified in response to local 
advertisement (as per chapter 6). Exclusion criteria were loss of more than 
5kg body weight in the preceding 6 months, treatment with 
thiazolidinediones, GLP-1 agonists, steroids or atypical anti-psychotic 
medications, untreated thyroid disease, renal dysfunction (serum creatinine 
>150 µmol/l), contraindication to MR scanning or alcohol consumption >3 
units per day for women and >4 units per day for men. The history of the 
diagnosis of diabetes was taken carefully to clinically exclude alternate 
diagnoses than type 2 diabetes. Participants discontinued all anti-diabetic 
therapy prior to the baseline study (as described in chapter 6) but remained 
on their usual lipid lowering treatment.  Anti-hypertensive medications 
were decreased as necessary throughout the study. As per a previous study, 
weight loss of >2.8% body weight at day 7 of the VLCD was considered 
necessary to continue in the study (Lim et al., 2011). One participant did not 
meet this weight loss target and left the study after week one, hence the 
final participant number of 29: age 56.7±1.8 yr, weight 98.0±2.6 kg, BMI 
34.2±0.7 kg/m2, HbA1c 62.4±2.7 mmol/mol, diabetes duration 4 (0.5-23) yr.  
The study protocol was approved by Newcastle and North Tyneside 2 Ethics 
Committee and all participants gave informed written consent.  
7.2.2 Experimental protocol 
This prospective, longitudinal, single centre study comprised 3 phases: an 8 
week weight loss phase using a VLCD; a stepped return to isocaloric intake 
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of normal food over 2 weeks; and a 6 month structured, individualised 
weight maintenance program. Assessments were carried out on 3 occasions: 
at baseline prior to the VLCD, at week 10 following a gradual return to a 
diet isocaloric with their achieved weight, and then at the end of the 6 
month weight maintenance period. Studies were performed after an 
overnight fast and took place over 2 days. On the first half day, individuals 
underwent assessment of body composition with electrical bioimpedence 
using a Bodystat1500 (Bodystat Ltd, Isle of Man, UK) (see section 2.1.3) 
and then measurement of pancreatic and hepatic triglyceride content and 
visceral and subcutaneous adipose tissue areas using the 3 point Dixon 
method on a 3 Tesla Achieva MRI scanner (Philips, Best, The Netherlands) 
(see section.2.2.2 & 2.2.3). Thereafter, cannulae were inserted into both 
antecubital veins for infusion and blood sampling respectively. Assessment 
of VLDL1- triglyceride production was then performed using competitive 
blockade of lipoprotein lipase with an Intralipid infusion (see section 2.3.8). 
Baseline physical activity levels (MET-min/week) were measured using a 
standard questionnaire (International Physical Activity Questionnaire). On 
the second day, after an overnight fast, a cannula was inserted into an 
antecubital vein for infusions and a second cannula was inserted into the 
contralateral wrist vein for arterialised blood sampling. Assessment of 
hepatic glucose production and insulin sensitivity were carried out using an 
isoglycaemic hyperinsulinaemic clamp (see sections 2.3.3 & 2.3.4). 
Isoglycaemia rather than euglycaemia was selected to ensure that the true 
fasting condition of each participant could be observed at each time point 
given the anticipated change in fasting glucose between the first two 
studies. Following the clamp study participants rested until stable fasting 
glycaemia had been restored (and a minimum of 60 minutes) and then a 
stepped insulin secretion test was used to assess first phase insulin 
secretion and maximal insulin secretory capacity in response to arginine 
(see section 2.3.5). PNPLA3 genotyping was performed on DNA extracted 
from white blood cells. 10 ml of whole blood was collected in EDTA and after 
thorough mixing was then stored at -40°C. DNA was isolated and 
genotyping performed (blinded to the clinical parameters) using TaqMan 
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SNP Genotyping Analysis (Applied Biosystems, USA) as described 
previously (section 2.3.7) (Liu et al., 2014). 
7.2.3 Weight loss phase 
The VLCD consisted of a liquid formula diet (43% carbohydrate, 34% protein 
and 19.5% fat; 2∙6 MJ/day [624 kcal/day]; Optifast; Nestlé Nutrition, 
Croydon, UK) taken as 3 sachets per day. In addition, up to 240g of non-
starchy vegetables were consumed, making total daily energy intake 624-
700 kcal. Participants were given suitable vegetable recipes, were 
encouraged to drink at least two litres of calorie-free beverages per day and 
to maintain their habitual level of physical activity. To maximise adherence 
to the diet, one-to-one support was provided weekly and as required by 
telephone, e-mail, text message or face-to-face contact. Stepped 
reintroduction of food took place over one week with sachets gradually being 
replaced by solid foods. Isocaloric intake was determined from resting 
energy expenditure measured by indirect calorimetry using an open circuit 
calorimeter (Quark RMR; COSMED, Rome, Italy) and a canopy hood at 
week 8 (section 2.1.4). The post-VLCD studies were conducted a minimum of 
6 days after full return to solid foods. At the week 10 studies, the standard 
threshold for remission of diabetes (fasting plasma glucose <7 mmol/l) was 
used to define the group of responders (Buse et al., 2009). 
7.2.4 Weight maintenance phase 
The primary goal of this phase was to prevent weight regain through use of 
a structured individualised weight maintenance program. The isocaloric diet 
was individualised both in respect of personal food preferences and in 
relation to observed body weight. Dietary advice was guided by weight 
trajectory and participants were asked to weigh themselves weekly. The 
individualised program was delivered by two investigators (myself and a 
health psychologist (LA)), and was based on goal setting, action planning 
and barrier identification with reviews at monthly visits (Michie et al., 
2011). Participants were given verbal and written information including a 
daily calorie prescription, informed by indirect calorimetry. Individualised 
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daily meal plans, recipes and snack ideas were provided. During the 6 
month weight maintenance phase, monthly assessments of weight, waist 
and hip circumference, blood pressure and fasting blood tests were made. In 
addition, all participants were encouraged to maintain telephone/email or 
text message contact between monthly visits with updates on progress or to 
discuss challenges. If fasting plasma glucose exceeded 10 mmol/l on 2 
occasions, anti-diabetic agents were recommenced.  Physical activity was 
encouraged but the primary focus was on weight maintenance. Physical 
activity levels were measured objectively using a validated multisensor 
array (SenseWear Pro3; BodyMedia Inc., Pittsburgh, USA) worn for 5 days 
after the VLCD and then at the end of the weight maintenance period. Data 
were analysed using the InnerView Professional software which contains 
activity detection and lifestyle algorithms based on gender, age, weight, 
height, smoking status and hand dominance.  
7.2.5 Statistical analysis 
Statistical analysis was performed using Minitab 16 statistical program 
(Minitab Inc.; State College, PA: www.minitab.com). Prior to any 
comparison, the data were tested for normality using the Kolmogorov 
Smirnov test. Data are presented as mean ± SEM for parametric and 
median (range) for non-parametric data. Insulin secretion rates and hepatic 
insulin resistance indices are expressed as median and 25th and 75th 
percentile. Statistical analysis used Student’s paired and 2-sample t-test, 
Mann Whitney U, Wilcoxon Rank and Spearman Rank correlation as 
appropriate. Statistical significance was accepted at p<0.05.  
7.3 Results 
7.3.1 All participants: weight loss and glucose response 
Weight fell from 98.0±2.6 kg at baseline to 83.8±2.4 kg following the VLCD 
(p<0.001) and remained stable for the subsequent 6 month period (84.7±2.5 
kg). Fasting plasma glucose decreased from 11.9 (6.6-17.3) to 7.3 (5.4-22.3) 
mmol/l (p<0.001) then remained stable at 7.2 (4.7-15.9) mmol/l. HbA1c 
decreased from 62.5±2.7 to 54.2±3.7 mmol/mol (p=0.020) and then remained 
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stable at 53.7±2.8 mmol/mol. Resting energy expenditure decreased from 
1983.3±61.9 at baseline to 1647.8±51.1 kcal/day at week 8 (end of the VLCD) 
(p<0.001) and remained stable over the weight maintenance period 
1706.6±49.9 kcal/day. There was no change in physical activity levels during 
the weight maintenance period; measured as metabolic equivalents of task 
(METs): 1.1 (0.9-1.6) to 1.3 (0.9-1.7); p=0.355; daily step count: 8139±622 to 
8450±617 steps; p=0.488; light activity time (1.5-3.0 METS) per day: 210±14 
to 214±12 min; p=0.676; or as sedentary time per day: 19.5±0.4 to 19.1±0.3 
hr; p=0.246.  
After the VLCD, 41% of the group (12/29) achieved a fasting plasma glucose 
of <7.0 mmol/l and were defined as responders. At the end of the weight 
maintenance period, 45% of the group (13/29) had a fasting plasma glucose 
<7 mmol/l off all oral hypoglycaemic agents or insulin. In the responder 
group, 9 were from the short duration group and 3 from the long duration 
group.  
7.3.2 Responders vs. non-responders: weight loss & glucose response 
There was no significant difference in achieved weight loss after VLCD 
between the responders and non-responders (15.8±0.5 vs. 13.6±0.7 % 
respectively; p=0.057). Weight remained constant over 6 months in both 
responders (84.1±3.1 to 84.4±3.2 kg; p=0.826) and non-responders (83.6±3.5 
to 84.8±3.7 kg; p=0.198) (Figure 7-1A). In the responders, fasting plasma 
glucose fell from 8.9±0.7 to 6.2±0.1 mmol/l (p=0.002) post-VLCD then 
remained constant at 6.2±0.3 mmol/l (Figure 7-1B). In the non-responders, 
fasting plasma glucose fell from 13.2±0.6 to 10.9±1.1 mmol/l (p=0.016) post-
VLCD and remained constant at 9.4±0.7 mmol/l. In the non-responder group 
6 individuals restarted medication during the 6 month weight maintenance 
period: metformin only (n=2), metformin and sulfonylurea (n=3) and insulin 
(n=1) but all required less treatment at the end of the study than at 
baseline. The increase in fasting plasma glucose during solid food 
reintroduction (between week 8 and week 10) was significantly greater in 
the non-responders compared to the responders (2.4±0.4 vs 1.0±0.3 mmol/l; 
p=0.019) (Figure 7-1B). This occurred despite no weight gain in the non-
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responders and only minimal weight gain in the responders (-0.18±0.27 vs. 
0.43±0.42 kg; p=0.208). HbA1c remained stable throughout the weight 
maintenance period in both groups (responders: 40±2 to 41±2 mmol/mol; 
p=0.543) and non-responders: 64±5 to 62±3 mmol/mol; p=0.505) (Figure 
7-1C).  
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Figure 7-1 Change in weight (A), fasting plasma glucose (B) and HbA1c (C) 
over the study in responders (circles) and non-responders (triangles). The 
grey band represents the stepped transition from VLCD to isocaloric solid 
foods. Results are mean ± SEM. 
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7.3.3 Responders vs. non-responders: insulin secretion 
Fasting insulin levels decreased in both groups following the VLCD and 
stayed stable during the weight maintenance period (Table 7-1). First phase 
insulin response improved after the VLCD in the responders: 0.11 (0.00-
0.19) to 0.19 (0.15-0.23) nmol min-1 m-2 (p=0.025) and did not change over 
the weight maintenance period (0.21 (0.15-0.31) nmol min-1 m-2) (Figure 
7-2). There was only a marginal increase in first phase insulin secretion in 
the non-responder group (0.01 (0.00-0.02) to 0.03 (0.00-0.04) nmol min-1 m-2; 
p=0.039, with no change during weight maintenance (0.02 (0.01-0.05) nmol 
min-1 m-2). There was no significant change in maximal insulin secretory 
capacity (baseline to peak insulin secretion rate in response to arginine 
bolus) in the responders following the VLCD (0.57 (0.45-0.94) to 0.70 (0.46-
0.92) nmol min-1 m-2; p=0.969) or after the weight maintenance period (0.67 
(0.57-1.09) nmol min-1 m-2) (p=0.255 from baseline). There was no change in 
maximal insulin secretory capacity in non-responders either: 0.19 (0.15-
0.30) to 0.18 (0.13-0.41) nmol min-1 m-2 following VLCD (p=0.538) and then 
0.32 (0.10-0.37) nmol min-1 m-2 (p=0.242 from baseline).  
   
 
 
 Responders Non-Responders 
 Baseline Post VLCD After 6 
months 
Baseline Post VLCD After 6 
months 
BMI (kg/m2) 34.0±0.8 28.6±0.8 * 28.7±0.7 # 34.4±1.1 29.8±1.1 * 30.2±1.1 # 
Waist:hip ratio 0.97±0.02 0.93±0.02 * 0.93±0.02 # 0.96±0.02 0.91±0.01 * 0.92±0.01 # 
Fat mass (%) 36.2±1.9 30.1±2.0 * 31.5±1.9 # 42.6±2.2 ˟ 37.2±2.0 * 40.8±2.5 
Plasma glucose (mmol/l) 8.9±0.7 6.2±0.1 * 6.2±0.3 # 13.2±0.6 ˟ 10.9±1.1 * 9.4±0.7 # 
Serum insulin (mU/l) 20.4 (5.7-48.1) 7.9 (3.4-16.6) * 7.6 (3.1-31.6) # 9.3 (3.9-48.9) 5.5 (1.4-22.9) * 5.9 (1.2-14.9) # 
Serum ALT (U/l) 43 (11-151) 26 (18-42) * 21 (7-27) # 22 (12-61) ˟ 19 (13-47) 18 (9-33) # 
Serum GGT (U/l) 67±16 32±11 * 40±17 # 33±5 ˟ 19±2 * 27±5 
Plasma NEFA (mmol/l) 0.51±0.05 0.46±0.05 0.46±0.04 0.69±0.04 0.53±0.04 * 0.53±0.03 # 
β-hydroxybutyrate (mmol/l) 0.1 (0.1-0.3) 0.1 (0.0-0.9) 0.1 (0.0-0.2) 0.2 (0.1-1.1)  ˟ 0.2 (0.1-1.5) 0.1 (0.0-0.3) # 
Table 7-1 Fasting anthropometric and metabolic data in responders and non-responders at baseline, after VLCD, and then after a 
6 month weight maintenance period (* = p<0.05 for baseline to post-VLCD difference; # = p<0.05 for baseline to month 6 difference, 
and ˟ = p<0.05 for between group difference at baseline).
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Figure 7-2 Insulin secretion rates (median and interquartile range) during the stepped insulin secretion test in responders and 
non-responders at baseline, after VLCD and after 6 months weight maintenance. 
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7.3.4 Responders vs. non-responders: liver metabolism 
Serum ALT and GGT levels decreased in both groups and remained stable 
during weight maintenance (Table 7-1). Basal hepatic glucose production 
decreased in both groups after the VLCD (responders: 2.58 (2.23-4.01) to 
2.38 (2.06-3.46) mg/kgffm/min; p=0.055 and non-responders: 3.33 (2.59-8.10) 
to 2.97 (2.41-4.46) mg/kgffm/min; p=0.020). Hepatic insulin resistance index 
also decreased in both groups after the VLCD and remained stable with 
weight maintenance (responders: 2153 (1199-2484) to 851 (641-1020); 
p=0.003 and then 750 (662-1010) µmol.min-1.kgffm-1.pmol.l-1 and non-
responders: 1237 (910-1475) to 773 (424-989); p=0.001 and then 755 (466-
1209) µmol.min-1.kgffm-1.pmol.l-1 ( 
Figure 7-3). Hepatic VLDL1-triglyceride production rate appeared to 
decrease in both groups following the VLCD and remained stable with 
maintenance of weight loss (responders: 125.3±22.9 to 102.7±19.6; p=0.148 
then 102.0±18.9 mg/kg/day and non-responders: 150.0± 14.0 to 120.3±12.0; 
p=0.015 then 118.0±12.2 mg/kg/day (Figure 7-3).




Figure 7-3 Hepatic insulin resistance index (upper panel) and hepatic 
VLDL1-triglyceride production (lower panel) in responders and non-
responders at baseline (hatched), after VLCD (chequered) and after 6 
months weight maintenance (striped). * denotes p<0.05 for baseline to post-
VLCD difference and # denotes p<0.05 for baseline to month 6 difference.  
In the whole group (n=29), the rs738409 C to G adiponutrin/PNPLA3 
genotype (coding for I148M) was found in 8 individuals: 6 were heterozygous 
for the SNP: CG (148I/M) and 2 homozygous: GG (148M/M). There was no 
difference in mean baseline hepatic triglyceride content in wild type 
compared to individuals with a mutation (9.9±1.2 vs. 10.6±3.9 % 
respectively; p=0.836). Similarly there was no difference in the achieved 
hepatic triglyceride content following the VLCD (2.3±0.1 and 2.0±0.1% 
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respectively; p=0.189). Baseline serum triglycerides appeared higher in wild 
type compared to those with a mutation but the difference was not 
significant (1.5 (0.7-8.1) vs. 1.2 (0.5-4.8) mmol/l; p=0.242). There was no 
difference in the serum triglycerides following the VLCD (1.2±0.1 in wild 
type and 1.2±0.2 mmol/l in those with a mutation; p=0.694). 
7.3.5 Responders vs. non-responders: intra-organ triglyceride content 
and body composition 
Marked normalisation in hepatic triglyceride content was seen in both the 
responders (12.8±2.7 to 2.2±0.2 %; p=0.002) and non-responders (8.2±1.1 to 
2.2±0.1 %; p<0.001) following the VLCD (Figure 7-4A). There was no re-
accumulation of hepatic triglyceride following the 6 month weight 
maintenance period in either responders or non-responders: 2.1±0.3 vs. 
2.3±0.2 % respectively. Following the VLCD, there was a significant 
decrease in pancreatic triglyceride content in both groups (responders: 
5.3±0.4 to 4.5±0.3 %; p=0.039 and non-responders: 5.9±0.7 to 5.3±0.5 %; 
p=0.004) (Figure 7-4B). Pancreatic triglyceride content remained stable 
during weight maintenance in responders and non-responders (4.4±0.3 % 
and 5.0±0.5 % respectively).  
In responders, subcutaneous adipose tissue area decreased from 319.6±31.0 
to 232.0±23.1 cm2 (p<0.001) after VLCD then remained stable during weight 
maintenance at 238.6±20.3 cm2. Visceral adipose tissue area decreased from 
287.0±23.1 to 191.9±18.9 cm2 (p<0.001) and then 179.5 ±22.3 cm2. In non-
responders, subcutaneous adipose tissue area decreased from 285.4±24.7 to 
223.3±23.5 cm2 (p<0.001) and remained stable at 219.3±22.8 cm2 after 6 
months and visceral adipose tissue area decreased from 289.6±23.7 to 
209.5±22.1 cm2 (p<0.001) and then 198.9±4.8 cm2 after 6 months.  
Hepatic VLDL1-triglyceride production rate did not correlate with baseline 
hepatic triglyceride content (Pearson=0.143; p=0.467) even after exclusion of 
the main outlier with baseline hepatic triglyceride content of 36% (Pearson= 
-0.303; p=0.124). There was no correlation between hepatic VLDL1-
triglyceride production rate and pancreatic triglyceride content at baseline 
(Spearman = -0.049; p=0.807). There was no correlation between the change 
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in hepatic VLDL1-triglyceride production rate and the change in hepatic 
triglyceride content or pancreatic triglyceride content over the VLCD (Whole 
group: Pearson=0.116; p=0.566 and Pearson=0.035; p=0.867 respectively; 
Responders only: Pearson=0.266; p=0.430 and Pearson=0.049; p=0.894). The 
absolute change in hepatic triglyceride and pancreatic triglyceride content 
over the VLCD was weakly and negatively correlated (Spearman rank=-
0.384; p=0.044) (Figure 7-4C).  
There was no significant correlation between the change in hepatic VLDL1-
triglyceride production rate and the change in first phase insulin response 
between baseline and following the VLCD (Spearman rank 0.316; p=0.109). 
There was no correlation between the change in hepatic VLDL1-triglyceride 
production and the change in NEFA between baseline and following the 
VLCD (Pearson=0.069; p=0.731). Neither was there any correlation between 
the change in hepatic VLDL1-triglyceride production rate and change in 
serum triglycerides after the VLCD (Spearman rank=0.269; p=0.175).  
The correlation between hepatic VLDL1-triglyceride production rate and 
fasting plasma glucose only became significant at month 6 (Spearman rank: 
baseline: 0.179; p=0.362; week 10: 0.322; p=0.095 and month 6: 0.463; 
p=0.011). There was no correlation between hepatic VLDL1-triglyceride 
production rate and either fasting serum triglycerides or fasting insulin.




Figure 7-4 Change in hepatic (A) and pancreatic (B) triglyceride content in 
responders and non-responders at baseline (hatched), after VLCD 
(chequered) and after 6 months weight maintenance (striped). * denotes 
p<0.05 for baseline to post-VLCD difference and # denotes p<0.05 for 
baseline to month 6 difference. Correlation of absolute change in hepatic 
and pancreatic triglyceride during the VLCD (Spearman rank=-0.384; 
p=0.044) (C). 
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7.3.6 Responders vs. non-responders: peripheral insulin sensitivity 
Peripheral insulin sensitivity increased in responders following the VLCD 
(Mffm: 3.06 (1.55-4.55) to 3.93 (2.11-8.93) mg/kgffm/min; p=0.038) and was 
3.29 (2.29-12.35) mg/kgffm/min after weight maintenance. In non-responders 
the increase following the VLCD was not significant (Mffm: 3.97 (1.25-15.89) 
to 5.41 (2.12-14.85) mg/kgffm/min; p=0.421 and remained stable after 6 
months weight maintenance 5.53 (2.43-22.99) mg/kgffm/min. 
7.3.7 Responders vs. non-responders: lipids and blood pressure 
Serum triglycerides decreased by 37% in the responders and 23% in the 
non-responders over the VLCD period (Table 7-2). The significant 
improvements in total cholesterol and non-HDL cholesterol were also 
maintained over 6 months. Although plasma NEFA appeared to decrease in 
both groups, the change was only significant in the non-responder group. 
HDL-cholesterol appeared to have increased in both groups by the end of the 
study. There was an approximately 40% reduction in VLDL1 mass following 
the VLCD in both groups which was sustained with weight maintenance 
(Table 7-2). The decrease in VLDL1 apoB in both groups was also sustained. 
The triglyceride to apoB ratio did not change significantly over the course of 
the study suggesting that the particle size stays the same. There was a 
clinically significant and sustained improvement in both systolic and 
diastolic blood pressure in both groups (Table 7-2).   
 Responders Non-Responders 
 Baseline Post VLCD After 6 
months 
Baseline Post VLCD After 6 
months 
VLDL1-TG (mg/dl) 62.6±12.8 33.4±7.4 * 30.1±3.6 # 37.2 (4.4-431.8) 22.7 (5.0-77.6) * 21.3 (4.6-110.7) # 
VLDL1 -apoB (mg/dl) 2.6±0.5 1.5±0.3 * 1.4±0.1 # 1.7 (0.3-15.7) 1.2 (0.3-3.2) * 1.0 (0.2-4.8) # 
TG:apoB ratio 23.1±0.7 22.6±1.2 20.9±0.9 22.0±1.1 19.8±0.8 21.3±1.1 
VLDL1-TG production 
rate (mg/kg/day) 
125.3±22.9 100.3±18.1 102.0±18.9   # 150.6±13.2 120.3±12.0 * 118.0±12.2 # 
Triglycerides (mmol/l) 1.97±0.32 1.25±0.16 * 1.15±0.12 # 1.30 (0.50-8.10) 1.00 (0.60-2.00) 
* 
1.20 (0.50-3.10) # 
Total cholesterol 
(mmol/l) 
4.7±0.3 3.9±0.2 * 4.2±0.3 # 4.7±0.3 4.0±0.3 * 4.2±0.2 # 
Non-HDL cholesterol 
(mmol/l) 
3.6±0.3 2.8±0.3 * 2.8±0.3 # 3.3±0.3 2.7±0.3 * 2.7±0.2 # 
HDL cholesterol 
(mmol/l) 
1.1±0.1 1.1±0.1 1.4±0.1 # 1.3±0.1 ˟ 1.3±0.1 1.5±0.1 
Systolic blood 
pressure (mmHg) 
142±5 129±7 * 128±5 # 159±6 139±5 * 143±6 # 
Diastolic blood 
pressure (mmHg) 
91±2 84±4 * 82±2 # 90±2 84±2 * 85±2 # 
Table 7-2 Changes in lipid profile and blood pressure in responders and non-responders. (* = p<0.05 for baseline to post-VLCD 
difference; # = p<0.05 for baseline to month 6 difference, and ˟ = p<0.05 for between group difference at baseline).
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7.3.8 Characteristics of responders vs. non-responders 
The responders had a shorter diabetes duration, were younger, and had 
better glucose control at baseline (fasting plasma glucose and HbA1c) 
compared to the non-responders (Table 7-3). Achieved fasting glucose level 
after the VLCD was positively correlated with diabetes duration in the 
whole group (Spearman rank=0.59; p=0.001). Although there was no 
difference between non-responders and responders in terms of initial weight 
or BMI, the total fat mass appeared to be higher in non-responders at 
baseline (p=0.042). Prior to the study, the responders required less 
medication compared to non-responders (Table 7-3). There was no difference 
in baseline physical activity levels. Responders were characterised by higher 
baseline serum insulin levels compared to non-responders. This state of 
relative insulin deficiency in the non-responders is supported by higher 
baseline fasting β-hydroxybutyrate and NEFA compared to the responders 
(Table 7-3). 
First phase insulin response was diminished at baseline in non-responders 
compared to responders (0.01 (0.00-0.02) vs. 0.11 (0.00-0.19) nmol min-1 m-2; 
p=0.060) (Figure 7-2). Baseline maximal insulin secretory capacity (baseline 
to peak ISR) was also markedly lower in the non-responders group (0.19 
(0.15-0.30) vs. 0.57 (0.45-0.94) nmol min-1 m-2; p<0.001). Pancreatic 
triglyceride content was similar in responders and non-responders: 5.3±0.4 
vs. 5.9±0.7 %; p=0.494.  
Hepatic triglyceride content appeared higher at baseline in the responders 
compared to the non-responders although this was not significant (12.8±2.7 
vs. 8.2±1.1 %; p=0.092). Basal hepatic glucose production was higher in non-
responders than responders at baseline (3.33 (2.59-8.10) vs 2.58 (2.23-4.01) 
mg/kgffm/min; p=0.010). At baseline, the responders tended to have greater 
hepatic insulin resistance (Hepatic IR index: 2153 (1199-2484) vs. 1237 
(910-1475) µmol.min-1.kgffm-1.pmol.l-1; p=0.060). Hepatic VLDL1-triglyceride 
production rate was similar in the two groups at baseline (125.3±22.9 vs. 
150.6±13.2 mg/kg/day; p=0.312). There was no difference at baseline 
between responders and non-responders in subcutaneous (319.6±31.0 vs. 
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285.4±24.7 cm2; p=0.397) or visceral adipose tissue areas (287.0±23.1 vs. 
289.6±5.7 cm2 ; p=0.940). There was no significant difference at baseline 
between responders and non-responders in peripheral insulin sensitivity 
(Mffm: 3.06 (1.55-4.55) vs. 3.97 (1.25-15.89) mg/kgffm/min; p=0.088). 
 Responders  Non-Responders  p-
value 
Age (yr) 52.0±2.9 59.9±2.1 0.032 
Gender 8M:4F 7M:10F  
Diabetes duration (yr) 3.8±1.0 9.8±1.6 0.007 
Physical activity (MET-
min/week) 
4446 (509-24581) 5337 (378-29985) 0.900 
Fasting plasma glucose 
(mmol/l) 
8.9±0.7 13.2±0.6 <0.001 
HbA1c (mmol/mol) 55±4 68±3 0.01 
Fasting β-
hydroxybutyrate (mmol/l) 
0.10 (0.10-0.30) 0.20 (0.10-1.10) 0.02 
Fasting insulin (mU/l) 20.4 (5.7-48.1) 9.3 (3.9-48.9) 0.005 
Plasma NEFA (mmol/l) 0.51±0.05 0.69±0.04 0.011 
Medications: 
   diet control  
   metformin only 
   metformin and SU  
   metformin, SU & insulin  














Table 7-3 Baseline clinical characteristics of responders (n=12) and non-
responders (n=17).  
 
7.4 Discussion 
This study demonstrates that weight loss can be maintained for 6 months 
following a very low calorie diet using a structured individualised 
programme. Crucially, in those who respond to the VLCD and maintain 
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weight loss, normal blood glucose control is sustained at 6 months. Of the 
pathophysiological changes demonstrated following the VLCD, namely 
improved first phase insulin secretion, decreased pancreatic triglyceride 
content, decreased hepatic triglyceride content, improved hepatic insulin 
sensitivity and decreased hepatic VLDL1-triglyceride production, restoration 
of first phase insulin secretion seems to be a prerequisite for normalisation 
of blood glucose control.  
In this study, the low dropout rate during the VLCD (1/30) indicates that it 
is an acceptable therapeutic option, albeit in this self-selected and highly 
motivated population. Re-introduction of normal eating was done in a 
planned manner, with definitive prescription of food type and amount, with 
emphasis on continuing high vegetable intake as during the VLCD but 
adding in other foods up to the specified restricted daily calorie intake. The 
participants reported that the weight maintenance phase of the study was 
more challenging than the VLCD phase, but the structured, individualised 
weight maintenance program was successful in avoiding weight gain during 
the 6 month follow up period in the majority of individuals.  
Clinical characteristics associated with a glucose response to the VLCD 
were younger age, shorter diabetes duration, better baseline glycaemic 
control and less requirement for diabetes therapies, however, the critical 
factor in determining outcome seems to be a degree of first phase insulin 
secretion at baseline and the recovery of this following VLCD. Moreover, the 
non-responders showed signs of insulin deficiency: lower fasting insulin 
levels and almost absent first phase insulin response, with higher fasting 
ketone and NEFA levels. The responders appeared to have higher hepatic 
triglyceride content, lower hepatic insulin sensitivity and lower hepatic 
VLDL1-TG production, characteristics that would be consistent with an 
environment of hyperglycaemia and hyperinsulinaemia. It may be that once 
insulin secretion becomes significantly impaired, the insulinopaenic 
environment results in less de novo lipogenesis with lower hepatic 
triglyceride content and consequently improved hepatic insulin sensitivity. 
However, the improvements in these parameters do not seem to outweigh 
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the loss of insulin secretory capacity in terms of glucose levels. The presence 
of the PNPLA3 mutation is known to dissociate the relationship between 
hepatic triglyceride content and insulin resistance (Kantartzis et al., 2009). 
In this study, the presence of the mutation did not affect either baseline 
hepatic triglyceride content or serum triglyceride levels, nor did it affect the 
capacity of the VLCD to reduce these parameters. 
The metabolic change occurring during the VLCD that seems to define 
glucose response is an improvement in first phase insulin secretion. It has 
been hypothesised that the restoration of insulin secretion occurs due to 
resolution of the burden of toxic fatty acids on pancreatic islet cells allowing 
recovery of insulin secretion (Morgan et al., 2008). However, it may be that 
there is a minimum functional beta cell mass required to allow regain of 
function.  Theoretically, ongoing reduction in the exposure to toxic fat 
metabolites could suppress beta cell apoptosis and data demonstrating 
ongoing beta cell neogenesis and redifferentiation could mean that beta cell 
mass could recover over time, thereby improving  insulin secretory capacity 
(Szabat et al., 2012; White et al., 2013). The importance of pancreatic 
triglyceride in the pathogenesis of type 2 diabetes was initially 
demonstrated in obese rodents (Lee et al., 2009). Beta cells have been shown 
to take up fatty acids and store them as intracellular triglyceride (Pinnick et 
al., 2010). In the human pancreas the magnetic resonance technique detects 
the total intra- and extra-cellular triglyceride in exocrine and endocrine 
cells of the pancreas (Pinnick et al., 2008; Hollingsworth et al., 2015). 
However, evidence is accumulating that whole organ pancreas fat may be a 
biomarker for the burden of toxic fat metabolites on beta cell function (Lim 
et al., 2011; Szczepaniak et al., 2012). Human islets in vitro accumulate 
triglyceride on exposure to low concentrations of fatty acids (Lalloyer et al., 
2006) and this will result in local lipolysis sufficient to bring about 
inhibition beta cell function (Lee et al., 1994; Tushuizen et al., 2007). 
Pancreatic triglyceride content is decreased with weight loss uniquely in 
type 2 diabetes compared to those with normal glucose tolerance (see data in 
chapter 4).  The extent of decrease in pancreatic triglyceride content 
following the VLCD was similar in responders and non-responders, however 
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it appears that only in responders was the capacity for return of acute 
insulin secretory after release from fat-mediated inhibition by fat intact 
(Dubois et al., 2004; Tang et al., 2015).  
The hypothesis that the decrease in pancreatic triglyceride is due to the 
decrease in delivery of hepatic VLDL1-triglyceride from the liver to all extra-
hepatic cells and tissues but specifically the pancreas is not supported by 
this study. However, a larger study of a responder group would be required 
to test the hypothesis definitively. There was a negative correlation between 
hepatic and pancreatic triglyceride content but no correlation between the 
change in hepatic triglyceride content and hepatic VLDL1-triglyceride 
production nor between the change in pancreatic triglyceride content and 
hepatic VLDL1-triglyceride production. In the study there was no 
correlation between hepatic VLDL1-triglyceride production and fasting 
glucose levels until month 6. This is in contrast to a previous study which 
demonstrated, using multiple regression analyses, that in a group of 30 
individuals (in which one third had type 2 diabetes) that plasma glucose was 
significantly associated with hepatic VLDL1-triglyceride production (Adiels 
et al., 2005). The reduction in hepatic VLDL1-triglyceride production with 
weight loss seen in this study is in keeping with previous findings following 
weight loss achieved after gastric bypass surgery (Klein et al., 2006).  
VLDL1-triglyceride secretion is largely dependent on the availability of fatty 
acids which are derived from de novo lipogenesis (5-25%), lipolysis of 
triglyceride stores in adipose tissue (60-80%) or dietary fatty acids. A 
gradual increase in insulin levels can promote hepatic triglyceride 
production by upregulation of lipogenic enzymes which promotes de novo 
lipogenesis and results in an increased flux of fatty acids to the hepatic 
NEFA pool. This ultimately results in increased VLDL1-triglyceride 
secretion. In contrast, acute increases in insulin secretion seem to inhibit 
hepatic VLDL1-triglyceride production probably through suppression of 
plasma NEFA. The decreased fasting insulin levels seen following the VLCD 
in this study are likely to divert NEFA flux from lipogenesis to oxidation, 
thus decreasing hepatic triglyceride content. The potential relationship 
between hepatic VLDL1-triglyceride production and intra-organ triglyceride 
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content is complex and likely to depend on NEFA concentration, degree and 
chronicity of hyperinsulinaemia, insulin sensitivity of lipolysis and current 
nutritional status.  
The post-VLCD studies were performed at week 10 rather than at week 8 in 
order to report the change in metabolism during conditions of usual 
isocaloric diet as opposed to reflecting ongoing strict calorie restriction. 
There was a marked increase in glucose levels occurring between the end of 
the 8 week VLCD and the week 10 studies, most prominent in the non-
responder group, despite negligible weight gain. This is likely to reflect a 
refeeding phenomenon; it has previously been demonstrated that after 10 
days of an isocaloric diet following a very low calorie diet, basal hepatic 
glucose output increases and this correlates with fasting plasma glucose 
levels (Henry et al., 1985).  
Although both groups achieved significant weight loss during the VLCD 
phase and maintained this for 6 months, they remained similarly obese or 
overweight at the end of the study (BMI 28.7±0.7 in responders and 30.2±1.1 
kg/m2 in non-responders; p=0.308). It is notable that despite ongoing excess 
body fat there was no redistribution of fat to the liver from subcutaneous or 
other adipose tissue deposits over 6 months of weight stability. This 
supports the concept of a personal fat threshold rather than a genetically 
determined percentage of body fat being stored within the organs. Above a 
certain threshold, specific to each individual, excess triglyceride cannot be 
stored in adipose tissue and spills over into ectopic sites such as the liver 
(Taylor and Holman, 2015). It could be hypothesised that non-responders, 
despite achieving substantial weight loss during the VLCD, may not have 
crossed their personal fat threshold to regain normal metabolic function.  
This study has demonstrated durability of the effect of a VLCD over a 6 
month period. However, the permanency of the effect and potential impact 
on clinical outcomes of prolonged avoidance of weight recidivism remain to 
be demonstrated. Long-term follow-up data from the Swedish Obese 
Subjects Study demonstrated a diabetes remission rate of 72.3% in the 
bariatric surgery group at 2 years and only 30.4% at 15 years. Even in this 
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setting there was weight gain over the follow-up period, particularly in the 
gastric bypass group (Sjostrom et al., 2014). We have previously reported 
one individual with type 2 diabetes who successfully lost 41kg and has 
maintained normal glucose levels and remission of painful neuropathy for 
over 3 years (Peters et al., 2015). The current study did not aim to look at 
clinical outcomes from long term maintenance of weight loss and non-
diabetic blood glucose levels. However, we know that risk and progression of 
long term complications from diabetes relates to ambient blood glucose 
levels, therefore durable reversal of diabetes would be expected to be 
associated with long term health (Stratton et al., 2000). Furthermore, even 
if hyperglycaemia were to recur, the ‘legacy effect’ suggests that a period of 
normoglycaemia would confer substantial benefit in terms of risk reduction 
(Holman et al., 2008). A previous study of 18 obese individuals with type 2 
diabetes showed sustained improvement in cardiovascular risk profiles at 18 
months following a 30 day VLCD (Jazet et al., 2007). The clinical 
implication from information comparing responders and non-responders in 
this study is that a VLCD would be best attempted in individuals with 
preservation of some beta cell function and/or beta cell mass, as indicated by 
lower glucose levels and higher fasting insulin levels. However, there are 
still considerable benefits to be gained even in those individuals who do not 
have a glucose response to a VLCD. In the non-responder group the 
improvements in blood pressure and lipid profile are likely to confer long 
term benefit in terms of cardiovascular risk. In addition, the improvement 
in wellbeing and quality of life reported by participants should not be 
overlooked.   
The limitations of the study must be considered. The use of gold standard 
imaging techniques and detailed metabolic tests necessitates the small 
numbers studied; however the group sizes have allowed significant 
differences to be detected. The heterogeneous population studied represents 
the spectrum of individuals with type 2 diabetes who may wish to undertake 
calorie restriction. Pancreatic triglyceride measurements reported are 
necessarily of both intra- and extra-cellular triglyceride as current 
methodology precludes measurement of potentially more relevant intra-islet 
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triglyceride content. To further investigate the refeeding phenomenon it 
would have been informative to have performed the detailed metabolic 
studies at week 8 in addition to week 10, however, the burden on 
participants was considered prohibitive. The inclusion of individuals with 
alternative diagnoses to type 2 diabetes is a possibility as we did not 
measure auto-antibodies as part of the screening process. However, detailed 
clinical history taking was performed to minimise this where possible.    
This study has demonstrated durability of the effects of an 8 week VLCD for 
6 months in individuals who maintain weight loss with 45% of participants 
achieving a fasting glucose <7 mmol/l at month 6.  Restoration of first phase 
insulin secretion is the pathophysiological change which appears to define a 
glucose response to the VLCD. The study has indicated which individuals 
are more likely to achieve a glucose response: younger age, shorter diabetes 
duration, with higher fasting insulin and better glycaemic control on fewer 
diabetes medications. The decreases in hepatic and pancreatic triglyceride 
content are durable as are the improvements in cardiovascular risk factors, 
notably blood pressure and lipid profile.  
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These studies confirm the previous observations that type 2 diabetes is a 
reversible syndrome and provide insight into how this knowledge may be 
applied in clinical practice. The insights could lead to a paradigm shift in 
the way that the condition is viewed. Rather than a chronic, progressive 
disease with a requirement for the sequential addition of therapies over 
time and the inevitable development of multi-system complications, type 2 
diabetes could be tackled pro-actively with targeted strategies implemented 
at diagnosis.  
Diabetes reversal using VLCD or bariatric surgery   
Similar overall weight loss (on average 14% of initial body weight) was 
achieved over 8 weeks either by VLCD or bariatric surgery. 
Correspondingly, rates of reversal of diabetes (defined as achieving a fasting 
plasma glucose level of <7 mmol/l) were similar at week 8 following VLCD 
or bariatric surgery (69% vs. 67% respectively). The cohort studied was 
representative of the heterogeneous type 2 diabetes population. The 
mechanisms responsible for normalisation of glucose levels after either 
intervention appear similar: early change in fasting plasma glucose due to 
rapid change in hepatic insulin sensitivity, but primarily as a consequence 
of restoration of first phase insulin secretion. Work from this thesis supports 
the theory that negative calorie balance, particularly acute and significant 
calorie restriction, rather than weight loss per se has a profound role in 
regulating glucose metabolism. The bidirectional nature of this relationship 
is clear in the longer term study reported in Chapter 7. These showed 
significant improvement in fasting glucose levels after VLCD but an 
increase in fasting glucose levels following resumption of normal diet. These 
rapid changes go beyond that which can be explained by the modest change 
in body weight over these short time periods. The main advantage of 
bariatric surgery over VLCD is widely considered to be the higher success 
rates of achieving long term maintenance of weight loss (Sjostrom et al., 
2004) however, a study using the National Weight Control Registry showed 
comparable weight loss maintenance at 1 year following surgical and non-
surgical interventions (Bond et al., 2009). Data in this thesis demonstrate 
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that weight loss can be maintained for 6 months following a VLCD using a 
structured individualised programme based on goal setting, action planning 
and barrier identification.   
Impact of decreased intra-organ fat on glucose metabolism 
There are epidemiological, genetic and clinical data to support the  
importance of excess intra-organ fat as a causal risk factor for type 2 
diabetes (Sattar and Gill, 2014). Data from this thesis are concordant with 
previous work showing higher intra-organ fat levels in individuals with type 
2 diabetes compared to those with normal glucose tolerance, specifically 
triglyceride content in the liver (Kotronen et al., 2008) and pancreas 
(Tushuizen et al., 2007; Gaborit et al., 2015). Use of the 3 point Dixon 
magnetic resonance technique rather than other methods such magnetic 
resonance spectroscopy or computed tomography, has allowed more precise 
determination of fat content particularly in the pancreas (Hu et al., 2010). 
The latter is a small organ, which moves with respiration, therefore careful 
delineation of regions of interest after image acquisition is preferable to 
data obtained from pre-selected voxels which is likely to include 
surrounding visceral fat. An important observation has been made in these 
studies: hepatic and pancreatic triglyceride levels decrease with acute 
calorie restriction, achieved by bariatric surgery or VLCD, with no 
difference between those who achieved normalisation of fasting glucose 
levels and those who did not. The association between increased hepatic 
triglyceride content and decreased hepatic insulin sensitivity is clear (Nobili 
et al., 2006; Gastaldelli et al., 2007) and data from the present studies are in 
line with this; hepatic insulin resistance index and hepatic triglyceride 
content were positively correlated in all participants with diabetes 
(Spearman rank=0.386; p=0.008). However, in terms of achieving 
normalisation of glucose levels, a decrease in liver fat content with 
concurrent improvement in hepatic insulin sensitivity was insufficient by 
itself to ensure reversal of diabetes. Following 8 weeks of VLCD, individuals 
who did not achieve normal fasting glucose levels demonstrated a marked 
improvement in hepatic triglyceride content and hepatic insulin sensitivity, 
   
166 
 
similar to that seen in those who did achieve a glucose response. Also, in 
individuals with initially normal glucose tolerance, marked reduction in 
hepatic fat content after bariatric surgery was observed without a 
significant change in hepatic insulin sensitivity. In this latter group, it could 
be argued that the baseline levels of hepatic triglyceride could be below a 
threshold for inhibition of insulin action by the toxic metabolites of fat. 
However, in the former the lack of improvement in fasting glucose levels in 
some individuals despite the marked reduction in hepatic triglyceride 
content and hepatic insulin resistance index suggests that this mechanism 
is not of primary importance in the reversal of diabetes. Of great clinical 
importance for care of individuals with NAFLD and/or type 2 diabetes is the 
demonstration of longer term maintenance of low hepatic triglyceride levels. 
Weight loss achieved through lifestyle modification (Vilar-Gomez et al., 
2015) and bariatric surgery (Lassailly et al., 2015) has been shown to result 
in improvement in the histological features of non-alcoholic steatohepatitis, 
a precursor to the development of cirrhosis.  
The paradoxical relationship between the change in hepatic triglyceride 
content and achieved weight loss in the first week after bariatric surgery 
(chapter 5) has not been noted before to my knowledge. Individuals who 
achieved the greatest weight loss in the first 7 post-operative days had the 
smallest reduction in hepatic triglyceride content, but still achieved 
improved fasting glucose levels. This effect was not mediated by greater loss 
of lean mass compared to fat mass in these individuals, nor by the rs738409 
C/G polymorphism of the PNPLA3 gene. The potential for bariatric surgery 
to cause hepatic steatosis is well recognised (Peters et al., 1975; Pillai and 
Rinella, 2009), but it is also possible that the marked post-operative 
increase in GLP-1 could interrupt the usual relationship between weight 
loss and hepatic triglyceride content. Both GLP-1 agonist therapy and DPP-
4 inhibition have been reported to bring about a greater fall in hepatic 
triglyceride than would be expected by the degree of weight change 
(Cuthbertson et al., 2012; Macauley et al., 2015a). This could also be a 
potential explanation for the differing effect of the rs738409 C/G 
polymorphism of PNPLA3 on weight loss induced reduction in hepatic 
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triglyceride content achieved by bariatric surgery compared to VLCD. 
Following bariatric surgery the presence of a mutation appeared to blunt 
the weight loss induced reduction in hepatic triglyceride content, but this 
effect was not seen with equivalent weight loss achieved through VLCD. A 
previous study also demonstrated effective decrease in liver fat content 
through weight loss regardless of PNPLA3 genotype (Sevastianova et al., 
2011). It compared the effect of a 6 day hypocaloric low-carbohydrate diet in 
individuals who were homozygous for either the wild type or the mutant 
rs738409 polymorphism. Given that the PNPLA3 mutation is thought to 
impair the hydrolysis of triglyceride without increasing hepatic insulin 
resistance, this suggests that the method by which calorie restriction is 
achieved may influence hepatic lipid metabolism to a degree.    
Despite the wide scatter of absolute levels of pancreatic triglyceride content 
there were significantly higher levels in individuals with type 2 diabetes 
compared to weight matched individuals with normal glucose tolerance. 
This is in keeping with previous studies (Tushuizen et al., 2007; Lim et al., 
2011; Macauley et al., 2015b). Pancreatic triglyceride levels did not fall 
following bariatric surgery in individuals with normal glucose tolerance 
despite 15kg weight loss, suggesting that the change is disease specific 
rather than simply an effect of weight loss. In line with this specific link 
between pancreatic fat and diabetes, a recent study using magnetic 
resonance spectroscopy demonstrated higher pancreatic triglyceride content 
in individuals with type 2 diabetes, with no difference between lean and 
obese individuals with normal glucose tolerance (Gaborit et al., 2015). Data 
in this thesis demonstrates reduction in pancreatic triglyceride content 
following VLCD in individuals with type 2 diabetes. In those with low 
fasting plasma insulin levels and an absent first phase insulin response, the 
decrease in pancreatic triglyceride content could not restore beta cell 
functionality. Other recent work following gastric bypass surgery has shown 
a relationship between decrease in pancreatic fat and improvement in beta 
cell function (Honka et al., 2015). The cohort studied included obese non-
diabetic subjects who would be expected to have minimal change in beta cell 
function or pancreatic fat levels (chapter 4) and the imaging modality used 
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was computed tomography. Overall, it appears that chronic exposure to high 
fat levels within the pancreatic islet may eventually cause irreversible loss 
of glucose mediated insulin secretion as long duration type 2 diabetes was 
associated with negligible first phase insulin secretion, and removal of fat 
did not change this. The rate at which irreversible changes occur is likely to 
differ between individuals, and this may account for apparent lack of 
reversibility in a small number of people with type 2 diabetes of duration 
less than 4 years.  
Data from these studies indicate that the relationship between decreasing 
hepatic triglyceride content and return of hepatic insulin sensitivity, and 
decreasing pancreatic triglyceride and return of first phase insulin secretion 
are not linear and must be influenced by other factors. The absence of a 
technique to measure local concentrations of the metabolically inhibitory 
metabolites of fat, such as diacylglycerol, means that triglyceride content, as 
measured by MR, is being used as a biomarker: pancreatic triglyceride as a 
biomarker for the metabolic inhibition of insulin secretion by fat, and liver 
triglyceride as a biomarker of the metabolic inhibition of insulin action by 
fat.  This indirect measure could explain some of the dissociation in the 
relationship between intra-organ fat content and metabolic function. 
Although removal of excess intra-organ fat is an essential step to move an 
individual below their personal fat threshold, the limiting factor appears to 
be the potential for restoration of insulin secretory capacity from beta cells, 
that is the ability to respond to a glucose stimulus when the ambient 
metabolic inhibition by lipid metabolites is lifted. Regardless of intra-organ 
fat levels, if that individual does not have sufficient beta cell capacity for 
appropriate insulin secretion, normalisation of glucose levels will not occur. 
This limitation to diabetes reversal seems likely to be determined by a 
combination of residual beta cell mass and the state of de- or re-
differentiation of the beta cells (White et al., 2013). Using a mouse model of 
insulin secretory deficiency, recovery of beta cell function through re-
differentiation has been demonstrated by control of hyperglycaemia using 
insulin therapy (Wang et al., 2014). A human study looking at the effect of 
early short-term insulin therapy or oral agents for initial rapid correction of 
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hyperglycaemia in individuals with newly diagnosed type 2 diabetes, 
demonstrated that glycaemic control (capillary blood glucose <6.1mmol/l) 
was achieved in 95.2% of the multiple dose insulin group in 5.8 days 
compared to 83.5% of the oral agent group in 9.3 days (Weng et al., 2008). 
Remission rates at 1 year were significantly higher in the insulin group 
than the oral agent group. Also, the improvement in acute insulin response 
was sustained in the insulin group but significantly declined in the oral 
agent group. Further studies have found similar results and give support to 
the theory that early optimised glycaemic control with insulin may 
eliminate the deleterious effect of hyperglycaemia, and avoid irreversible 
loss of beta cell function and/or mass (Weng et al., 2015). It is difficult to 
determine whether the effect of early insulin therapy is exclusively due to 
avoidance of hyperglycaemia or whether the optimised metabolic milieu, 
including the beneficial effect on fatty acids, might be mechanistically 
important. Also, a direct effect of insulin on beta cell mass or function 
cannot be excluded from these studies. However, it must be acknowledged 
that any intervention which improves glucose levels is likely to have a 
beneficial effect on beta cell function.     
Weight loss results in decreased hepatic VLDL-triglyceride export  
Hepatic VLDL export is the only known mechanism by which liver fat 
content can be reduced other than through increasing fat oxidation. Data in 
this thesis demonstrate a decrease in hepatic VLDL-triglyceride secretion 
with weight loss which was maintained with weight maintenance. Similar 
to a recent study looking at VLDL-triglyceride secretion after RYGB 
(Magkos et al., 2010), there was no relationship between achieved weight 
loss and decrease in hepatic VLDL-triglyceride secretion seen following 
VLCD (Spearman rank=-0.048; p=0.812). Also, no relationship could be 
demonstrated between hepatic VLDL-triglyceride production rates and 
hepatic triglyceride content or hepatic insulin resistance index. This is in 
line with mouse models where inhibiting hepatic VLDL secretion increases 
hepatic triglyceride content but does not cause insulin resistance (Jacobs et 
al., 2010; Niebergall et al., 2011). One theory put forward to try to explain 
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this dissociation between liver fat and insulin resistance postulated that 
diacylglycerols sequestered in lipid droplets may not promote the PKC 
epsilon activation that has been shown to cause hepatic insulin resistance 
(Perry et al., 2014). It was hypothesised that increased VLDL-triglyceride 
export might be the source of inhibitory fat metabolites reaching the 
pancreas; this would mechanistically link excess liver fat with excess 
pancreas fat in type 2 diabetes (Taylor, 2008). However, in these studies 
there was no association between the weight loss induced decrease in 
VLDL1-triglyceride production and decrease in pancreatic triglyceride 
content or the improvement in insulin secretion rates in responders. It is 
important to acknowledge that the studies were not powered to test such a 
relationship and this needs to be investigated in a future study with a larger 
group size.  
Liposusceptibility and the implications for diabetes reversal    
The concept of liposusceptibility refers to an individual’s threshold for 
tolerating the deleterious metabolic effects of excess fat. In these studies 
this is best illustrated by the participants undergoing bariatric surgery who 
have managed to maintain normal glucose tolerance despite class II or III 
obesity. The lack of change in hepatic insulin sensitivity in this group 
suggests that the degree of liver fat accumulation was well tolerated, and 
the concept of the personal fat threshold could explain the lack of response 
to calorie restriction in some individuals in the study (Taylor and Holman, 
2015). This hypothesis suggests that individuals experience metabolically 
deleterious effects of intra-organ fat accumulation only when this exceeds a 
level of tolerability specific to an individual and unrelated to body weight or 
BMI. Despite achieving significant weight loss, this may have been 
insufficient for that individual to cross their personal fat threshold in order 
to regain normal metabolic function. Although baseline intra-organ fat 
levels were higher in those with diabetes compared to those with normal 
glucose tolerance, there was a wide range and overlap between the groups 
(hepatic triglyceride: 2.4-24.7 vs. 1.5-11.3 % and pancreatic triglyceride: 3.6-
10.5 vs. 4.2-6.1 % respectively). One individual in the normal glucose 
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tolerance group who did not have a PNPLA3 mutation had a hepatic 
triglyceride content of 11.3%. However, differences in liposusceptibility are 
likely to be only one factor implicated in determining reversal of type 2 
diabetes; the plateau in diabetes reversal rates following bariatric surgery, 
seen beyond 20% body weight loss (chapter 3), suggests that additional 
factors are important and specifically any irreversible loss of glucose 
sensitive insulin secretion.  
Factors determining reversibility of type 2 diabetes 
Adding to previous work showing reversibility of short duration type 2 
diabetes, these studies have demonstrated that reversal of long duration 
type 2 diabetes is also possible, although reversal rates are less than in 
short duration disease. Following either VLCD or bariatric surgery, reversal 
rates at 8 weeks according to diabetes duration were remarkably similar: 
Short (<4yr) vs. Long duration (>8yr): VLCD 87 vs. 50 % and Surgery 100 
vs. 40 %. These numbers are in keeping with previous findings on diabetes 
reversal rates after surgery where Hall et al. found a 75% reversal rate 
when diabetes duration was 0-4 yrs and a 44% reversal when diabetes 
duration was >8 yr (Hall et al., 2010). The response to calorie restriction in 
long duration diabetes was heterogenous, with the longest diabetes duration 
to achieve normalisation of glucose control in these studies being 18 years 
(following 21.4kg weight loss after bariatric surgery). Long duration type 2 
diabetes is characterised by higher fasting glucose levels and pancreatic 
triglyceride content, and lower fasting insulin, C-peptide, hepatic 
triglyceride content and hepatic insulin resistance compared to short 
duration type 2 diabetes. In individuals with longer duration disease, 
despite hyperglycaemia, the presence of diminishing portal insulin 
concentrations is likely to result in decreased hepatic de novo lipogenesis 
(Schwarz et al., 2003). Lower hepatic triglyceride levels in long duration 
compared to short duration disease could therefore simply be a consequence 
of relative insulinopaenia. In these studies, fasting insulin levels and 
hepatic triglyceride content were highly correlated both before (Spearman 
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rank=0.599; p<0.001) and after weight loss (Spearman rank=0.553; p<0.001) 
in all participants (including those with normal glucose tolerance). 
The metabolic characteristics of long duration type 2 diabetes were similar 
to those seen in individuals who did not achieve a glucose response to VLCD 
and are suggestive of relative insulin deficiency. However, the normalisation 
of glucose levels in a significant proportion of individuals with long duration 
disease through VLCD or bariatric surgery suggests that diabetes duration 
alone does not limit diabetes reversal. In fact diabetes duration may just 
represent a surrogate and insensitive marker for decreased insulin secretory 
capacity. Until specific interventions are developed specifically to augment 
beta cell mass/redifferentiation, it seems that bariatric surgery and VLCD 
would be best attempted earlier in the type 2 diabetes disease process given 
the higher diabetes reversal rates in short duration disease.  
Implications for the whole population  
One clinical implication of these studies is to direct public health strategies 
to focus on the prevention of weight gain in populations over time, 
recognising that, regardless of baseline weight, weight gain over many years 
in predisposed individuals is likely to result in metabolic disease. The 
remarkably low drop-out rate during VLCD in these studies demonstrates 
the viability of this intervention in general diabetes care. This is in 
accordance with a recent systematic review of VLCD in individuals with 
diabetes showing high tolerability and good safety outcomes (Sellahewa et 
al., 2015). Although the individuals in these studies represent a selected 
and highly motivated population, there is evidence to suggest that a 
significant proportion of the diabetes population would be willing to attempt 
such dietary restriction (Steven et al., 2013). A critical question for health 
care provision is whether truly long term reversal of diabetes can be 
achieved in Primary Care. To answer this question, a community based 
study (DiRECT: Diabetes REmission Clinical Trial) is now underway of 
individuals with type 2 diabetes randomised to VLCD with structured 
individualised weight maintenance or to best possible guideline-based care.   
Individuals can currently be counselled about the approximate chance of 
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achieving normal blood glucose levels with a VLCD. From data in Chapter 7 
it can be simply calculated that there is an 80% chance of reversal of type 2 
diabetes if duration is less than 10 years and fasting glucose is less than 9 
mmol/l.  Individuals can be reassured that even if normal glucose levels are 
not achieved with significant weight loss, they will reap benefits in terms of 
improved glucose control with decreased requirement for diabetes therapies, 
and improvement in cardiovascular risk factors such as blood pressure 
control and lipid profile. Finally, and of great importance, is the 
improvement in general well-being after significant weight loss which was 
universally reported by the participants studied.  
Future work 
Future work is required to establish whether modification of the VLCD 
could result in increased diabetes reversal rates. For example, could a more 
prolonged period of weight loss could result in a higher diabetes reversal 
rate? The mean BMI in individuals with diabetes in these studies at 8 
weeks after surgery or VLCD was 36.9±07 and 29.3 ± 0.7 kg/m2 respectively.  
Based on the personal fat threshold theory, further weight loss in some of 
these individuals might result in normalisation of glucose levels. In a larger 
cohort, studying individuals who regain weight following a VLCD may help 
strengthen the association between intra-organ triglyceride content and 
metabolic dysfunction. A bidirectional relationship would be expected to be 
seen, with any re-accumulation of hepatic and pancreatic triglyceride being 
associated with elevation of fasting glucose levels and loss of first phase 
insulin secretion. Development of an imaging modality that is able to 
quantify functional islet cell mass would be of great benefit. Also, the effect 
of a more prolonged period of isocaloric weight maintenance will be 
important to define. It could be hypothesised that over time, in the context 
of avoidance of weight gain and the toxic effect of excess fat metabolites, re-
differentiation of beta cells or neogenesis resulting in restoration of beta cell 
mass might restore insulin secretory capacity and result in higher diabetes 
reversal rates. Finally, to confirm the clinical relevance of these studies a 
long term prospective study evaluating rates of diabetes specific 
   
174 
 
complications and cardiovascular outcomes following a VLCD and weight 
maintenance programme is required.  
Conclusion 
The work presented in this thesis furthers understanding of both the 
mechanisms and the limits of reversibility of type 2 diabetes. Rather than 
diabetes duration itself being a limiting factor, it appears that the key factor 
determining reversibility is the potential for recovery of residual beta cell 
function. Substantial acute calorie restriction achieved by VLCD or bariatric 
surgery, with avoidance of weight regain, can restore normoglycaemia in a 
proportion of people with type 2 diabetes. 
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